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Background: 16 
Clostridium difficile infection (CDI) is the commonest nosocomial cause of diarrhoea. Faecal 17 
microbiota transplantation (FMT) is an approved treatment for recurrent or refractory CDI but there 18 
is uncertainty about its use. 19 
Aim:  20 
Evaluate the efficacy of FMT in treating recurrent and refractory CDI and investigate outcomes from 21 
modes of delivery and preparation.  22 
Methods: 23 
A systematic review and meta-analysis was performed. MEDLINE, EMBASE, CINAHL, Cochrane 24 
Library, trial registers and conference proceedings were searched. Studies on FMT in recurrent and 25 
refractory CDI were included. The primary outcome was clinical resolution with subgroup analyses of 26 
modes of delivery and preparation. Random effects meta-analyses were used to combine data.  27 
 28 
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Results: 29 
37 studies were included; 7 randomised controlled trials and 30 case series. FMT was more effective 30 
than vancomycin (RR: 0.23 95%CI 0.07 to 0.80) in resolving recurrent and refractory CDI. Clinical 31 
resolution across all studies was 92% (95%CI 89% to 94%). A significant difference was observed 32 
between lower GI and upper GI delivery of FMT 95% (95%CI 92% to 97%) versus 88% (95%CI 82% to 33 
94%) respectively (p=0.02). There was no difference between fresh and frozen FMT 92% (95%CI 89% 34 
to 95%) versus 93% (95%CI 87% to 97%) respectively (p=0.84). Administering consecutive courses of 35 
FMT following failure of first FMT resulted in an incremental effect. Donor screening was consistent 36 
but variability existed in recipient preparation and volume of FMT. Serious adverse events were 37 
uncommon. 38 
Conclusion: 39 
FMT is an effective treatment for recurrent and refractory CDI independent of preparation and route 40 
of delivery.  41 
 42 
 43 
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 45 
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Background 51 
Clostridium difficile infection (CDI) is the most important cause of nosocomial diarrhoea usually 52 
related to antibiotic use. It is associated with significant morbidity, mortality and cost worldwide.
1
 53 
UK National Institute for Health and Care Excellence (NICE) guidelines published in March 2014 54 
recommend the use of faecal microbiota transplantation (FMT) for patients with recurrent CDI that 55 
have failed to respond to antibiotics and other treatments.
2
 However, a recent survey across 56 
England revealed that only just over 25% of hospital trusts perform FMT for this indication. 
3
 This 57 
poor uptake has been attributed by physicians in part to paucity of randomised controlled trial (RCT) 58 
data, the lack of a standard treatment protocol, and uncertainty about long-term safety of FMT.
3
 59 
CDI occurs mainly in the elderly and those with significant chronic illnesses.
1
 The long-term cure rate 60 
from standard first line antibiotics (metronidazole or vancomycin) is low with CDI re-occurring after 61 
apparent resolution in about 35% of patients.
4
 Recurrent CDI is defined as complete recovery 62 
without symptoms followed by at least one further episode of diarrhoea confirmed to be secondary 63 
to CDI. Recurrent attacks of CDI expose patients to risk of complications such as toxic dilatation of 64 
the colon and septicaemia, which are associated with high mortality. Commonly, tapering doses of 65 
vancomycin are used for recurrent and refractory CDI although the effectiveness of this therapy is 66 
uncertain with sustained cure rates reportedly ranging widely between 49% and 100%. 
5
 While 67 
fidoxamicin has been shown to be more effective than vancomycin in the resolution of CDI as a first-68 
line agent, this agent has not been tested in recurrent CDI.
6,7
 69 
FMT for the treatment of CDI was attempted first in the modern era by Eiseman et al in 1958 in a 70 
small number of patients.
8
 Over the past decade or so, FMT has been studied by several centres 71 
worldwide for management of recurrent and refractory CDI. However, uncontrolled studies make up 72 
the bulk of the supporting evidence. Previous systematic reviews and meta-analyses either have 73 
methodological limitations as they have a restrictive selection criteria, do not have a comprehensive 74 
search strategy or do not consider the effect of different modalities of preparation or delivery of 75 
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FMT. Moreover, they do not include the most recent evidence, which to date includes more than 76 
five randomised controlled trials.
9–12
 In this systematic review and meta-analysis we therefore aim to 77 
address these issues to bring the evidence on FMT in recurrent and refractory CDI up to date.
13,14
 78 
Methods 79 
Objectives 80 
To systematically evaluate the effectiveness of FMT as treatment for recurrent and refractory CDI. 81 
The review and meta-analysis were undertaken in line with guidance from the Cochrane Handbook 82 
of Systematic Reviews of Interventions, and reported in line with preferred reporting items for 83 
systematic reviews and meta-analysis.
13,14
 84 
Search strategy 85 
The databases MEDLINE, EMBASE, CINAHL, and Cochrane Library were searched from 86 
commencement of databases to October 2016 for relevant articles. Free text and index terms for 87 
faecal microbial transplantation and Clostridium difficile were combined and no study design or 88 
language of publication filters were used. The MEDLINE and EMBASE strategy are shown in Appendix 89 
1. Details of ongoing trials and studies yet to be fully published were sought from trials registers 90 
(controlled-trials.com, clinicaltrials.gov), and microbiology, infection, and gastroenterology 91 
conferences proceedings (Digestive Diseases Week, British Society of Gastroenterology Conference, 92 
United European Gastroenterology Week) from September 2014 to October 2016. Reference lists of 93 
existing systematic reviews and articles included in this review were checked for additional studies.   94 
Search results were entered into a bibliography manager and duplicate entries removed. 95 
Study Selection 96 
Titles and abstracts of each article were screened for relevance. Copies of relevant articles were 97 
obtained and assessed for inclusion in the review using the criteria below.  Screening and selection 98 
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 5 
were undertaken independently by two reviewers and any disagreements resolved through 99 
discussion. The reason for not-selecting studies for review was recorded. 100 
Type of studies: 101 
RCTs, non-randomised trials and case series with 10 or greater participants were included. Studies 102 
published in abstract only format (for example from conference supplements) were only included if 103 
they were RCTs. 104 
Type of participants: 105 
Studies recruiting patients of all ages with refractory or recurrent CDI were included. Patients 106 
include those with ongoing diarrhoea without resolution of symptoms despite standard 107 
antimicrobial therapy. Recurrent and refractory CDI was taken as defined by the authors.  108 
Comparator: 109 
For comparative study designs there was no restriction on the type of comparator 110 
Primary outcome: 111 
Studies reporting clinical resolution of CDI based on improvement of symptoms or negative 112 
Clostridium difficile stool culture or toxin were included.  113 
Data extraction 114 
Data were extracted using a predesigned collection form on characteristics of study design, 115 
participants, type of CDI (recurrent and/or refractory) and outcomes. In addition data were 116 
extracted on donor screening, procedural aspects (FMT preparation, pre-medications and number of 117 
infusions) to establish variation of practice. Data on adverse events were also collected. 118 
There was no missing data or unclear information that necessitated contacting study authors for 119 
clarification. For papers not published in English partial translations were undertaken (in one case). 120 
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Data extraction and risk of bias assessment were undertaken by two reviewers independently. If 121 
there were any discrepancies, a third reviewer was consulted (in one case). 122 
Risk of Bias 123 
RCTs were assessed with the Cochrane Collaboration’s risk of bias tool.
13
 For non-randomised trials 124 
the same tool was to be used without application of criteria related to randomisation. Case series 125 
were assessed using the Centre for Reviews and Dissemination guidance.
15
  126 
Data assessment and analysis 127 
The effect of FMT on clinical resolution of recurrent and refractory CDI was evaluated by analysing 128 
studies with direct comparison against a non-FMT arm. The overall effect of FMT was analysed using 129 
data from all studies (including the FMT arm data from RCTs).  130 
The author’s definition of outcome of CDI resolution was used at the time point specified by the 131 
author following the delivery of FMT. In order to study the effect of multiple infusions, the data was 132 
analysed to compare rate of clinical resolution if only a single infusion was administered and if more 133 
than one infusion was delivered.  134 
Analysis was carried out to study the effects on FMT efficacy of mode of FMT delivery (upper GI 135 
(foregut) versus lower GI (colonic)) and different preparations of donor stool (fresh versus frozen). 136 
These comparisons were performed first with RCTs (if any) and then on subgroups of case series for 137 
each assessment.  As it was anticipated that studies on the whole would not clearly differentiate 138 
between patients with recurrent and refractory CDI, no separate analyse on these subgroups was 139 
undertaken.  A descriptive analyses of adverse event data was performed. 140 
Statistical analysis 141 
For the primary outcome pooled estimates of relative risk from the RCTs, and response rates from 142 
case series, were estimated with a random effect model using the method of DerSimonian & 143 
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 7 
Laird.
16,17
 For the latter the pooled estimate was calculated after the Freeman-Tukey Double Arcsine 144 
Transformation was applied to stabilise the variances facilitating synthesis of studies with 100% 145 
response rate.
18
 Exact confidence intervals were calculated for the individual studies. 146 
Heterogeneity was assessed using the I
2
 statistic and calculation of 95% prediction intervals for the 147 
response proportion in a new study.
19,20
 The latter were calculated using a logistic regression model 148 
with a random intercept. In interpreting I
2
 we describe values from 0%-30% as being likely minimal, 149 
values from 30-60% as likely moderate, and values from 60%-100% as likely substantial 150 
heterogeneity. The possibility of small study effects was assessed by asymmetry of funnel plots if 10 151 
or more studies contributed to a meta-analysis and the potential impact quantified using the Duval 152 
and Tweedie nonparametric "trim and fill" method.
21
 153 
Confidence intervals for relative risks from individual RCTs were calculated assuming the sampling 154 
distributions of the log-relative risk are normally distributed.  All analyses were performed in STATA 155 
version 14. 156 
RESULTS 157 
Study characteristics 158 
The initial search identified 2097 publications. Of these, 1179 duplicates were excluded and an 159 
additional 615 were removed after screening titles and abstracts. Consequently, 303 papers were 160 
retrieved in full text. Of these 19 were systematic reviews from which no additional papers were 161 
identified. From the remaining 284 papers, 102 were overviews, summaries, opinion pieces and 162 
narrative reviews, 83 were case reports or case series with a sample size of less than 10 patients and 163 
62 were case series published only as an abstract. Therefore 37 papers reporting studies met the 164 
selection criteria (Figure 1).  165 
The 37 included studies are summarised in Table 1 and Supplement 1. Supplement 1 elaborates on 166 
the primary response rate data and assessment of study quality. Seven studies were RCTs (of which 167 
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 8 
two were only published in abstract form) and 30 were case series. The different arms of the RCT 168 
data are summarised in Table 2. The included studies included a total of 1973 patients with 428 169 
enrolled in RCTs (360 in the donor FMT arm and 68 in the non-donor FMT arm) and 1545 described 170 
in case series. Two RCTS were open label comparisons of vancomycin and FMT (van Nood et al and 171 
Cammarota et al).
22,23
 Both were ended early following interim analysis by the respective data and 172 
safety monitoring boards due to observed efficacy of FMT. One RCT compared autologous versus 173 
donor FMT (Kelly et al), and the remaining RCTs compared different forms of FMT or modes of 174 
delivery: Fresh and frozen FMT (Lee et al), capsule versus colonoscopic delivery (Kao et al), low dose 175 
versus high dose FMT (Allegretti et al), nasogastric versus colonoscopic delivery (Youngster et al).
24–28
  176 
Of the case series, 25 performed FMT solely using fresh stool, two studies solely used frozen stool, 177 
two studies performed FMT with both fresh and frozen and one did not report on FMT preparation. 178 
Eight studies delivered FMT via the upper GI route, 18 studies delivered FMT via the lower GI route 179 
and one study delivered FMT via both routes. The remaining studies used a combination of both 180 
routes but did not report on data separately. Almost all the 30 studies had similar cohorts with 181 
regard to age and gender and similar response rates were observed in older and younger groups and 182 
those with male or female predominance as shown in Table 1 and Supplement 1. There was a female 183 
preponderance in the studies with a male: female distribution of 2:3. No studies solely used toxin 184 
negativity to define clinical resolution. Prior endoscopic evaluation was undertaken in six studies.  185 
Donor screening protocol  186 
Donors were a mixture of spouses, intimates, relatives and healthy volunteers. Most studies used a 187 
screening procedure to exclude individuals with known exposure to transmissible viruses, sexually 188 
transmitted disease, those involved in high-risk sexual behaviours and those with a history of drug 189 
abuse. Those with known gastrointestinal co-morbidity were excluded as were those who had 190 
recently taken antibiotics. With regard to donor screening there was considerable standardisation in 191 
screening for blood-borne viruses with screening for common transmissible agents such as hepatitis 192 
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A, B, C, HIV 1&2, Helicobacter pylori and Treponema in blood.  This also applied to stool pathogens 193 
including Clostridium difficile toxin, common pathogens including Cryptosporidium and Giardia and 194 
the majority of studies also reported microscopic examination for ova, cysts and parasites in stool 195 
samples.  196 
Procedural aspects 197 
i) FMT preparation 198 
In eight studies the solvent was water, saline in 20 and glycerol was used as a cytoprotectant in the 199 
three studies using frozen stool preparations. The remaining studies did not describe the diluent 200 
used to make up the transplant material.  Where stated, time from collection to administration 201 
varied from 1 hour to 8 weeks for frozen stool whilst the median time was six hours for studies using 202 
fresh stool samples. Quantity and volume of FMT material was very variable. In the studies using the 203 
upper route of delivery, the volume of material varied from 25ml to 500ml and the mass of faecal 204 
material also varied widely from 6g up to about 140g (median 40g). In the studies reporting on the 205 
lower GI route of delivery the volume of FMT was reported in 19 and this ranged from 100ml to 206 
1000ml with a mean volume of about 450ml. The fresh mass of faecal matter used was variably 207 
reported from 30g to 152g (median of 86g). Two RCTs used capsulated forms of stool however 208 
further details on the preparation of these capsules was not available as the data was only published 209 
in an abstract form.
26,32
  210 
ii) Pre-medication  211 
Standard colonoscopy bowel preparation was used in all studies undertaking FMT via the lower GI 212 
route.  Proton pump inhibitors were given in most studies using the upper route with the exception 213 
of the Van Nood randomised controlled trial.
22
 The use of anti-diarrhoeals to prolong retention of 214 
the faecal suspension in the colon was also reported in two studies. Antibiotics were generally 215 
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stopped 1-2 days before FMT with the exception of the van Nood RCT where antibiotics were 216 
continued until the day of the treatment.
22
 217 
iii) Number of infusions 218 
24 studies allowed more than one infusion / treatment of FMT in the event of failure of response. Of 219 
the 13 studies that only performed a signal infusion of FMT 9 were done using the lower GI route, 3 220 
used only the upper GI route and one used either route.
26,27,33–43
 Twelve studies used only fresh 221 
stool, and one used either fresh or frozen and 1 performed FMT also using a capsulated form. In the 222 
remaining studies FMT was administered up to 4 times for recurrent or unresolved symptoms.  223 
Assessment of study quality 224 
The seven RCTs were assessed to have a low risk of bias and demonstrated adequate randomisation 225 
with concealed automated allocation and performed an intention to treat analysis. For case series, 226 
although selection criteria were defined in most of these studies, all mentioned or implied 227 
consecutive recruitment of patients. Patients were followed up till achievement or failure of the 228 
primary outcome. Consequently, few studies reported long term outcomes and adverse events.  229 
Follow up ranged from 10 weeks to 8 years.  230 
Efficacy of FMT 231 
Most studies differed in their definition / criteria for resolution of CDI. Hence the author’s definition 232 
of outcome of CDI resolution at their specified time point following the delivery of FMT was used. 233 
Based on the variability of definitions used in the literature it was not possible to clearly separate 234 
data on “recurrent” versus “refractory” CDI. There were no true placebo controlled trials 235 
investigating the efficacy of FMT.  236 
Response to FMT - RCTs 237 
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There were 3 RCTs that compared FMT to a non-FMT intervention. In the two RCTs comparing FMT 238 
to vancomycin, the pooled relative risk of treatment failure of FMT against vancomycin was 0.23 239 
(95% CI 0.20 to 0.80) with moderate heterogeneity (I
2
 = 41%) indicating the superiority of FMT.
22,23
 240 
The relative risk against vancomycin and bowel lavage in the RCT by Camorotta et al was 0.08 (95% 241 
CI 0.01 to 0.05).
23
 The overall response rate from the two RCTs comparing FMT to vancomycin was 242 
90% in the FMT arm while the response rate was less than 30% in the antibiotic arms. The RCT by 243 
Kelly compared single infusion of donor versus autologous FMT.
27
 In the intention-to-treat analysis, 244 
20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure at 8 weeks compared with 245 
15 of 24 (62.5%) in the autologous FMT group (P = 0.042).  246 
The RCT by Lee and colleagues (comparing fresh versus frozen FMT) reported an overall combined 247 
clinical resolution rate with FMT of 72% in the intention-to-treat analysis, and 84% in the per 248 
protocol analysis across both arms.
24
 This was 52% for a single infusion but increased to 96% in 249 
patients who received more than two FMTs in the 13 week period. The RCT by Youngster (comparing 250 
nasogastric versus colonic FMT) reported a primary response rate (one infusion) of 70% across both 251 
arms and this increased to 90% with a second infusion in those that failed to respond to the first.
28
 A 252 
further two RCTs published in abstract form comparing efficacy with capsule versus colonic delivery 253 
and low dose versus high dose capsulated FMT both showed a response rate of 95% across both 254 
FMT arms.
26,32
 Kao demonstrated a cure rate of 100% versus 92% in colonoscopy and capsule 255 
delivered FMT respectively.
26
 In the Allegretti study presented at the Digestive Diseases Week in San 256 
Diego 2016, the authors reported on encouraging remission in 14 out of 19 patients treated with 257 
either a low or high dose of capsules.
32
 The abstract reports the 5 non-responders at 8 weeks were 258 
all given a high dose of capsules with cure in 4.  259 
 260 
Response to FMT – all studies 261 
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The mean pooled overall response for FMT in recurrent and refractory CDI based on all the included 262 
37 studies regardless of the number of infusions was 92% (95% CI 89% to 94%) with likely moderate 263 
heterogeneity (I
2 
= 59%) (figure 2). From the 34 studies that presented efficacy data for a single FMT 264 
infusion, the mean pooled response rate was 84% (95% CI 79% to 89%) with a likely high degree of 265 
heterogeneity (I
2 
= 84%). For a single infusion a 95% prediction interval for the response proportion 266 
in a new study is 49% to 96%. On analysis by funnel plot, studies were not symmetrically distributed 267 
about the pooled estimate possibly indicating an absence of some smaller and medium sized studies 268 
with findings that, although favourable, are not as favourable as other small studies. There are many 269 
possible reasons for this including chance, small study effects and publication bias. When this funnel 270 
plot asymmetry was adjusted for, the efficacy of one or more FMT infusions was only reduced by a 271 
small amount to 79% (95% CI 73% to 84%) (supplement 2). 272 
The case series had cure rates ranging from 68 – 100% with only one study having an overall 273 
response rate of under 75% and eight case series demonstrating a response rate of 100% (although 274 
there was incomplete follow up in some of these studies).  275 
Only one study addressed the efficacy of FMT for treatment of CDI in immunocompromised patients. 276 
30
 This study included a series of patients with IBD, solid organ transplants on immunosuppression, 277 
HIV and cancers. The CDI cure rate observed after a single FMT was 78%, with an overall cure rate of 278 
89% following a second transplant. 279 
Comparison between upper GI and lower GI routes of delivery 280 
The RCT that compared nasogastric (upper GI) versus colonic delivery of FMT reported a cure rate of 281 
60% at 8 weeks with a single infusion and an overall cure rate 80% after second infusion when 282 
delivered via NG.
28
 The cure rate with colonic delivery was 80% with a single infusion at 8 weeks and 283 
an overall cure rate of 100% after a second infusion. 284 
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Of the remaining studies, 25 case series and 7 RCTs had separate outcome data for modes of FMT 285 
delivery. 22 delivered FMT by the lower GI route (colonoscopy or retention enema) and 11 delivered 286 
FMT by the upper gastrointestinal route (upper GI endoscopy, nasogastric tube or naso-jejunal 287 
tube). Results are displayed in figure 3. The pooled response of CDI to lower GI-delivered FMT was 288 
95% (95% CI 92% to 97%) with likely moderate heterogeneity between the studies (I
2 
= 48%). When 289 
adjusted for funnel plot asymmetry overall response was 90%. This compared to the overall pooled 290 
response rate to upper GI FMT of 88% (95% CI 82% to 94%) with moderate observed heterogeneity 291 
between the studies and adjusting for funnel plot asymmetry revealed a response rate of 83%. There 292 
was evidence of a difference between the delivery methods with respect to response to FMT 293 
(p=0.02). Analysis of cure rate with a single infusion did not show a significant difference with route 294 
of delivery with a response of CDI of 81% (95% CI 73% to 88%) to lower GI-delivered FMT and of 87% 295 
(95% CI 79% to 94%) for upper GI-delivered FMT (p=0.20).  296 
Comparison of freshly prepared versus frozen FMT 297 
In the RCT by Lee patients received either FMT prepared no more than five hours earlier (n=111) or 298 
FMT frozen for up to 30 days (n=108).
24
 The clinical resolution of diarrhoea using intention to treat 299 
analysis showed no evidence of a difference in outcome between preparations, with a relative risk of 300 
failure to respond of 1.19 (95%CI 0.77,1.84) with a 70% response in the fresh FMT group and 75% in 301 
the frozen FMT group. This increased to 85.6% and 90.7% respectively when patients were given 302 
multiple infusions FMT due to lack of response.  303 
Of the other studies, thirty case studies used fresh stool and 4 studies (2 case series, 2 RCTs) used 304 
frozen stool to prepare FMT and a response rate was calculable for each group.  For the fresh FMT 305 
studies the overall response rate was 92% (95% CI 89% to 95%) with moderate heterogeneity 306 
between the studies (I
2 
= 54%). When adjusted for funnel plot asymmetry the overall response rate 307 
was 87%. The overall response in frozen FMT studies was 93% (95% CI 87% to 97%) with minimal 308 
observed heterogeneity between the studies (I
2 
= 19%).  There were insufficient studies to assess 309 
Page 13 of 156 Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 14
funnel plot asymmetry. There was no evidence of a difference in response between the two groups 310 
(p=0.84) (figure 4). Analysis of a single infusion revealed a response rate of 85% (95% CI 79% to 90%) 311 
for fresh FMT and a lower response rate of 68% (95% CI 47% to 86%) for frozen FMT but there was 312 
only very weak statistical evidence of a difference (p=0.10).. 313 
Adverse Events 314 
The RCT by Van Nood reported no significant adverse events (SAEs) in 16 patients treated with FMT, 315 
however there were two urinary tract infections and one patient suffered from choledocholithiasis. 316 
22
 No SAEs related to FMT were reported in other RCTs. Transient mild diarrhoea and cramping was 317 
very common in the FMT arm of three RCTs by Lee, Cammarota, Van Nood, and about 25% of the 318 
recruits in the RCT by Lee reported long term constipation and flatulence following FMT. Similarly, 319 
19% of patients in the FMT arm report d constipation in follow up period in the van Nood RCT. Mild 320 
abdominal pain and bloating was reported in 20% of patients treated by a frozen inoculum of FMT.
28
 321 
In the RCT by Kelly et al comparing FMT with autologous vs heterologous (donor) stool administered 322 
by colonoscopy, chills were observed more frequently in autologous group.
27
 Rates of other minor 323 
AEs did not differ significantly between groups.  324 
In the case series most side effects were minor and often transient: bloating, belching, abdominal 325 
cramps, pain or discomfort, nausea, vomiting, excess flatulence, constipation, transient fever, 326 
urinary tract infections, self-limiting diarrhoea, and irregular bowel movement. However, recurrent 327 
and refractory CDI negative diarrhoea or worsening diarrhoea following FMT was also reported 328 
although the duration of this adverse event was not reported.
37,44
 The data from these case series 329 
did not allow an assessment of any differences in adverse events by route of treatment or use of 330 
fresh or frozen transplant.  331 
There were no reported cases of aspiration following FMT delivery via the upper GI route. In one 332 
case the patient vomited immediately after FMT application via nasogastric tube.
45
 There was only 333 
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one reported case of mucosal tear and micro perforation following colonoscopic delivery of FMT. 334 
30,46
 Hospitalisation with self-limited FMT related abdominal pain, was reported in one patient.
30
 335 
There were 50 deaths reported in the studies reviewed, however these were almost all due to 336 
critical illness of elderly patients with multiple comorbidities or unrelated illness and were not 337 
directly attributed to the FMT.  However, there was a death as a result of aspiration at the time of 338 
sedation for the colonoscopy to administer the FMT.
30
  Two patients with recurrent diarrhoea and 339 
initial response to the FMT died subsequently from complications of ileus and colonic perforation 340 
Four deaths in patients infected with the ribotype 027 strain who did not respond to FMT and died 341 
within 3 months were also reported.
47
  342 
Of note, a case series of FMT in 80 immunocompromised patients with three month follow up did 343 
not report any serious adverse events.
30
 However, four patients with inflammatory bowel disease 344 
experienced a flare up of their condition after FMT.  Similarly a case series of 146 elderly patients 345 
that were followed up for one year did not report any serious adverse events.
48
 346 
 347 
DISCUSSION 348 
This systematic review and meta-analysis has demonstrated that FMT is a highly effective treatment 349 
for resolution of recurrent and refractory CDI.  Even the most conservative analysis gives an estimate 350 
of efficacy of a 49% response rate for FMT in this setting based on the lower prediction interval for a 351 
single infusion.  Previous systematic reviews and meta-analysis have reported the marked efficacy of 352 
FMT for treatment of CDI in the range of 88 to 92%, similar to our findings.
9,10
 These, however, pre-353 
dated or failed to include the five recent RCTs and included far fewer case series.
23,24
  There is good 354 
agreement between the efficacy demonstrated in observed response rates in the seven RCTs (only 355 
three of which have a non-FMT comparator arm) performed to date and the reports from case 356 
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series. The limited data on mortality and significant adverse events suggests that FMT is safe and 357 
generally well tolerated, even in sick immunocompromised elderly patients.
30
  358 
 No previous meta-analysis has compared fresh and frozen FMT in treatment of recurrent CDI, whilst 359 
the present study shows no difference in efficacy between these modes of stool preparation. The 360 
review also demonstrates that repeated infusions of FMT in non-responders resulted in a higher 361 
cure rate albeit with some limited data for this analysis.  Previous reviews have suggested that the 362 
efficacy for lower GI route is greater than upper GI route (Kassam et al, (91% vs 80% respectively 363 
(p=0.046)).
10
 We have however shown that this difference was no longer significant when efficacy 364 
with only a single infusion was analysed. 365 
With regard to attempting to differentiate between the efficacy of FMT for recurrent or refractory 366 
CDI, we found that the distinction between recurrent and refractory disease in the case series is 367 
often vaguely reported and not robust enough to allow for meaningful sub-group analysis. Similarly, 368 
previous reviewers have reported that no studies have compared refractory CDI to standard therapy 369 
and from the small numbers of patients being treated for solely refractory CDI meaningful analysis is 370 
difficult.
11,12
  371 
This systematic review and meta-analysis is a comprehensive ascertainment of the available 372 
evidence through a detailed search strategy, and includes the seven RCTs to date. Structured 373 
analyses were performed to address key issues with regards to storage and administration of FMT 374 
that may improve wider uptake of this treatment strategy. There are, however, limitations to our 375 
analysis.  Characterisation of initial /primary response depended on the authors’ definitions, hence 376 
varying between studies and being sometimes poorly defined. Although almost all studies defined 377 
initial response as resolution or improvement of diarrhoea, but the time to response varied from 1 378 
day to 90 days and the overall response varied from 7 days to 3 months. Most studies failed to 379 
report C. difficile toxin for assessment of clearance in several studies lacked long-term data. A recent 380 
paper has highlighted the high incidence of IBS after an attack of CDI.
48
 There was significant 381 
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variability of dose of FMT and several studies defined their clinical resolution following use of more 382 
than one infusion of FMT. The use of concomitant medications and other biases may be greatly 383 
underestimated given the retrospective nature of most of the case series included in this review.  384 
The data suggest that, irrespective of route of delivery or method of preparation repeated 385 
treatments have an incremental benefit. There are no clear strategies for this and guidelines are 386 
required, as well as additional RCTs to further determine the optimal dose and long-term outcomes 387 
and side effects of FMT are required. Finally, ‘corrected’ estimates calculated using the Trim and Fill 388 
method should be treated with great caution and as indicative as the method does not take into 389 
account reasons for funnel plot asymmetry other than publication bias and limited numbers to 390 
detect differences in subgroup analyses.
13
  391 
Included studies exhibited substantial heterogeneity in procedural aspects of FMT preparation and 392 
delivery. Donor screening appeared to be robust and studies consistently had strict exclusion criteria 393 
based on history of high-risk behaviours, recent antibiotic use and a comprehensive serology of 394 
blood borne viruses and stool cultures for pathogens.  FMT was prepared using water or saline along 395 
with glycerol in most studies. However the quantity and volume of stool and solvent used to prepare 396 
the transplant was very variable.  397 
Patients who underwent FMT via a lower GI route received a larger amount / concentration of FMT 398 
compared to those who had it delivered via the upper GI route. The number of infusions prior to 399 
achieving clinical resolution as defined by the authors also varied significantly between studies 400 
although most studies only gave a single infusion. There is little uniformity of practice with regard to 401 
treatment protocol with respect to the triggering of subsequent treatments after the first.  402 
This review is focussed on FMT and, as such, we have not included emerging data from 403 
investigations using faecal bacteriotherapy in which the microbiota is altered or in which specific 404 
bacteria are infused.
49,50
 405 
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Short-term adverse events were reported in almost all the studies however there was lack of 406 
consistency in long-term follow up for adverse events in uncontrolled studies and this was often 407 
reported on an ad-hoc basis. Follow up was also limited to 10 -13 weeks in RCTs. Most adverse 408 
events were self-limiting gastrointestinal symptoms including abdominal cramps, constipation, 409 
diarrhoea and usually occurred within 24 hours of the procedure and resolved within a week of the 410 
FMT. Deaths reported following FMT were almost always due to inter-current illness unrelated to 411 
CDI, FMT and overt failure to respond to FMT. On the whole the current evidence suggests a good 412 
short-term safety of FMT however data is limited and uncertainty remains concerning unrecognised 413 
long-term consequences.  It should also be noted that in this review studies were selected based on 414 
whether they reported an outcome related to resolution of CDI and that case series with less than 415 
ten patients were not analysed. Thus it could be argued that this review is not comprehensive of all 416 
studies that might report adverse events. 417 
Despite uncertainty FMT for the treatment of CDI associated colitis has been adopted as the 418 
biological rationale for its use is compelling and the treatment is cheap. The second line antibiotic 419 
treatment for CDI associated colitis after standard antibiotics (metronidazole and vancomycin) is 420 
fidaxomicin and this is vastly more expensive than FMT.
1
 Moreover, there is no current evidence for 421 
fidaxomicin in the treatment of recurrent CDI and as yet no direct comparison of the effectiveness of 422 
this antibiotic against FMT. 423 
In the UK NICE has approved FMT “for patients for with recurrent CDI that have failed to respond to 424 
antibiotics and other treatments”. 
2
 However, despite this official stamp of approval, standards of 425 
governance with respect to the procedure itself remain undefined. This is perhaps particularly 426 
pertinent now that manipulation of the microbiome is being considered in younger cohorts of 427 
patients for indications other than CDI associated colitis.
51,52
 428 
Most studies appear to comply with the donor screening criteria outlined by the American 429 
Gastroenterology Association.
53
,
54
 However there is no agreement as to what constitutes an 430 
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acceptable donor with respect to, for example, relatedness to the patient, lifestyle, diet, co-431 
morbidity, body mass index and there is no mandate with regard to follow up of donors.  Similarly no 432 
consensus exists about fundamental aspects concerning the actual process of delivering FMT. Some 433 
investigators use the upper GI route for the administration of FMT others (the majority of published 434 
studies) use colonoscopy or retention enemas. There is little evidence of uniformity with respect to 435 
stopping other treatments prior to FMT or concomitant treatments to be used to facilitate FMT. 436 
However despite a lack of consistent approach the clinical efficacy for FMT is universally positive and 437 
much greater than that seen with antibiotics. A recent International Consensus has highlighted the 438 
uncertainties concerning route of delivery, donor selection (household members/healthy 439 
volunteers), the place of routine pre-treatment with antibiotics and bowel preparation and, in light 440 
of long term safety concerns, the desirability of establishing a patient registry. 
55
The utility of frozen 441 
FMT has gained significant interest as it allows the ability to deliver treatment on demand and to a 442 
wider population. As a result recent regulatory discussions concerning FMT provision in the 443 
European Union have led to the situation that FMT use in the context of clinical trials is to be 444 
controlled by regulatory authorities.
56
  445 
Data is beginning to emerge regarding the association of microbiome alteration with response to 446 
FMT. In a recent study from the US, the authors reported specific gut microbiota signatures 447 
associated with response to or recurrence after FMT.
57
 This raises the possibility of predicting which 448 
patients may not respond to primary treatment with antibiotics and those then likely to need FMT.  449 
In another intriguing study from this group it was reported that microbiota changes associated with 450 
bile salt metabolism following FMT may also indicate patients likely to progress to recurrent CDI and 451 
the need for FMT.
58
 452 
In the future it is likely that we will see further data emerging from investigators who prepare 453 
“designer” FMT or by culturing specific organisms in vitro particularly as we better understand 454 
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microbiota profiles which differentiate health from disease and the profile which is associated with 455 
successful FMT.
49,50
 456 
In conclusion, FMT appears to be an effective and possibly a safe treatment strategy for recurrent 457 
and refractory CDI. The efficacy is similar in both controlled and uncontrolled studies. The current 458 
data is relatively heterogeneous with regards to the methodology for transplantation and the 459 
outcome measure for resolution of CDI. Whilst this could be explored with the current evidence base 460 
to refine estimates and potentially suggest effect modifiers, the effect of FMT on resolution of 461 
recurrent/refractory CDI markedly evident and appears to be quantitatively in excess of that seen 462 
with other antimicrobial therapies such as vancomycin. Further studies should be of robust design 463 
and focus on determining the optimal procedures and long-term outcomes and side effects of FMT 464 
in order that FMT is available to help alleviate the burden of this significant iatrogenic hazard. 465 
466 
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Figure 1. Flowchart of search 467 
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 484 
 485 
486 
Records identified through database 
searching 
(n = 2097) 
Additional records identified through 
other sources 
(n = 0 ) 
Records screened 
(n = 2097 ) 
Records excluded 
(n = 1794) 
Full-text articles assessed for 
eligibility 
(n = 303) 
Articles excluded  
(n = 266) 
• Systematic reviews – 19  
• Other reviews – 102  
• Case reports or case series 
with a sample size < 10 -  83  
• Case series only in an abstract 
format – 62) 
Studies included in 
qualitative synthesis  
(n = 37) 
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Figure 2 Forest plot of the proportion responding to treatment for all included studies  487 
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b) Single infusion 497 
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Figure 3. Forest plot of the proportion responding to treatment by Upper GI ad Lower GI routes of 507 
delivery. 508 
a) Multiple infusions 509 
Upper
Aas 2003 [33]
Allegretti 2016 [32]
Ganc 2015 [34]
Kronman 2015 [45]
MacConnachie 2009 [64]
Rubin 2013 [39]
Van Nood 2013 (FMT arm of RCT) [22]
Vigvari 2014 [72]
Youngster 2014 (NGT arm of RCT) [71]
Youngster 2014 [28]
Zainah 2015 [67]
Subtotal  (I^2 = 38.75%, p = 0.09)
Lower
Allegretti 2014 [42]
Brandt 2012 [68]
Cammarota 2015 (FMT arm) [23]
Costello 2015 [69]
Dutta 2014 [43]
Emmanuelson 2014 [70]
Hamilton 2012 [60]
Kao 2016 [26]
Kassam 2012 [61]
Kelly 2012 [36]
Kelly 2016 (donor FMT arm) [27]
Khan 2014 [62]
Lee 2014 [63]
Lee 2016 (Both FMT arms of RCT) [24]
Mattila 2012 [47]
Patel 2013 [46]
Pathak 2014 [65]
Ray 2014 [37]
Rohlke 2010 [38]
Satokari 2015 [40]
Yoon 2010 [41]
Youngster 2014 (Colonoscopy arm of RCT) [71]
Subtotal  (I^2 = 48.10%, p = 0.01)
Author
0.94 (0.70, 1.00)
0.95 (0.74, 1.00)
0.83 (0.52, 0.98)
1.00 (0.69, 1.00)
0.80 (0.52, 0.96)
0.79 (0.68, 0.87)
0.94 (0.70, 1.00)
0.97 (0.83, 1.00)
0.60 (0.26, 0.88)
0.90 (0.68, 0.99)
0.79 (0.49, 0.95)
0.88 (0.82, 0.94)
0.86 (0.65, 0.97)
0.91 (0.82, 0.96)
0.90 (0.68, 0.99)
1.00 (0.83, 1.00)
1.00 (0.87, 1.00)
0.70 (0.47, 0.87)
0.95 (0.84, 0.99)
1.00 (0.84, 1.00)
0.93 (0.76, 0.99)
0.92 (0.75, 0.99)
0.95 (0.77, 1.00)
1.00 (0.83, 1.00)
0.86 (0.78, 0.92)
0.88 (0.83, 0.92)
0.94 (0.86, 0.98)
0.97 (0.83, 1.00)
1.00 (0.74, 1.00)
1.00 (0.83, 1.00)
1.00 (0.83, 1.00)
0.96 (0.86, 1.00)
1.00 (0.74, 1.00)
1.00 (0.69, 1.00)
0.95 (0.92, 0.97)
ES (95% CI)
8.38
9.34
6.91
6.08
8.04
17.42
8.38
12.06
6.08
9.63
7.68
100.00
3.82
7.07
3.59
3.59
4.33
3.93
5.56
3.71
4.33
4.23
3.82
3.59
7.54
9.13
6.83
4.60
2.52
3.59
3.59
5.91
2.52
2.19
100.00
Weight
%
  
0 .2 .4 .6 .8 1
proportion responding
 510 
ES (95% CI) is the proportion responding with its 95% confidence interval. 511 
 512 
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b) Single infusion 514 
Upper
Aas 2003 [33]
Ganc 2015 [34]
Kronman 2015 [45]
MacConnachie 2009 [64]
Rubin 2013 [39]
Van Nood 2013 (FMT arm of RCT) [22]
Vigvari 2014 [72]
Youngster 2014 (NGT arm of RCT) [71]
Zainah 2015 [67]
Subtotal  (I^2 = 24.51%, p = 0.23)
Lower
Allegretti 2014 [42]
Brandt 2012 [68]
Cammarota 2015 (FMT arm) [23]
Costello 2015 [69]
Dutta 2014 [43]
Emmanuelson 2014 [70]
Hamilton 2012 [60]
Kao 2016 [26]
Kassam 2012 [61]
Kelly 2012 [36]
Kelly 2016 (donor FMT arm) [27]
Khan 2014 [62]
Lee 2014 [63]
Lee 2016 (Both FMT arms of RCT) [24]
Mattila 2012 [47]
Patel 2013 [46]
Pathak 2014 [65]
Ray 2014 [37]
Rohlke 2010 [38]
Satokari 2015 [40]
Yoon 2010 [41]
Youngster 2014 (Colonoscopy arm of RCT) [71]
Subtotal  (I^2 = 89.56%, p = 0.00)
Author
0.94 (0.70, 1.00)
0.83 (0.52, 0.98)
0.90 (0.55, 1.00)
0.73 (0.45, 0.92)
0.79 (0.68, 0.87)
0.81 (0.54, 0.96)
0.90 (0.73, 0.98)
0.60 (0.26, 0.88)
0.57 (0.29, 0.82)
0.81 (0.73, 0.88)
0.86 (0.65, 0.97)
0.88 (0.79, 0.95)
0.65 (0.41, 0.85)
0.85 (0.62, 0.97)
1.00 (0.87, 1.00)
0.65 (0.43, 0.84)
0.86 (0.72, 0.95)
1.00 (0.84, 1.00)
0.81 (0.62, 0.94)
0.92 (0.75, 0.99)
0.91 (0.71, 0.99)
0.90 (0.68, 0.99)
0.48 (0.37, 0.58)
0.52 (0.45, 0.58)
0.90 (0.80, 0.96)
0.87 (0.69, 0.96)
0.92 (0.62, 1.00)
1.00 (0.83, 1.00)
0.95 (0.75, 1.00)
0.96 (0.86, 1.00)
1.00 (0.74, 1.00)
0.80 (0.44, 0.97)
0.87 (0.79, 0.94)
ES (95% CI)
9.78
7.81
6.74
9.31
25.66
9.78
15.37
6.74
8.82
100.00
4.46
5.05
4.39
4.39
4.60
4.49
4.85
4.42
4.60
4.57
4.46
4.39
5.10
5.24
5.03
4.66
3.94
4.39
4.39
4.90
3.94
3.75
100.00
Weight
%
  
0 .2 .4 .6 .8 1
proportion responding
 515 
ES (95% CI) is the proportion responding with its 95% confidence interval. 516 
 517 
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Figure 4. Forest plot of the proportion responding to treatment by freshly prepared versus frozen 525 
FMT. 526 
a) Multiple infusions 527 
Fresh
Aas 2003 [33]
Agrawal 2016 [44]
Allegretti 2014 [42]
Brandt 2012 [68]
Cammarota 2015 (FMT arm) [23]
Dutta 2014 [43]
Emmanuelson 2014 [70]
Ganc 2015 [34]
Garborg 2010 [35]
Hamilton 2012 [60]
Kao 2016 [26]
Kassam 2012 [61]
Kelly 2012 [36]
Kelly 2016 (donor FMT arm) [27]
Khan 2014 [62]
Kronman 2015 [45]
Lee 2014 [63]
Lee 2016 (FMT) [24]
MacConnachie 2009 [64]
Mattila 2012 [47]
Patel 2013 [46]
Pathak 2014 [65]
Ray 2014 [37]
Rohlke 2010 [38]
Rubin 2013 [39]
Tauxe 2016 [66]
Van Nood 2013 (FMT arm of RCT) [22]
Vigvari 2014 [72]
Yoon 2010 [41]
Zainah 2015 [67]
Subtotal  (I^2 = 54.20%, p = 0.00)
Frozen
Costello 2015 [69]
Lee 2016 (FMT) [24]
Youngster 2014 (Both FMT arms) [71]
Youngster 2014 [28]
Subtotal  (I^2 = 19.14%, p = 0.29)
Author
0.94 (0.70, 1.00)
0.83 (0.76, 0.89)
0.86 (0.65, 0.97)
0.91 (0.82, 0.96)
0.90 (0.68, 0.99)
1.00 (0.87, 1.00)
0.70 (0.47, 0.87)
0.83 (0.52, 0.98)
0.82 (0.67, 0.93)
0.95 (0.84, 0.99)
1.00 (0.84, 1.00)
0.93 (0.76, 0.99)
0.92 (0.75, 0.99)
0.95 (0.77, 1.00)
1.00 (0.83, 1.00)
1.00 (0.69, 1.00)
0.86 (0.78, 0.92)
0.86 (0.78, 0.92)
0.80 (0.52, 0.96)
0.94 (0.86, 0.98)
0.97 (0.83, 1.00)
1.00 (0.74, 1.00)
1.00 (0.83, 1.00)
1.00 (0.83, 1.00)
0.79 (0.68, 0.87)
0.87 (0.70, 0.96)
0.94 (0.70, 1.00)
0.97 (0.83, 1.00)
1.00 (0.74, 1.00)
0.79 (0.49, 0.95)
0.92 (0.89, 0.95)
1.00 (0.83, 1.00)
0.90 (0.83, 0.95)
0.90 (0.68, 0.99)
0.90 (0.68, 0.99)
0.93 (0.87, 0.97)
ES (95% CI)
2.44
5.77
2.95
5.00
2.80
3.30
3.03
2.02
3.97
4.09
2.88
3.30
3.23
2.95
2.80
1.78
5.27
5.47
2.34
4.86
3.48
2.02
2.80
2.80
4.96
3.53
2.44
3.48
2.02
2.24
100.00
15.70
52.91
15.70
15.70
100.00
Weight
%
  
0 .2 .4 .6 .8 1
proportion responding
 528 
ES (95% CI) is the proportion responding with its 95% confidence interval. 529 
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b) Single infusion 536 
Fresh
Aas 2003 [33]
Agrawal 2016 [44]
Allegretti 2014 [42]
Brandt 2012 [68]
Cammarota 2015 (FMT arm) [23]
Dutta 2014 [43]
Emmanuelson 2014 [70]
Ganc 2015 [34]
Garborg 2010 [35]
Hamilton 2012 [60]
Kao 2016 [26]
Kassam 2012 [61]
Kelly 2012 [36]
Kelly 2016 (donor FMT arm) [27]
Khan 2014 [62]
Kronman 2015 [45]
Lee 2014 [63]
Lee 2016 (FMT) [24]
MacConnachie 2009 [64]
Mattila 2012 [47]
Patel 2013 [46]
Pathak 2014 [65]
Ray 2014 [37]
Rohlke 2010 [38]
Rubin 2013 [39]
Tauxe 2016 [66]
Van Nood 2013 (FMT arm of RCT) [22]
Vigvari 2014 [72]
Yoon 2010 [41]
Zainah 2015 [67]
Subtotal  (I^2 = 82.54%, p = 0.00)
Frozen
Costello 2015 [69]
Lee 2016 (FMT) [24]
Youngster 2014 (Both FMT arms) [71]
Subtotal  (I^2 = 77.32%, p = 0.01)
Author
0.94 (0.70, 1.00)
0.83 (0.76, 0.89)
0.86 (0.65, 0.97)
0.88 (0.79, 0.95)
0.65 (0.41, 0.85)
1.00 (0.87, 1.00)
0.65 (0.43, 0.84)
0.83 (0.52, 0.98)
0.73 (0.56, 0.85)
0.86 (0.72, 0.95)
1.00 (0.84, 1.00)
0.81 (0.62, 0.94)
0.92 (0.75, 0.99)
0.91 (0.71, 0.99)
0.90 (0.68, 0.99)
0.90 (0.55, 1.00)
0.48 (0.37, 0.58)
0.50 (0.41, 0.60)
0.73 (0.45, 0.92)
0.90 (0.80, 0.96)
0.87 (0.69, 0.96)
0.92 (0.62, 1.00)
1.00 (0.83, 1.00)
0.95 (0.75, 1.00)
0.79 (0.68, 0.87)
0.77 (0.59, 0.90)
0.81 (0.54, 0.96)
0.90 (0.73, 0.98)
1.00 (0.74, 1.00)
0.57 (0.29, 0.82)
0.85 (0.79, 0.90)
0.85 (0.62, 0.97)
0.53 (0.43, 0.62)
0.70 (0.46, 0.88)
0.68 (0.47, 0.86)
ES (95% CI)
2.97
4.13
3.25
3.96
3.17
3.40
3.28
2.70
3.66
3.70
3.21
3.40
3.37
3.25
3.17
2.51
4.02
4.07
2.91
3.92
3.48
2.70
3.17
3.17
3.95
3.50
2.97
3.48
2.70
2.85
100.00
29.87
40.25
29.87
100.00
Weight
%
  
0 .2 .4 .6 .8 1
proportion responding
 537 
ES (95% CI) is the proportion responding with its 95% confidence interval. 538 
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Name, Year 
Type of study i.e RCT, case 
control etc
No. of patients, years, location,
selection criteria,
Mean or median age, Gender 
distribution;
other
Diagnosis of C.diff i.e 
Elisa/PCR, 
duration from diagnosis to 
transplant
Aas 2003 Case series
19 recruited over 9 years (1994-2002) 
at a single centre (USA); two or more 
lab confirmed relapses after initial 
specific AB treatment, adequate clin 
and lab documentation of post 
transplant course; Mean age 73+9 
(SEM) (Range: 51-88 years); F: 13/18 
(72%); Hospitalised=5; nursing 
home=3; outpatient-GI clinic=10)
Lab confirmed via stool 
sample, toxin A only, then 
B added from 2001.
2 or more positive test 
stool tests (mean 3.2, 
range 2-7).
Mean period from 
diagnosis of c/diff colitis 
and stool transplantation 
102+24 (SEM) days (range 
25-497)
Allegretti 2016
Open label cluster dose finding 
trial comparing low dose (30 
pills) vs high dose (30 pills on 2 
consecutive days)
19-age/gender not stated
Diagnosis method not 
stated
Cammarota 2015 Open label RCT
prospective RCT comparing FMT plus 
vancomycin to vancomycin therapy 
alone for recurrent CDI; 39 patients 
over 12 months July 2013 to June 
2014; single centre; FMT group (n=20) 
mean age 71 years (range 29-89) F 12 
(60%); Vanc group (n=19) mean age 
75 (49-93) F 11 (58%)
CDI diagnosis was based on 
symptoms and toxin 
confirmed in 23/39(59%) 
positive ulture.mean 
duration of CDI diagnosis 
prior to FMT not stated
Fischer 2016 Retrospective cohort study
Of 328 patients in the developmental 
cohort, 73.5% (N=241) were females 
with a mean age of 61.4±19.3 years; 
19.2% (N=63) had inflammatory 
bowel disease (IBD), and 23.5% 
(N=77) were immunocompromised. 
Two academic centres. 2011-
2015. Of 134 patients in the 
validation cohort, 57% (N=77) 
were females with a mean age of 
66±18.1 years; 9.7% (N=13) had 
IBD, and 17.9% (N=24) were 
immunocompromised. Single 
centre. 2011-2015
Diagnosis of Cdiff if 
recurrent at least 3 
episodes of CDI and failure 
of 6-8 week vancomycin 
taper. Severe based on 
albumin, elevated white 
cell count and abdominal 
pain. Severe complicated 
defined as admission to ITU 
hypotension, fever, ileus, 
reduced GCS, elevated 
white cell count and lactate 
with end organ 
dysfunction.
Study details
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Ganc 2015 Case series, retrospective
12 patients. No other variables 
reported
Not reported
Garborg 2010 Case series, retrospective
39 patients (one had 2 FMTs). 
Treated single centre 1994-2008. 
Mean age 75y (range 53-94). F=21 
(53%)
Toxin positivity or clinical 
findings (37/40 toxin 
positive)
Hamilton 2012 Case series
43 patients. Single centre.  29 non-IBD 
and 14 IBD patients. Non IBD cohort 
(mean age 64.7y SEM 3.3; F 20 (69%)); 
IBD cohort (mean age 44.6 SEM 5.8; F 
11 (79%))
Inclusion criteria for FMT 
included a history of 
symptomatic, toxin-
positive, infection by C. 
difficile, and at least two 
documented subsequent 
recurrences despite use 
of standard antibiotic 
therapy.
Kao D 2016 - abstract (FMT 
arm of RCT)
Double blind RCT (capsule vs 
fresh)
43 patients, mean 67 years, F:30/43 
(70%). Two centres. 22 capsule 
group and 21 in colonoscopy group
Not reported
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Kassam 2012 Case series
27 patients: the mean age was 69.4 
years (range, 26-87 years) with 14 
male subjects (52%) and 22 in-
patients (81%).
Inclusion criteria were (1) 
laboratory-confirmed C 
difficile toxin using 
enzyme immunoassay 
with no other cause for 
diarrhea; (2) refractory 
CDI (defined as ongoing 
diarrhea despite 
antimicrobial treatment) 
or recurrent CDI (defined 
as symptom resolution 
for at least 2 days after 
discontinuation of 
treatment with 
recurrence of diarrhea); 
Kelly 2012 Case series
26 recruited over 28 months;single 
centre;at least 3 recurrences of CDI 
following multiple antibiotic 
courses;adequate clinical and lab 
documentation post transplant; Mean 
age 59 (19-86 yrs); F: 24/26 (92%)
Method of CDI diagnosis 
not stated;mean duration 
of diagnosis of CDI prior to 
FMT 12.6 M (range 4 to 84 
M);
Kelly 2014 Case series
retrospective study of 
immunocompromised patients 
receiving FMT for CDI; 80 patients 
data analysed from 16 
centres;eligibilty assessed by 32 point 
questionairre;75 adults and 5 
children; Mean age in Adults 53 
(range 20-88) in children 10.9 (range 
6.5-16); Adults (n=75) F:38 (48%)
4 categories; 1 
recurrent/relapsing at least 
3 episodes with failure of 
up to 8 week taper with 
vancomycin or at least 2 
episodes of severeCDI 
resulting in hospitalisation 
and associated with 
significant morbidity.2 
Refractory CDI-moderate 
CDI not responding to 
standard therapy for at 
least a week 3 Severe CDI 
elevated WBC., low 
albumin and abdominal 
tenderness. 4 complicated 
CDI- Admission to ITU, low 
blood pressure, fever, ileus, 
mental state changes, 
elevated WBC, high lactate 
and evidence of end organ 
failure
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Kelly 2016
Double blind RCT (donor vs 
autologous FMT)
46 patients . Two centres. Donor 
FMT group n=22, mean age=48 
(SD 16); F=18 (82%); Autologous 
FMT group n=24, mean age = 
55(SD 14), F=19 (79%).
≥3 unformed stools over 24 
hours for 2 consecutive 
days and either a positive 
stool test result for C 
difficile or 
pseudomembranes on 
colonoscopy 
Khan 2014 Case series
retrospective analysis of 20 cases over 
13 months (July 2012 to Aug 2013); 
selection criteria: all patients recieving 
FMT for CDI at their centre; single 
centre; adequate post transplant 
documentation and assessment; 
Demographic data presented 
seperately for community aquired and 
hospital aquired CDI; Calculated 
Overall Mean age 66.4 years; F 13 
(65%); Mean number of CDI episodes 
pre-FMT:5.6 community aquired and 
4.6 for hospital aquired
Method of CDI diagnosis 
not stated; data presented 
seperately for community 
aquired CDI and hospital 
aquired CDI; median 
duration of symptoms pre 
FMT for community 
aquired CDI was 7 months; 
5 months for hospital 
aquired CDI
Kronman 2015 Case series
retrospective study of 10 children in 
single centre over 3 years (between 
Aug 2011 and May 2014); At least 3 
episodes of CDI; adequate post 
transplant documentation and 
assessment; Mean age 5.4 years; F 
7/10 (70%);
C diff toxin A&B and/or 
PCR; median duration of 
symptoms pre-FMT 250 
days (range 90-541 days);
Lee 2014 Case series
retropsective analysis of 94 patients 
from 2008-2012; single centre; 
mixture of recurrent and refractory 
CDI definitions given; Mean age 71.8 
years (range 24-95 years); F 53/94 
(56.4%) 
C diff toxin A&B and/or 
PCR; duration of symptoms 
pre-FMT not stated
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Lee CH 2016 (FMT arm of 
RCT)
FMT arm of double blind RCT 
(Fresh vs Frozen)
219 patients, mean 73 years, 
F:146/219 (67%)
Toxin and PCR
MacConnachie 2009 Case series
retrospective analysis of 15 patients 
since 2003;single centre; recurrent 
CDI following succesful antibiotic 
therapy; Median age 81.5years (range 
68-95); F 14/15 (93.3%)
Method of CDI diagnosis 
not stated;mean duration 
of diagnosis of CDI prior to 
FMT not stated
Mattila 2012 Case series
70 patients over 3 years (2007-2010) 
all laboratory confirmed recurrent CDI 
refractory to standard treatment. 
Mean age 73(22-90) F=42(60%). 
60(86%) outpatients
positive culture and toxin; 
strain typing . Time from 
diagnosis to CDI mean 133 
days (46-360). 36(51%0 
had ribotype 027
Patel 2013 Case series
31 patients over 2 years (2011-2013) 
all had recurrent (at least 2 previouslt 
documented CDI episodes). Mean age 
61 (SD19) F=17(55%).17/31 (55%) gi 
comorbdiity. Diverticulitis (5), IBS (5), 
UC (3), CD(2), gastroparesis (1), 
coloanal fistula(1)
Diagnosis method not 
stated. Medain time(range) 
from index diagnosis to 
FMT 340 days(18-2205)
Pathak 2014 Case series
12 patients with recurrent or relapsing 
CDI with at least 3 episodes and 
failure of treatm nt with vancomycin 
+/- additional antibiotic such as fidox 
or patients wuth at least two episodes 
of severe CDI or patients with 
moderate CDI not responding to vanc 
for a week or patients with 
severe/fulminant CDI not responding 
to standar treatment for 48 h. 12 
patients over 3 years. mean age 72 
(SD 15) range 37-90; F 8/12 (67%) 
Diagnosis method not 
stated
Ray 2014 Case series
20  (August 2012-November 2013) 2 
recurrences as defined by diarrhoea 
OR positive Cdiff after antibiotics 
(m,v,or f). Or if life threatening  
and/or admission to ICU. 20 patients 
mean age 62 (SD 18). F 16(80%). 15 
(75%) out patients. Average time from 
diagnosis to FMT 49.6 weeks
Diagnosis method not 
stated
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Rohlke 2010 Case series
19 patients over 5 years(September 
2004-July 2009). At lesat 3 courses or 
treatment included vanc amn tapered 
vanc over 6 months.Mean age 49 (SD 
15). F17 (90%). All out-patients
Diagnosis method 
confirmed by lab in all 
cases but method not 
specified
Rubin TA 2013 Case series, retrospective
74 patients (75 courses), mean age 63 
years, F 49/74 (65%)
Diagnosis of CDI confirmed 
by lab only in a few cases. 
Method not specified.
Satokari R 2015 Case series, retrospective
49 patients, mean age 56 years, F 
34/49 (69)
Culture and toxin
Tauxe 2016 Case series, retrospective
31 patients, mean age 77 years, F 
18/31 (58%)
Not reported
Yoon 2010 Case series, retrospective
12 patients, mean age 66 years, F 
9/12 (75%)
Toxin positivity or clinical 
findings
Youngster2014 Case series, prospective
20 patients, Median age 64.5; F 9/20 
(45%). Exclusion criteria - delayed 
gastric emptying synd, recurrant 
aspiration, pregnancy, significant 
immunocompromise, history of signif 
food allergy to food included in donor 
diet.
Toxin and ELISA, PCR if 
toxin negative but ELISA is 
positive or indeterminate
Zainah 2015 Case series, retrospective 14 patients, mean age 73 years, 
C. difficile toxin EIA and/or 
PCR
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Brandt LJ 2012 Case series, retrospective
77 patients in 5 centres, mean age 65, 
F 56/77 (73%). 
Not reported
Allegretti 2014 Case series, retrospective
22 patients, mean age 55, F 18/22 
(82%)
C. difficile toxin EIA and/or 
PCR
Costello 2015 Case series, prospective
20 patients , median age 69 years, 
gender distribution not reported 
Not reported
Agrawal 2016
multicentre, retrospective, lon 
term follow up study
146 patients, 100 (68.5%) women; 
mean age (range) 79. 
Not reported
Dutta 2014 Case series, prospective
27 patients, mean age 64.5y, F 22/27 
(81.5%)
Cdiff toxin positivity by 
ELISA
Emmanuelson 2014 Case series, retrospective 23 patients, mean age 66y, F 61% Culture and/or toxin EIA
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Van Nood 2013
FMT arm of RCT (FMT versus 
vancomycin)
From January 2008 through April 
2010, 43 patients were randomly 
assigned to receive donor-feces 
infusion (17 patients), vancomycin 
(13), or vancomycin and bowel lavage 
(13). One patient assigned to receive 
donor-feces infusion was 
subsequently excluded from further 
analysis. Baseline demographics per 
groups: Donor Feces Infusion: 16 
patients; mean age +/-SD (73 +/-13); 
F: 8/16 (50%); Vancomycin only: 13 
patients; mean age +/-SD (66 +/-14); 
F: 7/13 (54%); Vancomycin and Bowel 
Lavage: 13 patients; mean age +/-SD 
(69 +/-16); F: 3/13 (23%)
Toxin and PCR. In 39 
patients, a positive toxin 
test before inclusion was 
confirmed by a positive 
C.difficile  culture. PCR 
ribotyping was performed 
on strains obtained from 
34 patients
Youngster 2014
FMT arm of open-label RCT (NG 
versus colonic delivery of FMT)
37 patients were assessed for 
eligibility and 20 patients underwent 
randomisation: Colonoscopy arm: 10 
patients, mean age +/-SD (50.4 +/-
28.8); F:6/10 (60%); Nasogastric 
tube:10 patients; mean age +/-SD 
(58.6 +/- 19.6); F: 5/10 (50%)
Toxin: initial 
toxin/glutamate 
dehydrogenase (GDH) 
enzyme-linked 
immunosorbent assay, 
followed by PCR only if the 
GDH test is positive or 
indeterminate, and does 
not routinely test for the 
NAP-1/B1/207 strain
Vigvari 2014 Case series, retrospective
30 patients, mean age 70.1 years (26-
88 years), Female: 18/30 (60%)
Not reported
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Pre FMT Abx +/- other therapy 
(M,V,Fidox,IVG)/How many courses 
i.e M(2), V(1), IVG(1), Fidox(1).
Were abx stopped prior to FMT
Refractory / Recurrent Flexi sigi / Colonoscopy findings
Healthy 
volunteer/Spouse/Related i.e 
mother/Other non related i.e 
friend
Mean 3.6 courses of abs (range 2-7)
abs varied (Clm, Cm, Cpfx, Ctri, Ctox, 
Amp, Gm, Clex, Mtz, Pen, Pip, tMp-
SMZ, Taz, Lev, Tet, Vm) number of 
courses prior to transplant varied: 2-7;
Recipients were pre-treated with vm 
(250mg q8h) for 4 or more days and 
this was discontinued the night before 
transplant.
recurrent (two or more lab confirmed 
relapses)
Not reported
15/18 were family members 
of recipient; no member 
availabe for remaining 3 so 
donors were healthy clinic 
staff. Hierachy of ideal donor 
described: intimate physical 
contact with patients 
(spouse/partner) > family 
houshold member > other 
healthy donor
Not stated Not stated Not reported
Healthy donors from 
OpenBiome stool bank mean 
age 36 years
All patients had antibiotics prior to 
diagnosis of CDI  but specifics not 
stated; FMt group patients had 3 days 
vanc prior to FMT which stopped the 
day before; vanc group had 10 days of 
standard vanc followed by at least 
three weeks of pulsed vanc
recurrent with lab confirmation
6 out of 20 patients in FMT group 
had pseudomembranous colitis
Healthy volunteers less than 
50 years old from which 16/20 
donors related; 2 intimates; 2 
unrelated
Not reported
split into refractory, recurrent and 
severe complicated
Colonoscopies done on most
Mix of healthy volunteers (319 
69%) and family (143 31%)
Patient characteristics Donor Characteristics
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Not reported Recurrent N/A
The donor is usually a family 
member of the patient who 
meets certain criteria, such as 
not having used antibiotics in 
the previous six months, being 
immunocompromised, and 
having no history of illicit drug 
use, tumors or inflammatory 
bowel disease. 
The patients were treated with 
metronidazole or vancomycin until 
reduction of symptoms. All anti- 
microbial therapy was discontinued on 
the evening prior to stool 
transplantation.
Recurrent
1 patient with 
pseudomembranous colitis
Close relatives or other 
household members were 
selected as stool donors. 
Individuals without symptoms 
of gastrointestinal disease or a 
history of chronic infectious 
disease were considered 
suitable for stool donation. 
At least one failed antibiotic regimen 
had to include a minimum of a 6-week 
course of tapered or pulsed 
vancomycin dosage, or at least a 1-
month vancomycin course followed by 
a minimum of 2-week rifaximin 
“chaser.” 
Recurrent Not reported
patients were asked to self-
identify potential donors. 
These included mothers (n=2), 
daughters (n = 1), sons (n = 3), 
wives (n = 1), husbands (n = 1), 
and friends (n = 2).
Not reported Recurrent Not reported Unrelated volunteers
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All had at least metronidazole; 19 
had subsequent vancomycin 
monotherapy. 8 had combination 
metronidazoleand vancomycin 
therapy.
Recurrent or refractory Not reported
Two healthy volunteers served 
as donors and were evaluated 
for transmissible pathogens. 
The donors took no 
antibiotics for 6 months 
prior to stool donation. 
antibiotics prior to CDI diagnosis- clind, 
cipro, metro, moxiflox, levoflox, 
azithro, cefurox, amox, augmentin; 
treatment for CDI-all had 
metronidazole, Sacchromyces 
bourladii, 4 had lactobacillus, 2 had IV 
IG, 19 had had rifaximin; pre-FMT all 
had 2 weeks of metronidazole or vanc, 
discontinued 2-3 days before FMT
recurrent at least 3 episodes (lab 
confirmation not stated)
11 had diverticular disease; 3 had 
colitis; 8 normal; 2 polyps; 2 
haemorrhoids; 2 previous surgery
25/26 family memebers; 1 
friend
79/80 had been treated with 
vancomycin. 55/80 had metronidazole, 
23 had fidaxomicin, 13 had rifaximin 
and 30 had probiotics
recurrent CDI (at least 3 episodes and 
failure of vanc taper for 6-8 weeks); 
refractory (no improvement after 1 
week of vanc); Severe CDI or 
complicated (definitions given)
Not reported Not reported
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3 or more recurrences of CDI and 
received a full course of vancomycin for 
their most recent acute episode.
Recurrent Colonoscopies done on all
All prospective donors 
underwent a medical 
interview and physical 
examination and were 
excluded if they had a known 
communicable disease, 
features of the metabolic 
syndrome, a diarrheal 
disorder, an autoimmune or 
atopic disease, a tumor, a 
neurologic disorder, or chronic 
pain syndrome or if they had 
used antibiotics for any 
indication within 3 months. 
Potential donors also 
completed a modified AABB 
full-length donor history 
questionnaire, and those with 
risk factors for infectious 
agents were ex- cluded 
(Supplement). 
Antibiotic treatment for CDI: 
metronidazole (1 patient had 1 course; 
7 patients had 2 courses; 12 patients 
had 3 courses); vancomycin (2 patients 
had 1 course; 12 patients had 2 
courses; 4 patients had 3 courses; 2 
patients had pulsed vanc); 9 had 
fidaxomicin; all antibiotics stopped 48 
hours before FMT
not explicityly stated but patients had a 
mean of 4.6-5.6 episodes of CDI prior 
to FMT
Not reported
5/20 from spouse/partner; 
14/20 family member;1 non-
relative
Antibiotics used prior to CDI diagnosis-
metronidazole, augmentin, ampicillic, 
amoxycillin, cefdinir, cefuroxime, 
penicillin; CDI tretament all had 
metronidazole, 6/10 had vancomycin, 
8/10 had vancomycin taper; pre-
transplant all had vanc or fidaxomicin 
for 7 days, last dose given 24 hours pre-
transplant
recurrent CDI; mean of 3.2 episodes 
pre-FMT
Not reported 9/10 parents; 1 sibling
Mean of 2,1 courses of antibiotics for 
CDI prior to FMT (metronidazole 79.3%, 
vancomycin 75%, vancomycin taper 
15.2%, combination metro and vanc 
17.4%, 3 patients had IVIG); pre-
tranplant all antibiotic therapy for Cdi 
was discontinued 24 hours before FMT
recurrent (recurrent diarrhoea after at 
least 2 days of resolution following 
antibiotic therapy) or refractory 
(ongoing diarrhoea despite at least 5 
days of oral vancomycin)
Not reported 2 unrelated donors
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Metronidazole and Vancomycin Both Not reported Unrelated volunteers
Antibiotics prior to CDI diagnosis not 
stated; 15/15 received 
metronidazole;15/15 received vanc, 3 
received iVIG; vanc given pre-
procedure but length of course not 
stated; stopped 12 hours before FMT
recurrent CDI defined as recurrence of 
diarrhoea after successful antibiotic 
therapy typically within 7 days of 
stopping antibiotics; 
Not reported
related donors specifics not 
given
mean 4.5 courses of antibiotics. Metro, 
vanc, rifax, 1 IVIGStopped 36 hours 
before FMT
recurrent (two or more lab confirmed 
relapses)
Not reported
61(87%) family members; 
9(13%) healthy donors
Stopped (usually vanc) 4 hours before 
bowel prep. Loperamide 4mg either 
before or immediately after FMT
recurrent (two or more lab confirmed 
relapses)
Not reported
"Mostly" family. 14 spouses, 9 
children, 5 siblings, 3 parents, 
1 niece, 1 friend
Antibiotics stopped 24 hours prior to 
procedure
Refractory / Recurrent and severe
8 colitis, 1 Cdiff, 1 haemorrhoid, 1 
pseudomembranous colitis, 1 
diverticulosis
10 family, 2 spouses
Antibiotics stopped 48 hours prior to 
procedure
16 recurrent; 4 severe/complicated Not reported
10 family, 8 spouses, 2 healthy 
donors
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Antibiotics stopped 1-3 days before 
FMT
recurrent Not reported
4 family, 14 partner, 1 
housemate
Vancomycin and / or metronidazole Recurrent Not reported Healthy household members
Not reported Refractory Not reported
Frozen stool: 2 unrelated 
donors. Fresh stool: Family 
members, healthy volunteers, 
or the same universal donors.
Combinations of Vancomycin, 
Metronidazole, Fidoxamicin, Rifaximin
Both Not reported
7 were from family members, 
rest were volunteers
Combination of metronidazole, 
vancomycin,
rifaximin, bacitracin, nitazoxanide
Both
9/12 normal colonic mucosa, 3/12 
had pseudomembranes
All family members (partner:8; 
child or grandchild:4)
Failed vancomycin taper and or 
fidaxomycin. 
Refractory or recurrent. Defined 3 
episodes of mild to moderate CDI or 
failure of 6-8 week taper with 
vancomycin, or atleast two episodes of 
severe CDI resulting in hospitalisation 
and associated with significant 
morbidity. Active CDI defined as more 
than 3 loose stools per day with a 
positive stool test.
Not reported Unrelated adult volunteers
Vancomycin and / or metronidazole Both Not reported
12 from family members, 1 
from unrelated volunteer
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Failed on average of five conventional 
antimicrobial regimes; including 
metronidazole (81%), vancomycin (99% 
standard and pulsed) and/or tapered 
regime with or without rifaxmin (22%) 
or probiotics (77%).
Recurrent CDI (unresponsive to 
standard therapy)
Not reported
60% partners/spouses; 27% 
were either first degree 
relatives or otherwise related 
to the patient. ; one case - 
unknown person.  In all, 56 of 
77 donors resided in the same 
household as patient.
Several but eligibility included starting 
vancomycin for 7 days before 
procedure and stopping day before
Both. Relapsing defined as three or 
more episodes of CDI or refractory 
disease that is unreponsive to 
traditional antibiotics.
Not reported
Patient identified donors-
spouse, family, friend. My co-
inhabit
Not reported Recurrent disease Not reported Healthy volunteers 
Conventional therapy with met, van 
and/or fidaxomicin had failed in all. 
Some takinh probiotics. Om average 
Recurrent defined as recurrentce of 
diarrhoea after completion of 
treatment. Severe CDI defined as low 
Not reported
Donors usually identified by 
patient. One healthy volunteer 
not identified by patient
Most patients received metronidazole 
and/or vancomycin Other antibiotics 
included fidaxomicin, rifaximin.
Recurrent (>2 recurrences)
Active colitis seen in 26/27 
patients with pseudomembranes 
in 2
Healthy donors selected via 
thorough clinical evaluation to 
exclude any transmissible 
disease. 10 spouse, 12 son or 
daughter, 1 parent, 4 friends.
Metronidazole and/or Vancomycin Relapsing and recurrent Not reported
Spouse or close relative of 
good health
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At least one course of adequate 
antibiotic therapy (>=10 days of 
Vancomycin at a dose of >=125mg four 
times a day or >=10 days of 
Metronidazole at a dose of 500mg 
three times per day). In FMT group: 
patients received an abbreviated 
regimen of Vancomycin (500mg orally 
four times per day for 4 or 5 days), 
followed by bowel lavage with 4 liters 
of macrogol solution (Klean-Prep) on 
the last day of antibiotic treatment and 
the suspension of donor feces through 
a nasoduodenal tube the next day
Recurrent Not done
Healthy volunteers <60 years 
of age (faces from 15 donors 
were used for 43 infusions in 
the infusion group and for 
patients who had a relapse 
after vancomycin treatment)
Patients had a median of 4 (range, 2-
16) relapses prior to study enrollment, 
with 5 (range, 3-15) antibiotic 
treatment failures of a 6- to 8-week 
taper with Vancomycin (95% of 
patients) with or without an alternative 
antibiotic, including Fidaxomicin (70% 
of participants).Patients were required 
to discontinue all antibiotics at least 48 
hours prior to the procedure
Relapsing or recurring (having at least 3 
episodes of mild-to-moderate CDI OR 
at least 2 episodes of severe CDI 
resulting in hospitalization and 
associated with significant modbidity
Not reported
Healthy volunteer donor: 
nonpregnant adults, 18-50 
years of age, on no 
medications, with a normal 
body mass index
Not clear from paper, but it appears 
most patients had vancomycin
Refractory and recurrent Not reported
Donors were relatives in 22 
cases (73.3%) and unrelated 
volunteers in 8 cases (26.7%).
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Screening and abx cessation
Fresh/Frozen, Route 
administered
Sample preparation
Transplant sample sourcing, screening, preparation;
, volume, mixing solution, storage and time from 
collection to transplant 
Proceedure:
Bowel Prep/Drugs used prior 
to FMT i.e Moviprep 2 
sachets/PPI (dose), prokinetic 
(dose), Loperamide
FMT administration
Follow up method
Within 30 days before donation 
(usually 7 days) screened: 
Blood:HAV (HAV ab (IgM and IgG), 
HBV (ab to HepB surface antigen 
and core antigen), HCV (HCV ab 
RIBA-II), HIV-1 & 2 (EIA), 
Treponema pallidum (rapid plasma 
reagin test). 
Stool: C diff (Toxin A or B 
(cytotoxin) detection), enteric 
bacterial pathogens (selective 
stool culture), ova/parasites (light 
microscopy)
No antimicrobial therapy in 
previous 6 months
Fresh
nasogastric, with tube 
placement on morning 
of transplant and tube 
tip placement 
confirmed by 
radiography
Stool obtained 6 or less hours prior to transplant. 
Approx 30g or 2cm
3
 preferably soft stool selected and 
homogenised in 50-70ml 0.9N sterile saline (household 
blender - slow speed setting initially, rising gradually to 
maximum and continued then for 2-4 min) until sample 
smooth. Filtered through coffee paper filter x2 allowing 
adequate time for slow filtration to end.  
20mg omeprazole evening 
before and morning of 
transplant. 
25ml of stool suspension 
adminitered then tube flushed 
with 25ml sterile 0.9N saline.
Tube removal. Normal diet 
and physical activites allowed 
immediately.
Follow up by telephone or 
clinic visit and stool specimens 
examined for c.diff toxin A in 
most patients.
open Biome Criteria followed Frozen pills Not stated Not described
no antibiotics for 6 months; stool 
tested for C. diff , enteric 
pathogens, ova and parasites, 
MDR gram nehgatives, MRSA, VRE;  
Serum tested for Hep A, Hep B, 
Hep C, HIV 1 and 2, strongyloides, 
treponema, Entamoeba. High risk 
lifestyle, FH of GI cancer, IBD, 
systemic diseases, personal GI 
disease
fresh via colonoscopy
Mean time from donation to infusion was 3.8 
hours;mass of donation not stated but mixed with 
500mls saline and blended and strained; delivered to 
right colon through colonoscope
2 groups FMT group received 
4L of macrogol bowel 
cleansing solution for 1-2 days 
on the last 2 days of 
vancomycin followed by FMT. 
The other group had bowel 
cleansing and vancomycin 
standard treatment. 
Sporicidal disinfection was 
performed in patient rooms as per 
institutional protocols; specific 
instruc- tions with handouts 
regarding sporicidal home cleaning 
were provided to patients to 
prevent reinfection. 
Fresh or frozen via 
Colonoscopy and NG 
tube
Not reported Not reported
Donor Characteristics FMT characteristics
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Some tests are performed for 
screening: serology for hepatitis A, 
B and C, human immunodeficiency 
virus (HIV), fecal parasitology, fecal 
test for Clostridium difficile, and 
fecal culture. 
Fresh via 
enteroscope
Mixed in N. Saline. Volume and other variables not 
stated
Not reported
Donors were screened for 
hepatitis A, B and C and HIV 
infection, as well as enteric 
bacterial pathogens including 
Salmonella, Shigella, Campy- 
lobacter and Yersinia species. 
Fresh via Gastroscopy 
or colonoscopy
A fresh stool sample of 50–100 g was obtained from the 
donor on the day of the instillation procedure. The stool 
sample was spread out onto a gauze pad which was 
then placed in a strainer. The gauze was flushed with 
250 ml sterile 0.9% NaCl and the resulting suspension 
was collected and aspirated into syringes. A flexible 
videogastroscope was intro- duced into the distal 
duodenum. Approximately 200 ml of sample solution 
was introduced 
No bowel prep given to colonic 
delivered FMT
The donorshad to submit their 
medical records and  underwent 
serologic testing for HIV and 
Hepatitis B and C, and stool testing 
that included screening for routine 
enteric pathogens, C. difficile 
toxin B, and examination for 
ova and parasites, and Giardia 
and Cryptosporidium antigens. 
Donors were excluded if they 
had GI co-morbidities or had 
used antibiotics within 3 
months. 
Fresh or frozen via 
Colonoscopy
Approximately 50g of fecal material was placed into a 
standard commercial blender (Oster, Subeam, Rye, NY) 
and homogenized in 250 ml of sterile, non-bacteriostatic 
normal saline. Faceal suspension, if stored , was put in 
10% glycerol and stored at -80 for up to 8 weeks. The 
frozen preparation was diluted in 250ml salne before 
infusion.
Patients were maintained on 
full dose of vancomycin 
(125mg, four times daily by 
mouth) until 2 days before the 
FMT proce- dure. The day 
before the procedure, the 
patients were prepped using a 
split dosage polyethylene 
glycol purge (GoLYTELY or 
MoviPrep), which is standard 
in our endoscopy unit, before 
colonoscopies to wash out 
residual antibiotic and fecal 
material.
Not reported
Oral capsules vs 
colonoscopy
Not reported Not reported
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Blood was screened for hepatitis B 
surface antigen, hepatitis C 
antibody, Helicobacter pylori and 
syphilis serologic markers, human 
immunodeficiency virus types 1 
and 2, and human T-lymphotropic 
virus types I and II. Stool was 
processed for enteric bacterial 
pathogens, C difficile toxin, and 
ova and parasites. 
Retention enema
Approximately 150 g of fresh stool collected was 
emulsified in 300 mL of sterile water. The supernatant 
component was administered rectally by en- ema. 
All CDI therapy was 
discontinued at least 24 hours 
prior to FT.
no antibiotics in preceding 90 
days; blood for HAV, HBV, HCV, 
HIV 1&2, Treponema pallidum; 
stool for culture for bacteria, stain 
for ova and parasites, C. diff. toxin 
A and B
Fresh via colonoscopy
stool obtained 6 hours or less prior to transplant6=8 
tablespoons of donor stool added and shaken in 1litre of 
sterile water passed through gauze. Aliquoted in 60ml 
syringes.
polyethelene glycol bowel 
prep night before transplant; 
500-960mls administered via 
scope mainly to rightcolon; 
Avoid defecating for 30-45 
mins
Not reported
fresh or frozen not 
stated; 12 of 16 centres 
used colonoscopy 
route
Not reported
prep not stated; questionnaire 
sent out to 16 centres to 
retrospectively collect data; 
method of follow up at each 
centre not stated but had to 
have data for at least 12 weeks 
to be eligible for inclusion
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Testing for HIV-1 and HIV-2 was 
performed within 2 weeks before 
donation for FMT. Other serologic 
and stool testing was performed 
within 1 month before FMT and 
included testing for hepatitis A, B, 
and C viruses; testing for 
Treponema pallidum; polymerase 
chain reaction (PCR) testing for 
detection of C difficile toxin; 
culture for enteric pathogens (Esch- 
erichia coli, Salmonella, Shigella, 
Yersinia, Campylobac- ter, Listeria 
monocytogenes, Vibrio 
parahaemolyticus, and V 
cholerae); testing for fecal Giardia 
and Cryptosporidium antigens; 
acid-fast stain for detection of 
Cyclospora and Isospora; ova and 
parasite testing; and enzyme 
immunoassay for detection of 
Rotavirus.
Fresh via colonoscopy
The protocol specified a “dose” of 100 g of stool diluted 
in 500 mL of nonbacteriostatic 0.9% normal sa- line 
immediately before the procedure, but the study relied 
on fresh stool, which has unpredictable weight and 
volume, and most provided specimens were less than 
100 g. 
Donors took an osmotic 
laxative (magnesium 
hydroxide) the evening before 
and provided fresh stool the 
day of FMT. All donor 
specimens were transported 
on ice and processed within 6 
hours of collection. Patients 
were given a standard bowel 
purge (sodium sul- fate, 
potassium sulfate, and 
magnesium sulfate oral 
solution) the evening before 
the procedure. For patient 
convenience, sodium sulfate, 
potassium sulfate, and 
magnesium sulfate oral 
solution was substituted for 
the polyethylene glycol (PEG) 
bowel purge described in the 
study protocol. 
no antibiotics for 3 months; stool 
tested for C. diff toxin PCR, enteric 
pathogens, ova and parasites, 
Cryptosporidium, Microspora; 
Serum tested for Hep A, Hep B, 
Hep C, HIV 1 and 2; H. pylori' 
Human T lymphotropic virus
fresh via colonoscopy
stool obtained within 30 mins of transplantation; 50g of 
stool into 200mls of saline and blended; Aspirated into 
single 60ml syringe for delivery
4 litres polyethelene glycol 
bowel prep; 60mls 
administered via scope into 
right colon; follow up 
combination of clinic, 
telephone and questionairres
no antibiotics for 3 months; stool 
tested for C. diff , enteric 
pathogens, ova and parasites;  
Serum tested for Hep A, Hep B, 
Hep C, HIV 1 and 2; CMV, EBV, 
high risk behaviours, systemic 
antineoplastic drugs, 
immunosuppressives, history of GI 
disease. Directed donors to avoid 
foods which recipient may be 
allergic to for 5 days prior.
fresh via NGT
time from collection to transplant not stated; 30g stool 
added to 100mls saline and blended;filtered throgh 
gauze; 30-60mls infused
8.5g-17g polyethylene glycol in 
8oz of water 3 times a day for 
2 days prior to FMT; 
omeprazole 1mg/kg orally day 
before and on day of FMT; 
follow up all patients called 2 
days after FMT, further follow 
up combination of clinic, 
telephone and repeat C. diff. 
testing
no antibiotics for 6 months; stool 
tested for C. diff , enteric 
pathogens, ova and parasites, 
norovirus,enterovirus;  Serum 
tested for Hep A, Hep B, Hep C, 
HIV 1 and 2, human lT-cell 
ymphotrophic virus 1&2, 
treponema
retention enema
time from collection to transplant not stated; 150g stool 
added to 300mls water and homogenised with spatula 
100mls infused
no bowel prep stated;100mls 
infused via enema;follow up 
methods not stated but 
retrospective analysis 
extracted from clinical record
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Questionnaire. Pathogens, HIV, 
HABC, CMV, EBV, syphilis, 
strongyloides, entamoeba. 
Screening every 4 months
Fresh and Frozen. 
Lower GI route
100g of stool homogensied and mixed in 300mls of 
water. If frozen kept for 30 days at -20C. If fresh 
administered within 24hrs.
Nil
Within 30 days before donation 
(usually 7 days) screened: 
Blood:HAV (HAV ab (IgM and IgG), 
HBV (ab to HepB surface antigen 
and core antigen), HCV (HCV ab 
RIBA-II), HIV-1 & 2 (EIA), 
Treponema pallidum (rapid plasma 
reagin test). 
Stool: C diff (Toxin A or B 
(cytotoxin) detection), enteric 
bacterial pathogens (selective 
stool culture), ova/parasites (light 
microscopy)
No antimicrobial therapy in 
Fresh via NGT
time between stool collection and transplant not stated; 
30g of stool blended with 150mls saline and filtered; 
30mls infused via NGT
no bowel prep stated;30mls 
infused via NGT;omeprazole 
given prior to FMT; follow up 
methods not stated but 
retrospective analysis 
extracted from clinical record
No antibiotics for 6 months. Blood 
for FBC, CRP, protein,creatinine, 
LFTs, HBV, HCV, HIV 1 &2, 
treponema. Stools for Cdiff, 
pathogens, OCP, 
Fresh, within 6 hours 
colonoscopic
Stool obtained 6 or less hours prior to transplant. 
Homogenised in 100-200ml water.
Colonic lavage ith 4l PE 
solution.
No antibiotics for 3 months. 
Excluded chronic gastrointestinal 
condirions, active peptic ulcer 
disease, GERD, IBS,IBD,polyps, 
mlaignancy. Blood for HABCV, HIV, 
Treponema, stool for culture, OCP, 
cryptosporidium, microsporidia, 
Cdiff
Fresh, colonoscope
Donors given 30ml MgOh evening before donation. 
Stools within 6 hours of passage blended with 100ml 
Nsaline and sieved for delivery.
Bowel prep for colonoscopy 
(not stated which), 4mg 
operamide either before or 
after FMT
High risk behaviours, no antibiotics 
for 3 months, Blood for HIV, HABC, 
STDs, stooll for bacterial culture, 
OCP, Cdiff
Fresh, colonoscope 
(11); 1 nasoduodenal
Donor given mg citrate before. stool collected within 6 
hours of preocedure. 6-8 tablespoons to 1l tap water, 
shaken. 
PEG bowel prep, 400-500 ml 
to TI/Right colon. Patients 
given 2 tablets of 
diphenoxylate/atropine. A 
week later 2 month course of 
Saccharomyces boulardii
3 unscreened. High risk 
behaviours, antibiotics in 3 
months, blood for HIV, HABC, 
terponema, stool for Cdiff, 
bacterial culture, OCP, Giardia, 
Cryptosporidium, 
Fresh, colonoscope Time between donation and colonoscopy not stated
On day of treatment patients 
given 2 imodium tablets 2 
hours prior and 1 after. Bowel 
prep not recorded.
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Selective based on discretion. 
Blood from some for viruses 
(HABC, HIV), stool from some for 
Cdiff and enteric pathogens
Fresh colonoscope Time between donation and colonoscopy not stated
PEG bowel prep. Some (not 
clear how many) had 2 
immodium immediately after 
and then again6 hours after 
FMT
Screened for occult infectious 
conditions and no abx use in 
preceeding 3 months
Fresh, Upper GI (NG or 
PEG)
30 g of donor stool in mixed in saline. 25mls given in an 
infusion.
Pre-treated with 3 days of 
vancomycin and proton pump 
inhibitor prior to procedure
No significant medical history, no 
antibiotics for prior six months. 
Donor feces were screened for 
enteric pathogens and blood was 
screened for antibodies to 
hepatitis A, B, and C; HIV; and 
Treponema pallidum within 2 
weeks of donations
Fresh: 26 patients; 
Frozen: 23 patients. 
Administered by 
colonoscopy
30g of stool in 200mls of saline or glycerol. If frozen 
stored in -80C for up to 16 weeks.
Polyethylene glycol prior to 
procedure
Not reported Fresh, both routes Not reported Not reported
Donor feces were screened for 
enteric pathogens and blood was 
screened for antibodies to 
hepatitis A, B, and C; HIV
Fresh via colonoscopy
Stool collected morning of transplant, filtered and mixed 
with saline. 250 - 400mls infused into patient.
Abx stopped 3 days prior to 
FMT
Age range 18-50 years, BMI 18.5 - 
25. No significant medical history, 
not pregnant, no antibiotics for 
prior six months. Donor feces were 
screened for enteric pathogens 
and blood was screened for 
antibodies to hepatitis A, B, and C; 
HIV; and Treponema pallidum 
within 2 weeks of donations. 
Donors refrain from common 
allergens for 5 days before 
donation. 
Capsule (oral) frozen 
for mean of 113 days 
(range 30-252 days).
Each inoculum was prepared from the feces of a single 
donor. The final slurry was concentrated by 
centrifugation and resuspended in saline at one-tenth 
the volume. Fecal matter solution was pipetted into size 
0 capsules (650 μL), which were closed and then 
secondarily sealed in size 00 capsules. Capsules were 
stored frozen at −80°C (−112°F) Wll us . A full treatment 
of 30 capsules contained sieved, concentrated material 
derived from a mean of 48 g of fecal matter (mean per 
capsule, 1.6 g; range, 1.0-2.05 g). Samples stored for 4 
weeks without use to allow for retesting for HIV, hep B 
and C. (full screening and exclusion details given in 
appendix)
Abx stopped 48 hrs prior to 
FMT
Donor feces were screened for 
enteric pathogens and blood was 
screened for antibodies to 
hepatitis A, B, and C; HIV
Fresh. Upper GI in 13 
patients, lower GI in 1 
patient
Fresh stool sample (30–50 g) homogenized and mixed 
with water. About 120–180 ml of the suspension was 
instilled through NGT; 300–500 ml was administered if 
IMT was done via colonoscopy.
Abx stopped 24 hrs prior to 
FMT and given proton pump 
inhibitor prior to procedure
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Excluded if abx within preceding 3 
months. Exclusion criteria also 
included immunosuppressive 
agents, including 
chemotherapeutic agents; had 
known or recent exposure to 
HIV,hepatitis B or C;had a current 
communicable disease; 
participated in high-risk sexual 
behaviors; used illicit drugs; had a 
history of incarceration; traveled 
within 6 months to areas with 
endemic diarrheal illnesses; or had 
history of infl ammatory bowel 
disease, irritable bowel syndrome 
or chronic diarrhea, 
gastrointestinal malignancy or 
polyposis). Blood tested for HIV, 
Hep A/B/C and stool for OCP and 
giardia antigen and 
cryptosporidium
Fresh (within 8 hours), 
colonoscopy
Suspended in saline, mixed by hand or blender, filtered 
and infused as 300 to 700 mls 
Abx stopped 48 to 72 hrs prior 
to FMT. Bowel prep given 
before procedure
no abs for 3 months. No laxatives, 
hstory of constipation, no history 
of GI disease, travel in 3 months, 
not on immunosuppressives or 
chemo. No metabolic syndrome, 
autoimmune, atopic disease
Fresh (within 6 hours), 
colonoscopy
Fresh in blender 500ml Nsaline, strained. 60ml drawn up 
in 8-9 syringes per patient.
Abs stopped prior to 
procedure.
screening as per FDA guidelines 
2011
Frozen stool (> 2 
months in 16 patients 
and <2 months in 4 
patients), colonoscopy 
route in 19, jejunal 
30g in 120ml N.saline, divided into 50ml aliquots Not reported
Excluded if "history of antibiotic 
use" (time not specified), high risk 
behaviour, prisoners, GI disease, 
Fresh. Initial FMT in 
118(81%) colonoscope, 
13(9%) OGD, 3(2%) 
Milk of magnesia to donors. 60-100g stool suspended in 
300-500ml nsaline, mixed, sieved. 75-200ml for upper 
route (OGD, enteroscopy), 250-400ml colnoscopically, 
Bowel prep given. Loperamide 
after FMT
Blood and stool screened for 
transmissible diseases
Fresh, given via a 
combination of jejunal 
and colonic route
25-30g of stool given as 180mls via enteroscopy and 
270mls via colonoscopy
Not mentioned
Potential donors were accepted 
only if serum antibodies against 
HIV 1 and 2, hepatitis C virus, and 
hepatitis B surface antigen were 
negative, as were stool cultures for 
Salmonella, Shigella, 
Campylobacter, enterohemolytic 
Escherichia coli, and Clostridium 
Fresh, given as enema 
(lower GI
50g of fresh faeces prepared in an anaerobic cabinet by 
adding and stirring small portions of pre-reduced and 
pre-warmed (37 °C) sterile isotonic saline, to a total of 
500 ml.
Not mentioned
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Questionnaire adressing risk 
factors for potencially 
transmissible diseases. Donor 
feces were screened for parasites, 
including Blastocystis hominis and 
Dientamoeba fragilis; C.difficile, 
and enteropathogenic bacteria. 
Blood was screened for HIV; 
human T-cell lymphotropic virus 
types 1 and 2; hepatitis A,B, and C; 
cytomegalovirus; Epstein-Barr 
virus; Treponema pallidum; 
Strongyloides stercoralis; and 
Entamoeba histolytica. A dnor pool 
was created, and screening was 
repeated every 4 months. Before 
donation, another questionaire 
was used to screen for recent 
illnesses. 
Fresh via nasoduodenal 
tube
Feces were collected by the donor on the day of infusion 
and immediately transported to the hospital. Feces were 
diluted with 500mls of sterile saline 0.9%. This solution 
was stirred, and the supernatant strained and poured in 
a sterile bottle.  A mean (+-SD) of 141+-71g of feces was 
infused. The mean time from defecation to infusion was 
3.1+-1.9 hours
Bowel lavage with 4 liters of 
macrogol solution (Klean-Prep) 
on the last day of antibiotic 
treatment. Within 6 hours 
after collection of feces by the 
donor, the solution was 
infused through a 
nasoduodenal tube (2 to 3 
minutes per 50mls). The tube 
was removed 30 minutes after 
the infusion, and patients were 
monitored for 2 hours. 
Patients kept a stool diary and 
were questioned about stool 
frequency and consistency, 
medication use, and adverse 
effects. Stool tests for 
C.difficile toxin were 
performed on days 14,21,35, 
and 70 and whenever 
diarrhoea occured. 
Volunteers were excluded for any 
significant past medical history  or 
any use of antibiotics in the 
preceeding 6 months. Initial 
screening using the American 
Association of Blood Banks donor 
questionaire for exposure to 
infectious agents. Physical 
examination and general 
laboratory screening tests (within 
30 days of donations). All results 
had to be within normal range for 
age and sex. Donor feces were 
screened for enteric bacterial 
Frozen via colonoscopy 
or NGT
Donors were asked to take a dose of milk of magnesia 
the day before fecal collections to facilitate 
manipulation of the sample. A fecal suspension was 
generated in normal saline without preservatives, using 
commercial blender. Materials were passed through 4 
sieves to remove particulate material. The final slurry 
was concentrated 3-fold by centrifugation and then 
resuspended in sterile saline with 10% glycerol added as 
a bacterial cryoprotectant. Inocula were then frozen at -
80 C pending use. Each sieved inoculum was calculated 
to have been derived from approximately 41g of fecal 
material. Inocula were stored frozen for up to 156 days, 
range, 29-156 days; frozen material was thawed in a 37 
C water bath, and then kept on ice until delivery. 
Subjects assigned to 
colonoscopic administration 
underwent a standard bowel 
preparation with 4 liters of 
PEG solution, followed by 
endoscopic administration to 
the right colon of 90 cc thawed 
inoculum:further diluted to 
250cc for adults and 160 cc for 
paediatric patients. Patients 
were given a single oral dose 
of loperamide at the time of 
procedure. Subjects assigned 
to NGT delivery of FMT were 
Pre-medical examination was 
carried out with a questionnaire in 
order to rule out high-risk 
individuals (such as drug use, 
promiscuity, known illness, taking 
antibiotics or trips abroad in the 
past six months). Stool samples 
Fresh stool delivered 
via nasogastric route in 
15 patients and 
nasoduodenal route in 
15 patients
60 grams, it was placed in 200 mL of mortar 
physiological saline (0.9%) and harvested. then the 
homogenate of 4 × 4 cm was filtered sterile gauze pads 
transferred to another vessel and finally were taken 
from the filtrate up to 100 ml syringe and given to 
patient within 6 hours.
Antibiotics were stopped prior 
to transplant and patients 
were given laxatives. Patients 
received both metoclopramide 
and high dose proton pump 
inhibitor on the day of the 
transplant.
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Total no of infusions Define primary outcome Outcome 1 infusion 1 or more infusions Total follow up period
not explicitly stated. Data 
implies a single infusion 
on a single occasion for 
each patient
Not explictly stated, but 
authors report outcome 
based on symptom 
resolution and / or CDI 
toxin negativity
15/16 (94%) 15/16(94%)
90 days post 
transplantion, assessed 
by examination of 
medical records. 
NA
Clinical resolution of 
diarrhoea at 8 weeks
NA 19/20 (95%) Not reported
13/20 had 1 FMT; 6/20 
had co-existent PMC and 
received infusions every 3 
days until symptom 
resolution (4 had 2 
infusions, 1 had 3 
infusions and 1 had 4 
infusions
Resolution of diarrhoea 
10 weeks after the end of 
the treatments
13/20(65%) 18/20(90%)
primary end point 10 
weeks after end of 
treatment 
Not reported
Early Failure rate 
defined as non-
response or recurrence 
of diarrhoea with either 
toxin or PCR positive 
CDI within 1 month of 
FMT
not reported 375/462 (81.2%) 3 months
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1 infusion via 
enteroscopy
not defined in paper 
but implied symptom 
free to end of follow up
10/12 (83%) 10/12 (83%) 6 months
I infusion via gastroscopy 
or colonoscopy
successful treatment 
defined as no further 
contact with the clinic 
due to CDI symptoms 
within 80 days of FMT
29/40 (73%) 33/40 (82.5%) 80 days
4 of 43 had repeat 
infusion
Not specified 37/43 (86%) 41/43 (95%) 12 months
1 infusion via 
colonoscopy or 1 course 
of capsules.
Defined as cure but no 
time period given
41/43 (95%) 41/43 (95%) Not specified
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Five patients underwent 
a second FT because of 
ongoing diarrhea; 3 had 
symptom resolution and 
2 continued to 
experience diarrhea 
despite 2 FTs. 
resolution of symptoms-
no time period defined
22/27 (81%) 25/27 (93%)
mean follow-up at 
427.3 days after 
transplant. 
not explicitly stated but 
imples single infusion for 
all patients
Prevention of further CDI 
relapse and/or significant 
diarrhoea requiring 
vancomycin; time frame 
for outcome not stated
24/26 (92.3%) 24/26 (92.3%)
follow up  mean 10.7 
months ranged from 2-
30 months
78 patients had single 
infusion; 12 patients had 
2 infusions
response defined as 
absence of diarrhoea or 
marked reduction in stool 
frequency and without 
need for further 
antibiotics within 12 
weeks after 1 or more 
FMTs
62/80 (77.5%) 70/80 (87.5%)
minimum of 12 weeks 
required; mean follow 
up 11m (range 3-46m)
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1 infusion via 
colonoscopy
Resolution of diarrhoea 
without need for anti 
CDI therapy during 8 
week follow up
20 / 22  (90.9%) 21 / 22  (90.9%)
8 weeks for efficacy, 6 
months for safety
18 had single infusion; 2 
had 2 infusions
Resolution of diarrhoea 
without recurrence of 
symptoms within 3 
months of FMT
18/20 (90%) 20/20 (100%)
minimum of 6 months 
(range not stated) 
9 patients had single 
infusion, 1 patient had 2 
infusions
Not defined in paper but 
implied symptom free to 
end of follow up
9/10 (90%) 10/10 (100%)
median duration of 
follow up 44 days 
(range 13-700 days)
if no resolution of 
diarrhoea after 7 days 
post FMT then further 
enema give. Range given 
1-10(46/94 had 1 FMT, 
20/94 had 2 FMT, 17/94 
had 3 FMT, 11/94 had 4 
or more)
Cured following FMT if no 
recurrence of diarrhoea 
at 6 months follow up
45/94 (47.9%)  81/94 (86.2%) 6-24 months
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1, if no response at day 4, 
then further FMT and if 
no response then FMT or 
abx. Primary outcome 
based on up to 2 FMTs.
Clinical resolution of 
diarrhea without relapse 
at 13 weeks
113/219 (52%)  193/219 (88.1%) 13 weeks
14/15 had 1 FMT;1/15 
had 2 FMT
Not explicitly stated but 
implied that "cure" was 
no symptoms at follow 
up after 1 FMT
11/15 (73%) 12/15(80%)
median 16 weeks (4 
weeks to 24 weeks) not 
predefined
67 had 1; 3 had 2
Resolution diarrhea 
without a positive C 
difficile toxin stool test at 
12 weeks
63/70 (90%)  66/70 (94%)
1 year. 4 with initial 
favourable response 
had replase after 
receiving antibiotics. 2 
of these were 
successfully treated 
with  FMT; 2 with 
recurrent antibitics for 
CDI
28 had 1; 3 had 2 Not defined. 26/30 (87%) 29/30 (97%)
1 year 6 out of 6 
maintained 
imrpovemement
1 infusion in all but 1 
patient who had repeat 
via ND route 
No strict definition. 
Authors state : 'A 
successful treatment was 
determined by the 
resolution of diarrhea, a 
fall in white cell count, or 
absence of fever and an 
improvement in vital 
signs'.
11/12 (92%) 12/12 (100%)
No recurrences within 
90 days of FMT. Total 
follow up from 2 to 29 
months
1
Resolution defined as 
positive stools after FMT. 
20/20 (100%) 20/20 (100%)
Follow up mean 3 
months (range 0-10)
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1
not defined in paper but 
implied symptom free to 
end of follow up
19/20 (95%) 20/20 (100%) 6 months to 5 years
1
Resolution of diarrhea 
without recurrence 
within 60 days of FMT
59/75 (79%) 59/75 (79%) 60 days
1
Resolution of diarrhoea 
with a negative C. difficile 
toxin stool test at 3 
months
47/49 (96%) 47/49 (96%)
All followed up for 12 
weeks and 42 patients 
followed up for 1 year
1 infusion in 27 patients, 
multiple infusions in 4 
patients
Resolution was defined 
as the absence of 
significant diarrhea 
(diarrhea as defined by at 
least three episodes per 
day) or a marked 
reduction in diarrhea not 
requiring antibiotic 
therapy.
24/31 (77%) 27/31 (87%)
Mean 9 months (range 
2–24)
1
Clinical response was 
defined as absence of 
diarrhea, cramps, and 
fever within 3 to 5 days 
of transplant
12/12 (100%) 12/12 (100%) 3 weeks to 8 years
N/A
Response defined as less 
than 3 bowel movements 
in 24 hrs
NA 18/20 (90%)
Primary outcome based 
on 8 weeks however 
patients followed up 
for 6 months
 1 in 10 patients, 2 in 2 
patients, and 3 in 2 
patients received three 
FMTs 
 Defined as less than 3 
loose bowel movements 
a day for 2 consecutive 
days after FMT and no 
need for further CDI 
therapy on day 7. 
8/14 (57%) 11/14 (79%) 100 days
Page 65 of 156 Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
1 infusion in 75 patients, 
2 infusions in 2 patients
Resolution without 
recurrence within 90 days 
including those that 
needed a second infusion 
or antibiotics
70/77 (91%) 70/77 (91%)
Minimum 90 days, but 
median 17 months
1 infusion 
Primary outcome not 
defined
19/22 (86%) 21/22 (95%)
Range 2 weeks to 17 
months with ave length 
3 months
1 infusion in 17 patients, 
2 infusions in 3 patients
Resolution of diarrhoea 
and/or absence of CDI 
toxin in stool as 
measured by PCR after at 
least 3 months follow up 
17/20 (85%) 20/20 (100%)
Minimum 3 months 
(but up to 14 months)
 146 had one infusion, 12 
out of 25 early 
recurrences had another 
Initial Resolution of CDI 
symptoms with no 
recurrence after 12 
121/146 (82.9%) 121/146 (82.9%)
mean follow up 12.3 
(range 1-48) months
1
Resolution of diarrhoea 
and disappearance of 
stool Cdiff toxin
27/27 (100%) 27/27 (100%)
Ranged from 9.7 -34 
months (mean 20.6 
months)
1 in 22 patients and 2 in 1 
patient
Resolution of diarrhoea in 
3 days with no recurrence 
in 3 months
15/23 (65%) 16/23 (70%)
Median follow up of 18 
months (range 0-201 
months)
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16 patients had 1 
infusion; 3 who did not 
respond in this group had 
2nd infusion.
Cure without relapse 
within 10 weeks after the 
initiation of therapy. For 
patients in the infusion 
group who required a 
second infusion of donor 
feces, follow up was 
extended to 10 weeks 
after the second infusion. 
Cure was defined as an 
absence of diarrhoea or 
persisent diarrhoea that 
could be explained by 
other causes with three 
consecutive negative 
stool tests for C.difficile 
toxin. Relapse was 
defined as diarrhoea with 
a positive stool test for 
C.difficile toxin. 
13/16 (81%) 15/16(94%)
After first infusion at 10 
weeks; follow up was 
extended to 10 weeks 
after the second 
infusion
20 patients in both study 
arms had one infusion 
(14 was cured after the 
first infusion (70%)). One 
patient in the NGT arm 
refused subsequent 
retreatment. The 
ramaining 5 patients 
were given a second 
infusion (4 patients 
obtained cure after 
second infusion, resulting 
in an overall cure rate of 
90%). 
Clinical resolution of 
diarrhoea off antibiotics 
for C.difficile, without 
relapse within 8 weeks. 
For patients who 
required a second 
treatment dose, a follow-
up was calculated 
starting at the time of the 
second administration. 
14/20 (70%) 18/20 (90%)
8 weeks follow up for 
primary response
1 infusion in 27 patients 
and 2 infusions in 3 
patients.
Primary cure rate was 
defined as resolution of 
symptoms without 
recurrence within 6 
weeks after a single FMT, 
while secondary cure rate 
was calculated 
27/30 (90%) 29/30 (97%) 6 weeks
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Adverse events - mild Adverse events - serious
no mention
2 patients died between 
transplant and follow up 
stool testing for c.diff toxin. 
One had end stage renal 
disease and was receiving 
peritoneal dialysis. Developed 
peritonitis 3 days post 
transplant and died shortly 
after. The second patieint 
died 14 days post transplant 
of pneumonia complicating 
COPD and atherosclerosis 
(study authors state: "the 
possibility that the use of the 
nasogastric tube contributed 
to the peritonitis cannot be 
excluded" )
None reported none reported
none in vanc group; 
FMT group 19/20 had 
transient diarrhoea, 
12/20 had abdominal 
pain and bloating
2 deaths in FMT arm
Not reported Not reported formally
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Not reported None
Not reported
5 deaths; The remaining 5 
patients had serious co-
morbid conditions and died 3 
weeks–2 months after the 
FDIT procedure. Two of these 
5 patients were seriously 
weakened after long lasting 
diarrhoeal disease, 1 being 
the oldest patient in the 
series (94 y). Additionally, 1 
patient had advanced stage 
Wegener’s granulomatosis 
with complications, 1 patient 
had acute myelogenous 
leukaemia requiring repeated 
antibiotic treatment for other 
infections, and 1 patient with 
advanced cardiovascular 
disease developed fulminant 
colitis and underwent 
subtotal colectomy, and 
subsequently died of 
complications.
Not reported Not reported
Transient nausea and 
vomiting
None
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Not reported Not reported
mild diarrhoea post 
FMT in 3 patients
no serious adverse events
self limited diarrhoea in 
3, fever in 1, bloating 
and abdo discomfort in 
3, hip pain in 1, Crohn's 
flare in 1, Pertussis in 1, 
nausea in 1, minor 
mucosal tear at 
colonoscopy in 1
deaths- 1 due to pneumonia, 
1 due to aspiration at time of 
colonoscopy; hospitilisations- 
1 due to fever and 
encephalopathy, 1 due to 
abdo pain after FMT, 3 due to 
IBD flare, 1 colectomy, 1 hip 
fracture, 1 influenza, catheter 
infection
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Chills were reported 
more frequently after 
autologous than donor 
FMT (P = 0.053). Rates 
of other solicited AEs 
(fever, abdominal pain, 
bloating, nausea, 
vomiting, diarrhea, 
flatulence, anorexia, 
and constipation) did 
not differ significantly 
between groups. 
There were no SAEs related 
to FMT. 
self limited diarrhoea in 
4; abdominal pain in 3; 
nausea in 2; fatigue 13
none stated
vomiting post FMT in 1; 
mucoid stools for 2 
days after FMT
none stated
10% had transient 
constipation and 
flatulence post FMT
6 deaths due to critical 
illness, not felt to be due to 
FMT or CDI directly but these 
6 are included in the 8 who 
failed to respond overall
Page 71 of 156 Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Transient diarrhoea 
(70%), abdominal 
cramps (10%), nausea 
(5%) in 24 hours post 
FMT; constipation 
(20%) and flatulence 
(25%) in follow up 
period
19 deaths in total 13 week 
study period (unrelated). 12 
patients required 
hospitalization because of 
ilnesses unrelated to FMT
none none stated
None reported None related to FMT
Not reported
Micro-perforation but not 
related to FMT. One death at 
3 months afer due to 
,metastatic pancreatic 
cancer.
None reported None related to FMT
1 pain/nausea after 
colonoscopy, 1 
continued diarrhoea 
(CDIFF neg) ? Bile salt 
malabsorption after 
cholecystectom, 2 
transient bloat/ cramps
1 perforation related to 
colonoscopy sealed with clip
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None reported none reported
None None
Mild transient fever in 
2 (frozen FMT)
3 deaths (unrelated)
Worsening arthritis, 
constipation, 
diarrhoea, urinary tract 
infection.
5 deaths; not attributed to 
FMT. Stroke, myocardial 
infarction, aspiration 
pnuemonia, hospitalisation 
for CDI not as a consequnce 
of FMT.
Not reported None
Transient abdominal 
cramping and bloating 
in 6 patients (30%) that 
resolved in 72 hours
1 hospitalised with a 
documented relapse of 
severe CDI after taking 15 
capsules but had successful 
treatment after receiving the 
remaining 15 capsules after 
discharge. No other severe 
adverse events (grade 2 or 
above).
Not reported
4 deaths within 30 days of 
FMT unrelated to FMT.
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None reported
4 patients reported a new 
medical condition after FMT 
(peripheral neuropathy, 
Sjogrens, ITP and rheumatoid 
arthritis
pain in one patient none
None None
CDI-negative diarrhoea 
in 7(4.8%) and 
constipation in 4(2.7%)
within 12 weeks-6 
hospitalizations due to CDI 
and/or FMT. One debilitated 
Low grade fever 
(18.5%) and bloating 
(11.1%)
None
Nil Nil
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94% immediate 
diarrhoea, 31% 
abdominal pain with 
cramping, 19% 
belching - resolved 
within 3 hours. During 
follow up 3 patients 
had constipation (19%). 
2 patient had 
infections: one patient 
with recurrent UTI had 
UTI
1 hospitalisation for 
symptomatic 
choledocholithiasis 
(unrelated)
Mild abdominal 
discomfort and 
bloating in 4 patients 
(20%). One child 
treated 
colonoscopically had a 
transient fever of 38.8 
C on day 2 that 
resolved spontaneously
2 deaths (unrelated), 1 new 
diagnosis of malignancy 
(unrelated), 1 hospitalisation 
for Fournier gangrene 
(unrelated)
Nausea in one patient. 
Nil else
Nil
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Name et al Year RCT characteristics Arms of RCT
No. of patients, mean or median age, 
Gender distribution
Overall
219 patients, mean 73 years, 
F:146/219 (67%)
Frozen
108 patients, mean 73 years, F:72/108 
(67%)
Fresh
111 patients, mean 73 years, F:74/111 
(67%)
Overall
43 patients, mean 67 years, F:30/43 
(70%)
Capsule
22 patients, mean 66 years, F:17/22 
(77%)
Fresh (colonoscopy)
21 patients, mean 68 years, F:13/21 
(62%)
FMT
20 patients , mean 71 years, F:12/20 
(60%)
Vancomycin
19 patients , mean 79 years, F:11/19 
(60%)
high dose capsules FMT
9 patients demographics not stated 
(abstract)
low dose capsules FMT
10 patients demographics not stated 
(abstract)
donor FMT
22 patients, mean 48 years, F:18/22 
(82%)
autologous FMT
24 patients, mean 55 years, F:19/24 
(78%)
Vancomycin abbreviated 
regime (500mg orally 
four times per day for 4 
or 5 days) with bowel 
lavage and FMT
16 patients; mean age +/-SD (73 +/-
13); F: 8/16 (50%)
Vancomycin standard 
regime (500mg orally 
four times per day for 14 
days)
13 patients; mean age +/-SD (66 +/-
14); F: 7/13 (54%)
Vancomycin standard 
regime(500mg orally 
four times per day for 14 
days) with bowel lavage 
on day 4 or 5.
13 patients; mean age +/-SD (69 +/-
16); F: 3/13 (23%)
Frozen (colonoscopy)
10 patients, mean age +/-SD (50.4 +/-
28.8); F:6/10 (60%)
Lee CH 2016
Double blind RCT 
comparing fresh vs 
frozen FMT
Study characteristics
Kao D 2016 (abstract)
RCT comparring 
capsule versus 
colonoscopy 
delivered FMT
Cammarota 2015
RCT comparing 
FMT versus 
vancomycin
Allegretti 2016 (abstract)
RCT comparing 
FMT versus 
vancomycin
Kelly 2016
Double blind RCT 
comparing donor 
vs placebo 
(autologous) FMT
Van Nood 2013
RCT comparing 
FMT versus 
vancomycin
Youngster 2014
RCT comparing NG 
versus colonic 
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Frozen (NGT)
10 patients; mean age +/-SD (58.6 +/- 
19.6); F: 5/10 (50%)
Youngster 2014 versus colonic 
delivery of FMT
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Diagnosis of C.diff i.e Elisa/PCR, 
duration from diagnosis to transplant
Pre FMT Abx +/- other therapy 
(M,V,Fidox,IVG)/How many courses 
i.e M(2), V(1), IVG(1), Fidox(1).
Were abx stopped prior to FMT
Refractory / Recurrent
Toxin and PCR Metronidazole and Vancomycin Both
Patient characteristics
Not reported Not reported Recurrent
CDI diagnosis confirmed by toxin; in 
23/39(59%) positive culture as well as 
toxin.mean duration of CDI diagnosis 
prior to FMT not stated
All patients had antibiotics prior to 
diagnosis of CDI  but specifics not 
stated; FMt group patients had 3 days 
vanc prior to FMT which stopped the 
Recurrent with lab confirmation
Not stated Not stated Not stated
≥3 unformed stools over 24 hours for 2 
consecutive days and either a positive 
stool test result for C difficile or 
pseudomembranes on colonoscopy 
3 or more recurrences of CDI and 
received a full course of vancomycin 
for their most recent acute episode.
Recurrent
Toxin and PCR
At least one course of adequate 
antibiotic therapy (>=10 days of 
Vancomycin at a dose of >=125mg four 
times a day or >=10 days of 
Metronidazole at a dose of 500mg 
three times per day). In FMT group: 
patients received an abbreviated 
regimen of Vancomycin (500mg orally 
four times per day for 4 or 5 days), 
followed by bowel lavage with 4 liters 
of macrogol solution (Klean-Prep) on 
the last day of antibiotic treatment and 
the suspension of donor feces through 
a nasoduodenal tube the next day.
Recurrent
Toxin: initial toxin/glutamate 
dehydrogenase (GDH) enzyme-linked 
immunosorbent assay, followed by 
PCR only if the GDH test is positive or 
Patients had a median of 4 (range, 2-
16) relapses prior to study enrollment, 
with 5 (range, 3-15) antibiotic 
treatment failures of a 6- to 8-week 
Relapsing or recurring (having at least 
3 episodes of mild-to-moderate CDI OR 
at least 2 episodes of severe CDI 
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PCR only if the GDH test is positive or 
indeterminate, and does not routinely 
test for the NAP-1/B1/207 strain.
treatment failures of a 6- to 8-week 
taper with Vancomycin with or without 
an alternative antibiotic.
at least 2 episodes of severe CDI 
resulting in hospitalization and 
associated with significant modbidity. 
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Flexi sigi / Colonoscopy findings
Healthy volunteer/Spouse/Related i.e mother/Other 
non related i.e friend
Donor characteristics
Not reported Unrelated volunteers
Not done Unrelated volunteers
Not reported
Healthy donors from OpenBiome stool bank mean age 36 
years
6 out of 20 patients in FMT group had 
pseudomembranous colitis
16/20 donors related; 2 intimates; 2 unrelated
Not done
Healthy volunteers <60 years of age (faces from 15 donors 
were used for 43 infusions in the infusion group and for 
patients who had a relapse after vancomycin treatment).
Colonoscopies done on all
All prospective donors underwent a medical interview and 
physical examination and were excluded if they had a 
known communicable disease, features of the metabolic 
syndrome, a diarrheal disorder, an autoimmune or atopic 
disease, a tumor, a neurologic disorder, or chronic pain 
syndrome or if they had used antibiotics for any indication 
within 3 months. Potential donors also completed a 
modified AABB full-length donor history questionnaire, 
Colonoscopy or NGT
Healthy volunteer donor: nonpregnant adults, 18-50 years 
of age, on no medications, with a normal body mass 
Page 80 of 156Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Colonoscopy or NGT of age, on no medications, with a normal body mass 
index. 
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Screening and abx cessation Fresh/Frozen, Route administered
Sample preparation
Transplant sample sourcing, 
screening, preparation;
, volume, mixing solution, storage and 
time from collection to transplant 
Donor characteristics
Not reported
Questionnaire. Pathogens, HIV, HABC, CMV, EBV, syphilis, 
strongyloides, entamoeba. Screening every 4 months
Fresh vs Frozen. Lower GI route
100g of stool homogensied and mixed 
in 300mls of water. If frozen kept for 
30 days at -20C. If fresh administered 
within 24hrs.
Oral capsules vs colonoscopy Not reported
open Biome Criteria followed
No antibiotics for 6 months; stool tested for C. diff , 
enteric pathogens, ova and parasites, MDR gram 
nehgatives, MRSA, VRE;  Serum tested for Hep A, Hep B, 
Hep C, HIV 1 and 2, strongyloides, treponema, 
FMT delivered fresh via colonoscopy
mean time from donation to infusion 
was 3.8 hours;mass of donation not 
stated but mixed with 500mls saline 
and blended and strained; deliverd to 
Frozen pills Not stated
Questionnaire adressing risk factors for potencially 
transmissible diseases. Donor feces were screened for 
parasites, including Blastocystis hominis  and 
Dientamoeba fragilis ; C.difficile, and enteropathogenic 
bacteria. Blood was screened for HIV; human T-cell 
lymphotropic virus types 1 and 2; hepatitis A,B, and C; 
cytomegalovirus; Epstein-Barr virus; Treponema pallidum ; 
Strongyloides stercoralis ; and Entamoeba histolytica . A 
dnor pool was created, and screening was repeated every 
4 months. Before donation, another questionaire was 
used to screen for recent illnesses. 
Testing for HIV-1 and HIV-2 was performed within 2 weeks 
before donation for FMT. Other serologic and stool testing 
was performed within 1 month before FMT and included 
testing for hepatitis A, B, and C viruses; testing for 
Treponema, PCR detection of C difficile toxin; culture for 
enteric pathogens (Escherichia coli, Salmonella, Shigella, 
Yersinia, Campylobacter, Listeria, Vibrio, and V cholerae); 
testing for Giardia and Cryptosporidium, ova and parasite 
Fresh via colonoscopy
The protocol specified a “dose” of 100 
g of stool diluted in 500 mL of 
nonbacteriostatic 0.9% normal sa- line 
immediately before the procedure, but 
the study relied on fresh stool, which 
has unpredictable weight and volume, 
and most provided specimens were 
less than 100 g. 
Fresh via nasoduodenal tube
Feces were collected by the donor on 
the day of infusion and immediately 
transported to the hospital. Feces were 
diluted with 500mls of sterile saline 
0.9%. This solution was stirred, and the 
supernatant strained and poured in a 
sterile bottle.  A mean (+-SD) of 141+-
71g of feces was infused. The mean 
time from defecation to infusion was 
3.1+-1.9 hours. 
Volunteers were excluded for any significant past medical 
history  or any use of antibiotics in the preceeding 6 
months. Initial screening using the American Association 
of Blood Banks donor questionaire for exposure to 
infectious agents. Physical examination and general Frozen via colonoscopy or NGT
Donors were asked to take a dose of 
milk of magnesia the day before fecal 
collections to facilitate manipulation of 
the sample. A fecal suspension was 
generated in normal saline without 
Page 82 of 156Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
infectious agents. Physical examination and general 
laboratory screening tests (within 30 days of donations). 
All results had to be within normal range for age and sex. 
Donor feces were screened for enteric bacterial pathogens 
including rotavirus, Listeria monocytogenes, Vibrio 
Frozen via colonoscopy or NGT generated in normal saline without 
preservatives, using commercial 
blender. Materials were passed 
through 4 sieves to remove particulate 
material. The final slurry was 
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Proceedure:
Bowel Prep/Drugs used prior to FMT 
i.e Moviprep 2 sachets/PPI (dose), 
prokinetic (dose), Loperamide
FMT administration
Follow up method
Total no of infusions Define primary outcome
FMT Characteristics
1, if no response at day 4, then further 
FMT and if no response then FMT or 
abx. Primary outcome based on up to 2 
FMTs.
Clinical resolution of diarrhea without 
relapse at 13 weeks
Nil
Not reported
1 infusion via colonoscopy or 1 course 
of capsules.
Defined as cure but no time period 
given
13/20 had 1 FMT; 6/20 had co-existent 
PMC and received infusions every 3 
days until symptom resolution (4 had 2 
infusions, 1 had 3 infusions and 1 had 4 
Resolution of diarrhoea 10 weeks after 
the end of the treatments
FMT group received 4L of macrogol 
bowel cleansing solution for 1-2 days 
prior to procedure; patients followed 
up propectively by referring physicians; 
Not described NA
Clinical resolution of diarrhoea at 8 
weeks
1 infusion via colonoscopy
Resolution of diarrhoea without need 
for anti CDI therapy during 8 week 
follow up
Donors took an osmotic laxative 
(magnesium hydroxide) the evening 
before and provided fresh stool the 
day of FMT. All donor specimens were 
transported on ice and processed 
within 6 hours of collection. Patients 
were given a standard bowel purgethe 
evening before the procedure.
Bowel lavage with 4 liters of macrogol 
solution (Klean-Prep) on the last day of 
antibiotic treatment. Within 6 hours 
after collection of feces by the donor, 
the solution was infused through a 
nasoduodenal tube (2 to 3 minutes per 
50mls). The tube was removed 30 
minutes after the infusion, and 
patients were monitored for 2 hours. 
Patients kept a stool diary and were 
questioned about stool frequency and 
consistency, medication use, and 
adverse effects. Stool tests for 
C.difficile toxin were performed on 
days 14,21,35, and 70 and whenever 
diarrhoea occured. 
16 patients had 1 infusion; 3 who did 
not respond in this group had 2nd 
infusion
Cure without relapse within 10 weeks 
after the initiation of therapy. For 
patients in the infusion group who 
required a second infusion of donor 
feces, follow up was extended to 10 
weeks after the second infusion. Cure 
was defined as an absence of 
diarrhoea or persisent diarrhoea that 
could be explained by other causes 
with three consecutive negative stool 
tests for C.difficile toxin. Relapse was 
defined as diarrhoea with a positive 
stool test for C.difficile toxin. 
20 patients in both study arms had one 
infusion (14 was cured after the first 
infusion (70%)). One patient in the NGT 
arm refused subsequent retreatment. 
The ramaining 5 patients were given a 
Clinical resolution of diarrhoea off 
antibiotics for C.difficile, without 
relapse within 8 weeks. For patients 
who required a second treatment 
Subjects assigned to colonoscopic 
administration underwent a standard 
bowel preparation with 4 liters of PEG 
solution, followed by endoscopic 
administration to the right colon of 90 
Page 84 of 156Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
The ramaining 5 patients were given a 
second infusion (4 patients obtained 
cure after second infusion, resulting in 
an overall cure rate of 90%). 
who required a second treatment 
dose, a follow-up was calculated 
starting at the time of the second 
administration. 
administration to the right colon of 90 
cc thawed inoculum:further diluted to 
250cc for adults and 160 cc for 
paediatric patients. Patients were 
given a single oral dose of loperamide 
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Primary outcome One infusion One or more infusion
Intention to treat: 159/219 (73%) at 
13 weeks
113/219 (52%)  193/219 (88.1%)
Intention to treat:  81/108 (75%) at 
13 weeks
57/108 (52.8%) 98/109 (90.7%)
Intention to treat: 78/111 (70%) at 13 
weeks
56/111 (50.5%) 95/111 (85.6%)
41/43 (95%) Not reported 41/43 (95%)
20/22 (91%) Not reported 20/22 (91%)
21/21 (100%) Not reported 21/21 (100%)
18/20 (90%) 13/20 (65%) 18/20 (90%) 
5/19 (26%) Not applicable Not applicable
7/9 (77% resolution of diarrhoea at 8 
weeks )
Not applicable Not applicable
7/10 (70%) resolution of diarrhoea at 
8 weeks
Not applicable Not applicable
In the intention-to-treat analysis, 20 
of 22 patients (90.9%) in the donor 
FMT group achieved clinical cure at 8 
weeks
22/20 (90.9%) 22/20 (90.9%)
com- pared with 15 of 24 (62.5%) in 
the autologous FMT group (P = 0.042)
15/24 (62.5%) 15/24 (62.5%)
13/16 (81%) after first infusion at 10 
weeks; overall 15/16 (94%) after 
second infusion, follow up was 
extended to 10 weeks after the 
second infusion
13/16  (81%) 15/16(94%)
4/13 (31%) patients at 10 weeks 15/24 (62.5%) 15/24 (62.5%)
3/13 (23%) patients at 10 weeks 15/24 (62.5%) 15/24 (62.5%)
8 out of 10 (80%) at 8 weeks primary 
response; overall cure rate 100% 
after 2nd infusion but via NGT
8/10 (80%) 10/10 (100%)
Results
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6 out of 10 (60%) at 8 weeks primary 
response; overall cure rate 80% after 
second infusion via NGT
6/10 (60%) 8/10 (80%)
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Adverse events - serious
19 deaths in total 13 week study period 
(unrelated). 
6 deaths (unrelated to FMT)
13 deaths (unrelated to FMT)
None
None
None
2 deaths (unrelated to FMT)
none
Not stated (abstract)
Not stated (abstract)
None
None
1 hospitalisation for symptomatic 
choledocholithiasis (unrelated). 
1 death (unrelated)
None
2 deaths (unrelated), 1 new diagnosis of 
malignancy (unrelated)
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1 hospitalisation for Fournier gangrene 
(unrelated)
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Name et al Year 
Type of study i.e RCT, case 
control etc
No. of patients, years, location,
selection criteria,
Mean or median age, Gender 
distribution;
other
Diagnosis of C.diff i.e 
Elisa/PCR, 
duration from diagnosis to 
transplant
Aas 2003 Case series
19 recruited over 9 years (1994-2002) 
at a single centre (USA); two or more 
lab confirmed relapses after initial 
specific AB treatment, adequate clin 
and lab documentation of post 
transplant course; Mean age 73+9 
(SEM) (Range: 51-88 years); F: 13/18 
(72%); Hospitalised=5; nursing 
home=3; outpatient-GI clinic=10)
Lab confirmed via stool 
sample, toxin A only, then 
B added from 2001.
2 or more positive test 
stool tests (mean 3.2, 
range 2-7).
Mean period from 
diagnosis of c/diff colitis 
and stool transplantation 
102+24 (SEM) days (range 
25-497)
Allegretti 2016
Open label cluster dose finding 
trial comparing low dose (30 
pills) vs high dose (30 pills on 2 
consecutive days)
19-age/gender not stated
Diagnosis method not 
stated
Cammarota 2015 Open label RCT
prospective RCT comparing FMT plus 
vancomycin to vancomycin therapy 
alone for recurrent CDI; 39 patients 
over 12 months July 2013 to June 
2014; single centre; FMT group (n=20) 
mean age 71 years (range 29-89) F 12 
(60%); Vanc group (n=19) mean age 
75 (49-93) F 11 (58%)
CDI diagnosis was based on 
symptoms and toxin 
confirmed in 23/39(59%) 
positive ulture.mean 
duration of CDI diagnosis 
prior to FMT not stated
Study details
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Fischer et al. 2016 Retrospective cohort study
Of 328 patients in the developmental 
cohort, 73.5% (N=241) were females 
with a mean age of 61.4±19.3 years; 
19.2% (N=63) had inflammatory 
bowel disease (IBD), and 23.5% 
(N=77) were immunocompromised. 
Two academic centres. 2011-
2015. Of 134 patients in the 
validation cohort, 57% (N=77) 
were females with a mean age of 
66±18.1 years; 9.7% (N=13) had 
IBD, and 17.9% (N=24) were 
immunocompromised. Single 
centre. 2011-2015
Diagnosis of Cdiff if 
recurrent at least 3 
episodes of CDI and failure 
of 6-8 week vancomycin 
taper. Severe based on 
albumin, elevated white 
cell count and abdominal 
pain. Severe complicated 
defined as admission to ITU 
hypotension, fever, ileus, 
reduced GCS, elevated 
white cell count and lactate 
with end organ 
dysfunction.
Ganc et al 2015 Case series, retrospective
12 patients. No other variables 
reported
Not reported
Garborg et al. 2010 Case series, retrospective
39 patients (one had 2 FMTs). 
Treated single centre 1994-2008. 
Mean age 75y (range 53-94). F=21 
(53%)
Toxin positivity or clinical 
findings (37/40 toxin 
positive)
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Hamilton et al. 2012 Case series
43 patients. Single centre.  29 non-IBD 
and 14 IBD patients. Non IBD cohort 
(mean age 64.7y SEM 3.3; F 20 (69%)); 
IBD cohort (mean age 44.6 SEM 5.8; F 
11 (79%))
Inclusion criteria for FMT 
included a history of 
symptomatic, toxin-
positive, infection by C. 
difficile, and at least two 
documented subsequent 
recurrences despite use 
of standard antibiotic 
therapy.
Kao D 2016 - abstract (FMT 
arm of RCT)
Double blind RCT (capsule vs 
fresh)
43 patients, mean 67 years, F:30/43 
(70%). Two centres. 22 capsule 
group and 21 in colonoscopy group
Not reported
Kassam et al. 2012 Case series
27 patients: the mean age was 69.4 
years (range, 26-87 years) with 14 
male subjects (52%) and 22 in-
patients (81%).
Inclusion criteria were (1) 
laboratory-confirmed C 
difficile toxin using 
enzyme immunoassay 
with no other cause for 
diarrhea; (2) refractory 
CDI (defined as ongoing 
diarrhea despite 
antimicrobial treatment) 
or recurrent CDI (defined 
as symptom resolution 
for at least 2 days after 
discontinuation of 
treatment with 
recurrence of diarrhea); 
Kelly 2012 Case series
26 recruited over 28 months;single 
centre;at least 3 recurrences of CDI 
following multiple antibiotic 
courses;adequate clinical and lab 
documentation post transplant; Mean 
age 59 (19-86 yrs); F: 24/26 (92%)
Method of CDI diagnosis 
not stated;mean duration 
of diagnosis of CDI prior to 
FMT 12.6 M (range 4 to 84 
M);
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Kelly 2014 Case series
retrospective study of 
immunocompromised patients 
receiving FMT for CDI; 80 patients 
data analysed from 16 
centres;eligibilty assessed by 32 point 
questionairre;75 adults and 5 
children; Mean age in Adults 53 
(range 20-88) in children 10.9 (range 
6.5-16); Adults (n=75) F:38 (48%)
4 categories; 1 
recurrent/relapsing at least 
3 episodes with failure of 
up to 8 week taper with 
vancomycin or at least 2 
episodes of severeCDI 
resulting in hospitalisation 
and associated with 
significant morbidity.2 
Refractory CDI-moderate 
CDI not responding to 
standard therapy for at 
least a week 3 Severe CDI 
elevated WBC., low 
albumin and abdominal 
tenderness. 4 complicated 
CDI- Admission to ITU, low 
blood pressure, fever, ileus, 
mental state changes, 
elevated WBC, high lactate 
and evidence of end organ 
failure
Kelly et al. 2016
Double blind RCT (donor vs 
autologous FMT)
46 patients . Two centres. Donor 
FMT group n=22, mean age=48 
(SD 16); F=18 (82%); Autologous 
FMT group n=24, mean age = 
55(SD 14), F=19 (79%).
≥3 unformed stools over 24 
hours for 2 consecutive 
days and either a positive 
stool test result for C 
difficile or 
pseudomembranes on 
colonoscopy 
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Khan 2014 Case series
retrospective analysis of 20 cases over 
13 months (July 2012 to Aug 2013); 
selection criteria: all patients recieving 
FMT for CDI at their centre; single 
centre; adequate post transplant 
documentation and assessment; 
Demographic data presented 
seperately for community aquired and 
hospital aquired CDI; Calculated 
Overall Mean age 66.4 years; F 13 
(65%); Mean number of CDI episodes 
pre-FMT:5.6 community aquired and 
4.6 for hospital aquired
Method of CDI diagnosis 
not stated; data presented 
seperately for community 
aquired CDI and hospital 
aquired CDI; median 
duration of symptoms pre 
FMT for community 
aquired CDI was 7 months; 
5 months for hospital 
aquired CDI
Kronman 2015 Case series
retrospective study of 10 children in 
single centre over 3 years (between 
Aug 2011 and May 2014); At least 3 
episodes of CDI; adequate post 
transplant documentation and 
assessment; Mean age 5.4 years; F 
7/10 (70%);
C diff toxin A&B and/or 
PCR; median duration of 
symptoms pre-FMT 250 
days (range 90-541 days);
Lee 2014 Case series
retropsective analysis of 94 patients 
from 2008-2012; single centre; 
mixture of recurrent and refractory 
CDI definitions given; Mean age 71.8 
years (range 24-95 years); F 53/94 
(56.4%) 
C diff toxin A&B and/or 
PCR; duration of symptoms 
pre-FMT not stated
Lee CH 2016 (FMT arm of 
RCT)
FMT arm of double blind RCT 
(Fresh vs Frozen)
219 patients, mean 73 years, 
F:146/219 (67%)
Toxin and PCR
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MacConnachie 2009 Case series
retrospective analysis of 15 patients 
since 2003;single centre; recurrent 
CDI following succesful antibiotic 
therapy; Median age 81.5years (range 
68-95); F 14/15 (93.3%)
Method of CDI diagnosis 
not stated;mean duration 
of diagnosis of CDI prior to 
FMT not stated
Mattila 2012 Case series
70 patients over 3 years (2007-2010) 
all laboratory confirmed recurrent CDI 
refractory to standard treatment. 
Mean age 73(22-90) F=42(60%). 
60(86%) outpatients
positive culture and toxin; 
strain typing . Time from 
diagnosis to CDI mean 133 
days (46-360). 36(51%0 
had ribotype 027
Patel 2013 Case series
31 patients over 2 years (2011-2013) 
all had recurrent (at least 2 previouslt 
documented CDI episodes). Mean age 
61 (SD19) F=17(55%).17/31 (55%) gi 
comorbdiity. Diverticulitis (5), IBS (5), 
UC (3), CD(2), gastroparesis (1), 
coloanal fistula(1)
Diagnosis method not 
stated. Medain time(range) 
from index diagnosis to 
FMT 340 days(18-2205)
Pathak 2014 Case series
12 patients with recurrent or relapsing 
CDI with at least 3 episodes and 
failure of treatment with vancomycin 
+/- additional antibiotic such as fidox 
or patients wuth at least two episodes 
of severe CDI or patients with 
moderate CDI not responding to vanc 
for a week or patients with 
severe/fulminant CDI not responding 
to standar treatment for 48 h. 12 
patients over 3 years. mean age 72 
(SD 15) range 37-90; F 8/12 (67%) 
Diagnosis method not 
stated
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Ray 2014 Case series
20  (August 2012-November 2013) 2 
recurrences as defined by diarrhoea 
OR positive Cdiff after antibiotics 
(m,v,or f). Or if life threatening  
and/or admission to ICU. 20 patients 
mean age 62 (SD 18). F 16(80%). 15 
(75%) out patients. Average time from 
diagnosis to FMT 49.6 weeks
Diagnosis method not 
stated
Rohlke 2010 Case series
19 patients over 5 years(September 
2004-July 2009). At lesat 3 courses or 
treatment included vanc amn tapered 
vanc over 6 months.Mean age 49 (SD 
15). F17 (90%). All out-patients
Diagnosis method 
confirmed by lab in all 
cases but method not 
specified
Rubin TA 2013 Case series, retrospective
74 patients (75 courses), mean age 63 
years, F 49/74 (65%)
Diagnosis of CDI confirmed 
by lab only in a few cases. 
Method not specified.
Satokari R 2015 Case series, retrospective
49 patients, mean age 56 years, F 
34/49 (69)
Culture and toxin
Tauxe 2016 Case series, retrospective
31 patients, mean age 77 years, F 
18/31 (58%)
Not reported
Yoon 2010 Case series, retrospective
12 patients, mean age 66 years, F 
9/12 (75%)
Toxin positivity or clinical 
findings
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Youngster2014 Case series, prospective
20 patients, Median age 64.5; F 9/20 
(45%). Exclusion criteria - delayed 
gastric emptying synd, recurrant 
aspiration, pregnancy, significant 
immunocompromise, history of signif 
food allergy to food included in donor 
diet.
Toxin and ELISA, PCR if 
toxin negative but ELISA is 
positive or indeterminate
Zainah 2015 Case series, retrospective 14 patients, mean age 73 years, 
C. difficile toxin EIA and/or 
PCR
Brandt LJ 2012 Case series, retrospective
77 patients in 5 centres, mean age 65, 
F 56/77 (73%). 
Not reported
Allegretti Case series, retrospective
22 patients, mean age 55, F 18/22 
(82%)
C. difficile toxin EIA and/or 
PCR
Costello Case series, prospective
20 patients , median age 69 years, 
gender distribution not reported 
Not reported
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Agrawal 2016
multicentre, retrospective, lon 
term follow up study
146 patients, 100 (68.5%) women; 
mean age (range) 79. 
Not reported
Dutta 2014 Case series, prospective
27 patients, mean age 64.5y, F 22/27 
(81.5%)
Cdiff toxin positivity by 
ELISA
Emmanuelson 2014 Case series, retrospective 23 patients, mean age 66y, F 61% Culture and/or toxin EIA
Van Nood 2013
FMT arm of RCT (FMT versus 
vancomycin)
From January 2008 through April 
2010, 43 patients were randomly 
assigned to receive donor-feces 
infusion (17 patients), vancomycin 
(13), or vancomycin and bowel lavage 
(13). One patient assigned to receive 
donor-feces infusion was 
subsequently excluded from further 
analysis. Baseline demographics per 
groups: Donor Feces Infusion: 16 
patients; mean age +/-SD (73 +/-13); 
F: 8/16 (50%); Vancomycin only: 13 
patients; mean age +/-SD (66 +/-14); 
F: 7/13 (54%); Vancomycin and Bowel 
Lavage: 13 patients; mean age +/-SD 
(69 +/-16); F: 3/13 (23%)
Toxin and PCR. In 39 
patients, a positive toxin 
test before inclusion was 
confirmed by a positive 
C.difficile  culture. PCR 
ribotyping was performed 
on strains obtained from 
34 patients
Youngster 2014
FMT arm of open-label RCT (NG 
versus colonic delivery of FMT)
37 patients were assessed for 
eligibility and 20 patients underwent 
randomisation: Colonoscopy arm: 10 
patients, mean age +/-SD (50.4 +/-
28.8); F:6/10 (60%); Nasogastric 
tube:10 patients; mean age +/-SD 
(58.6 +/- 19.6); F: 5/10 (50%)
Toxin: initial 
toxin/glutamate 
dehydrogenase (GDH) 
enzyme-linked 
immunosorbent assay, 
followed by PCR only if the 
GDH test is positive or 
indeterminate, and does 
not routinely test for the 
NAP-1/B1/207 strain
Vigvari 2014 Case series, retrospective
30 patients, mean age 70.1 years (26-
88 years), Female: 18/30 (60%)
Not reported
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Pre FMT Abx +/- other therapy 
(M,V,Fidox,IVG)/How many courses 
i.e M(2), V(1), IVG(1), Fidox(1).
Were abx stopped prior to FMT
Refractory / Recurrent Flexi sigi / Colonoscopy findings
Healthy 
volunteer/Spouse/Related i.e 
mother/Other non related i.e 
friend
Mean 3.6 courses of abs (range 2-7)
abs varied (Clm, Cm, Cpfx, Ctri, Ctox, 
Amp, Gm, Clex, Mtz, Pen, Pip, tMp-
SMZ, Taz, Lev, Tet, Vm) number of 
courses prior to transplant varied: 2-7;
Recipients were pre-treated with vm 
(250mg q8h) for 4 or more days and 
this was discontinued the night before 
transplant.
recurrent (two or more lab confirmed 
relapses)
Not reported
15/18 were family members 
of recipient; no member 
availabe for remaining 3 so 
donors were healthy clinic 
staff. Hierachy of ideal donor 
described: intimate physical 
contact with patients 
(spouse/partner) > family 
houshold member > other 
healthy donor
Not stated Not stated Not reported
Healthy donors from 
OpenBiome stool bank mean 
age 36 years
All patients had antibiotics prior to 
diagnosis of CDI  but specifics not 
stated; FMt group patients had 3 days 
vanc prior to FMT which stopped the 
day before; vanc group had 10 days of 
standard vanc followed by at least 
three weeks of pulsed vanc
recurrent with lab confirmation
6 out of 20 patients in FMT group 
had pseudomembranous colitis
Healthy volunteers less than 
50 years old from which 16/20 
donors related; 2 intimates; 2 
unrelated
Patient characteristics Donor Characteristics
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Not reported
split into refractory, recurrent and 
severe complicated
Colonoscopies done on most
Mix of healthy volunteers (319 
69%) and family (143 31%)
Not reported Recurrent N/A
The donor is usually a family 
member of the patient who 
meets certain criteria, such as 
not having used antibiotics in 
the previous six months, being 
immunocompromised, and 
having no history of illicit drug 
use, tumors or inflammatory 
bowel disease. 
The patients were treated with 
metronidazole or vancomycin until 
reduction of symptoms. All anti- 
microbial therapy was discontinued on 
the evening prior to stool 
transplantation.
Recurrent
1 patient with 
pseudomembranous colitis
Close relatives or other 
household members were 
selected as stool donors. 
Individuals without symptoms 
of gastrointestinal disease or a 
history of chronic infectious 
disease were considered 
suitable for stool donation. 
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At least one failed antibiotic regimen 
had to include a minimum of a 6-week 
course of tapered or pulsed 
vancomycin dosage, or at least a 1-
month vancomycin course followed by 
a minimum of 2-week rifaximin 
“chaser.” 
Recurrent Not reported
patients were asked to self-
identify potential donors. 
These included mothers (n=2), 
daughters (n = 1), sons (n = 3), 
wives (n = 1), husbands (n = 1), 
and friends (n = 2).
Not reported Recurrent Not reported Unrelated volunteers
All had at least metronidazole; 19 
had subsequent vancomycin 
monotherapy. 8 had combination 
metronidazoleand vancomycin 
therapy.
Recurrent or refractory Not reported
Two healthy volunteers served 
as donors and were evaluated 
for transmissible pathogens. 
The donors took no 
antibiotics for 6 months 
prior to stool donation. 
antibiotics prior to CDI diagnosis- clind, 
cipro, metro, moxiflox, levoflox, 
azithro, cefurox, amox, augmentin; 
treatment for CDI-all had 
metronidazole, Sacchromyces 
bourladii, 4 had lactobacillus, 2 had IV 
IG, 19 had had rifaximin; pre-FMT all 
had 2 weeks of metronidazole or vanc, 
discontinued 2-3 days before FMT
recurrent at least 3 episodes (lab 
confirmation not stated)
11 had diverticular disease; 3 had 
colitis; 8 normal; 2 polyps; 2 
haemorrhoids; 2 previous surgery
25/26 family memebers; 1 
friend
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79/80 had been treated with 
vancomycin. 55/80 had metronidazole, 
23 had fidaxomicin, 13 had rifaximin 
and 30 had probiotics
recurrent CDI (at least 3 episodes and 
failure of vanc taper for 6-8 weeks); 
refractory (no improvement after 1 
week of vanc); Severe CDI or 
complicated (definitions given)
Not reported Not reported
3 or more recurrences of CDI and 
received a full course of vancomycin for 
their most recent acute episode.
Recurrent Colonoscopies done on all
All prospective donors 
underwent a medical 
interview and physical 
examination and were 
excluded if they had a known 
communicable disease, 
features of the metabolic 
syndrome, a diarrheal 
disorder, an autoimmune or 
atopic disease, a tumor, a 
neurologic disorder, or chronic 
pain syndrome or if they had 
used antibiotics for any 
indication within 3 months. 
Potential donors also 
completed a modified AABB 
full-length donor history 
questionnaire, and those with 
risk factors for infectious 
agents were ex- cluded 
(Supplement). 
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Antibiotic treatment for CDI: 
metronidazole (1 patient had 1 course; 
7 patients had 2 courses; 12 patients 
had 3 courses); vancomycin (2 patients 
had 1 course; 12 patients had 2 
courses; 4 patients had 3 courses; 2 
patients had pulsed vanc); 9 had 
fidaxomicin; all antibiotics stopped 48 
hours before FMT
not explicityly stated but patients had a 
mean of 4.6-5.6 episodes of CDI prior 
to FMT
Not reported
5/20 from spouse/partner; 
14/20 family member;1 non-
relative
Antibiotics used prior to CDI diagnosis-
metronidazole, augmentin, ampicillic, 
amoxycillin, cefdinir, cefuroxime, 
penicillin; CDI tretament all had 
metronidazole, 6/10 had vancomycin, 
8/10 had vancomycin taper; pre-
transplant all had vanc or fidaxomicin 
for 7 days, last dose given 24 hours pre-
transplant
recurrent CDI; mean of 3.2 episodes 
pre-FMT
Not reported 9/10 parents; 1 sibling
Mean of 2,1 courses of antibiotics for 
CDI prior to FMT (metronidazole 79.3%, 
vancomycin 75%, vancomycin taper 
15.2%, combination metro and vanc 
17.4%, 3 patients had IVIG); pre-
tranplant all antibiotic therapy for Cdi 
was discontinued 24 hours before FMT
recurrent (recurrent diarrhoea after at 
least 2 days of resolution following 
antibiotic therapy) or refractory 
(ongoing diarrhoea despite at least 5 
days of oral vancomycin)
Not reported 2 unrelated donors
Metronidazole and Vancomycin Both Not reported Unrelated volunteers
Page 103 of 156 Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Antibiotics prior to CDI diagnosis not 
stated; 15/15 received 
metronidazole;15/15 received vanc, 3 
received iVIG; vanc given pre-
procedure but length of course not 
stated; stopped 12 hours before FMT
recurrent CDI defined as recurrence of 
diarrhoea after successful antibiotic 
therapy typically within 7 days of 
stopping antibiotics; 
Not reported
related donors specifics not 
given
mean 4.5 courses of antibiotics. Metro, 
vanc, rifax, 1 IVIGStopped 36 hours 
before FMT
recurrent (two or more lab confirmed 
relapses)
Not reported
61(87%) family members; 
9(13%) healthy donors
Stopped (usually vanc) 4 hours before 
bowel prep. Loperamide 4mg either 
before or immediately after FMT
recurrent (two or more lab confirmed 
relapses)
Not reported
"Mostly" family. 14 spouses, 9 
children, 5 siblings, 3 parents, 
1 niece, 1 friend
Antibiotics stopped 24 hours prior to 
procedure
Refractory / Recurrent and severe
8 colitis, 1 Cdiff, 1 haemorrhoid, 1 
pseudomembranous colitis, 1 
diverticulosis
10 family, 2 spouses
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Antibiotics stopped 48 hours prior to 
procedure
16 recurrent; 4 severe/complicated Not reported
10 family, 8 spouses, 2 healthy 
donors
Antibiotics stopped 1-3 days before 
FMT
recurrent Not reported
4 family, 14 partner, 1 
housemate
Vancomycin and / or metronidazole Recurrent Not reported Healthy household members
Not reported Refractory Not reported
Frozen stool: 2 unrelated 
donors. Fresh stool: Family 
members, healthy volunteers, 
or the same universal donors.
Combinations of Vancomycin, 
Metronidazole, Fidoxamicin, Rifaximin
Both Not reported
7 were from family members, 
rest were volunteers
Combination of metronidazole, 
vancomycin,
rifaximin, bacitracin, nitazoxanide
Both
9/12 normal colonic mucosa, 3/12 
had pseudomembranes
All family members (partner:8; 
child or grandchild:4)
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Failed vancomycin taper and or 
fidaxomycin. 
Refractory or recurrent. Defined 3 
episodes of mild to moderate CDI or 
failure of 6-8 week taper with 
vancomycin, or atleast two episodes of 
severe CDI resulting in hospitalisation 
and associated with significant 
morbidity. Active CDI defined as more 
than 3 loose stools per day with a 
positive stool test.
Not reported Unrelated adult volunteers
Vancomycin and / or metronidazole Both Not reported
12 from family members, 1 
from unrelated volunteer
Failed on average of five conventional 
antimicrobial regimes; including 
metronidazole (81%), vancomycin (99% 
standard and pulsed) and/or tapered 
regime with or without rifaxmin (22%) 
or probiotics (77%).
Recurrent CDI (unresponsive to 
standard therapy)
Not reported
60% partners/spouses; 27% 
were either first degree 
relatives or otherwise related 
to the patient. ; one case - 
unknown person.  In all, 56 of 
77 donors resided in the same 
household as patient.
Several but eligibility included starting 
vancomycin for 7 days before 
procedure and stopping day before
Both. Relapsing defined as three or 
more episodes of CDI or refractory 
disease that is unreponsive to 
traditional antibiotics.
Not reported
Patient identified donors-
spouse, family, friend. My co-
inhabit
Not reported Recurrent disease Not reported Healthy volunteers 
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Conventional therapy with met, van 
and/or fidaxomicin had failed in all. 
Some takinh probiotics. Om average 
Recurrent defined as recurrentce of 
diarrhoea after completion of 
treatment. Severe CDI defined as low 
Not reported
Donors usually identified by 
patient. One healthy volunteer 
not identified by patient
Most patients received metronidazole 
and/or vancomycin Other antibiotics 
included fidaxomicin, rifaximin.
Recurrent (>2 recurrences)
Active colitis seen in 26/27 
patients with pseudomembranes 
in 2
Healthy donors selected via 
thorough clinical evaluation to 
exclude any transmissible 
disease. 10 spouse, 12 son or 
daughter, 1 parent, 4 friends.
Metronidazole and/or Vancomycin Relapsing and recurrent Not reported
Spouse or close relative of 
good health
At least one course of adequate 
antibiotic therapy (>=10 days of 
Vancomycin at a dose of >=125mg four 
times a day or >=10 days of 
Metronidazole at a dose of 500mg 
three times per day). In FMT group: 
patients received an abbreviated 
regimen of Vancomycin (500mg orally 
four times per day for 4 or 5 days), 
followed by bowel lavage with 4 liters 
of macrogol solution (Klean-Prep) on 
the last day of antibiotic treatment and 
the suspension of donor feces through 
a nasoduodenal tube the next day
Recurrent Not done
Healthy volunteers <60 years 
of age (faces from 15 donors 
were used for 43 infusions in 
the infusion group and for 
patients who had a relapse 
after vancomycin treatment)
Patients had a median of 4 (range, 2-
16) relapses prior to study enrollment, 
with 5 (range, 3-15) antibiotic 
treatment failures of a 6- to 8-week 
taper with Vancomycin (95% of 
patients) with or without an alternative 
antibiotic, including Fidaxomicin (70% 
of participants).Patients were required 
to discontinue all antibiotics at least 48 
hours prior to the procedure
Relapsing or recurring (having at least 3 
episodes of mild-to-moderate CDI OR 
at least 2 episodes of severe CDI 
resulting in hospitalization and 
associated with significant modbidity
Not reported
Healthy volunteer donor: 
nonpregnant adults, 18-50 
years of age, on no 
medications, with a normal 
body mass index
Not clear from paper, but it appears 
most patients had vancomycin
Refractory and recurrent Not reported
Donors were relatives in 22 
cases (73.3%) and unrelated 
volunteers in 8 cases (26.7%).
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Screening and abx cessation
Fresh/Frozen, Route 
administered
Sample preparation
Transplant sample sourcing, screening, preparation;
, volume, mixing solution, storage and time from 
collection to transplant 
Proceedure:
Bowel Prep/Drugs used prior 
to FMT i.e Moviprep 2 
sachets/PPI (dose), prokinetic 
(dose), Loperamide
FMT administration
Follow up method
Within 30 days before donation 
(usually 7 days) screened: 
Blood:HAV (HAV ab (IgM and IgG), 
HBV (ab to HepB surface antigen 
and core antigen), HCV (HCV ab 
RIBA-II), HIV-1 & 2 (EIA), 
Treponema pallidum (rapid plasma 
reagin test). 
Stool: C diff (Toxin A or B 
(cytotoxin) detection), enteric 
bacterial pathogens (selective 
stool culture), ova/parasites (light 
microscopy)
No antimicrobial therapy in 
previous 6 months
Fresh
nasogastric, with tube 
placement on morning 
of transplant and tube 
tip placement 
confirmed by 
radiography
Stool obtained 6 or less hours prior to transplant. 
Approx 30g or 2cm
3
 preferably soft stool selected and 
homogenised in 50-70ml 0.9N sterile saline (household 
blender - slow speed setting initially, rising gradually to 
maximum and continued then for 2-4 min) until sample 
smooth. Filtered through coffee paper filter x2 allowing 
adequate time for slow filtration to end.  
20mg omeprazole evening 
before and morning of 
transplant. 
25ml of stool suspension 
adminitered then tube flushed 
with 25ml sterile 0.9N saline.
Tube removal. Normal diet 
and physical activites allowed 
immediately.
Follow up by telephone or 
clinic visit and stool specimens 
examined for c.diff toxin A in 
most patients.
open Biome Criteria followed Frozen pills Not stated Not described
no antibiotics for 6 months; stool 
tested for C. diff , enteric 
pathogens, ova and parasites, 
MDR gram nehgatives, MRSA, VRE;  
Serum tested for Hep A, Hep B, 
Hep C, HIV 1 and 2, strongyloides, 
treponema, Entamoeba. High risk 
lifestyle, FH of GI cancer, IBD, 
systemic diseases, personal GI 
disease
fresh via colonoscopy
Mean time from donation to infusion was 3.8 
hours;mass of donation not stated but mixed with 
500mls saline and blended and strained; delivered to 
right colon through colonoscope
2 groups FMT group received 
4L of macrogol bowel 
cleansing solution for 1-2 days 
on the last 2 days of 
vancomycin followed by FMT. 
The other group had bowel 
cleansing and vancomycin 
standard treatment. 
Donor Characteristics FMT characteristics
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Sporicidal disinfection was 
performed in patient rooms as per 
institutional protocols; specific 
instruc- tions with handouts 
regarding sporicidal home cleaning 
were provided to patients to 
prevent reinfection. 
Fresh or frozen via 
Colonoscopy and NG 
tube
Not reported Not reported
Some tests are performed for 
screening: serology for hepatitis A, 
B and C, human immunodeficiency 
virus (HIV), fecal parasitology, fecal 
test for Clostridium difficile, and 
fecal culture. 
Fresh via 
enteroscope
Mixed in N. Saline. Volume and other variables not 
stated
Not reported
Donors were screened for 
hepatitis A, B and C and HIV 
infection, as well as enteric 
bacterial pathogens including 
Salmonella, Shigella, Campy- 
lobacter and Yersinia species. 
Fresh via Gastroscopy 
or colonoscopy
A fresh stool sample of 50–100 g was obtained from the 
donor on the day of the instillation procedure. The stool 
sample was spread out onto a gauze pad which was 
then placed in a strainer. The gauze was flushed with 
250 ml sterile 0.9% NaCl and the resulting suspension 
was collected and aspirated into syringes. A flexible 
videogastroscope was intro- duced into the distal 
duodenum. Approximately 200 ml of sample solution 
was introduced 
No bowel prep given to colonic 
delivered FMT
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The donorshad to submit their 
medical records and  underwent 
serologic testing for HIV and 
Hepatitis B and C, and stool testing 
that included screening for routine 
enteric pathogens, C. difficile 
toxin B, and examination for 
ova and parasites, and Giardia 
and Cryptosporidium antigens. 
Donors were excluded if they 
had GI co-morbidities or had 
used antibiotics within 3 
months. 
Fresh or frozen via 
Colonoscopy
Approximately 50g of fecal material was placed into a 
standard commercial blender (Oster, Subeam, Rye, NY) 
and homogenized in 250 ml of sterile, non-bacteriostatic 
normal saline. Faceal suspension, if stored , was put in 
10% glycerol and stored at -80 for up to 8 weeks. The 
frozen preparation was diluted in 250ml salne before 
infusion.
Patients were maintained on 
full dose of vancomycin 
(125mg, four times daily by 
mouth) until 2 days before the 
FMT proce- dure. The day 
before the procedure, the 
patients were prepped using a 
split dosage polyethylene 
glycol purge (GoLYTELY or 
MoviPrep), which is standard 
in our endoscopy unit, before 
colonoscopies to wash out 
residual antibiotic and fecal 
material.
Not reported
Oral capsules vs 
colonoscopy
Not reported Not reported
Blood was screened for hepatitis B 
surface antigen, hepatitis C 
antibody, Helicobacter pylori and 
syphilis serologic markers, human 
immunodeficiency virus types 1 
and 2, and human T-lymphotropic 
virus types I and II. Stool was 
processed for enteric bacterial 
pathogens, C difficile toxin, and 
ova and parasites. 
Retention enema
Approximately 150 g of fresh stool collected was 
emulsified in 300 mL of sterile water. The supernatant 
component was administered rectally by en- ema. 
All CDI therapy was 
discontinued at least 24 hours 
prior to FT.
no antibiotics in preceding 90 
days; blood for HAV, HBV, HCV, 
HIV 1&2, Treponema pallidum; 
stool for culture for bacteria, stain 
for ova and parasites, C. diff. toxin 
A and B
Fresh via colonoscopy
stool obtained 6 hours or less prior to transplant6=8 
tablespoons of donor stool added and shaken in 1litre of 
sterile water passed through gauze. Aliquoted in 60ml 
syringes.
polyethelene glycol bowel 
prep night before transplant; 
500-960mls administered via 
scope mainly to rightcolon; 
Avoid defecating for 30-45 
mins
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Not reported
fresh or frozen not 
stated; 12 of 16 centres 
used colonoscopy 
route
Not reported
prep not stated; questionnaire 
sent out to 16 centres to 
retrospectively collect data; 
method of follow up at each 
centre not stated but had to 
have data for at least 12 weeks 
to be eligible for inclusion
Testing for HIV-1 and HIV-2 was 
performed within 2 weeks before 
donation for FMT. Other serologic 
and stool testing was performed 
within 1 month before FMT and 
included testing for hepatitis A, B, 
and C viruses; testing for 
Treponema pallidum; polymerase 
chain reaction (PCR) testing for 
detection of C difficile toxin; 
culture for enteric pathogens (Esch- 
erichia coli, Salmonella, Shigella, 
Yersinia, Campylobac- ter, Listeria 
monocytogenes, Vibrio 
parahaemolyticus, and V 
cholerae); testing for fecal Giardia 
and Cryptosporidium antigens; 
acid-fast stain for detection of 
Cyclospora and Isospora; ova and 
parasite testing; and enzyme 
immunoassay for detection of 
Rotavirus.
Fresh via colonoscopy
The protocol specified a “dose” of 100 g of stool diluted 
in 500 mL of nonbacteriostatic 0.9% normal sa- line 
immediately before the procedure, but the study relied 
on fresh stool, which has unpredictable weight and 
volume, and most provided specimens were less than 
100 g. 
Donors took an osmotic 
laxative (magnesium 
hydroxide) the evening before 
and provided fresh stool the 
day of FMT. All donor 
specimens were transported 
on ice and processed within 6 
hours of collection. Patients 
were given a standard bowel 
purge (sodium sul- fate, 
potassium sulfate, and 
magnesium sulfate oral 
solution) the evening before 
the procedure. For patient 
convenience, sodium sulfate, 
potassium sulfate, and 
magnesium sulfate oral 
solution was substituted for 
the polyethylene glycol (PEG) 
bowel purge described in the 
study protocol. 
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no antibiotics for 3 months; stool 
tested for C. diff toxin PCR, enteric 
pathogens, ova and parasites, 
Cryptosporidium, Microspora; 
Serum tested for Hep A, Hep B, 
Hep C, HIV 1 and 2; H. pylori' 
Human T lymphotropic virus
fresh via colonoscopy
stool obtained within 30 mins of transplantation; 50g of 
stool into 200mls of saline and blended; Aspirated into 
single 60ml syringe for delivery
4 litres polyethelene glycol 
bowel prep; 60mls 
administered via scope into 
right colon; follow up 
combination of clinic, 
telephone and questionairres
no antibiotics for 3 months; stool 
tested for C. diff , enteric 
pathogens, ova and parasites;  
Serum tested for Hep A, Hep B, 
Hep C, HIV 1 and 2; CMV, EBV, 
high risk behaviours, systemic 
antineoplastic drugs, 
immunosuppressives, history of GI 
disease. Directed donors to avoid 
foods which recipient may be 
allergic to for 5 days prior.
fresh via NGT
time from collection to transplant not stated; 30g stool 
added to 100mls saline and blended;filtered throgh 
gauze; 30-60mls infused
8.5g-17g polyethylene glycol in 
8oz of water 3 times a day for 
2 days prior to FMT; 
omeprazole 1mg/kg orally day 
before and on day of FMT; 
follow up all patients called 2 
days after FMT, further follow 
up combination of clinic, 
telephone and repeat C. diff. 
testing
no antibiotics for 6 months; stool 
tested for C. diff , enteric 
pathogens, ova and parasites, 
norovirus,enterovirus;  Serum 
tested for Hep A, Hep B, Hep C, 
HIV 1 and 2, human lT-cell 
ymphotrophic virus 1&2, 
treponema
retention enema
time from collection to transplant not stated; 150g stool 
added to 300mls water and homogenised with spatula 
100mls infused
no bowel prep stated;100mls 
infused via enema;follow up 
methods not stated but 
retrospective analysis 
extracted from clinical record
Questionnaire. Pathogens, HIV, 
HABC, CMV, EBV, syphilis, 
strongyloides, entamoeba. 
Screening every 4 months
Fresh and Frozen. 
Lower GI route
100g of stool homogensied and mixed in 300mls of 
water. If frozen kept for 30 days at -20C. If fresh 
administered within 24hrs.
Nil
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Within 30 days before donation 
(usually 7 days) screened: 
Blood:HAV (HAV ab (IgM and IgG), 
HBV (ab to HepB surface antigen 
and core antigen), HCV (HCV ab 
RIBA-II), HIV-1 & 2 (EIA), 
Treponema pallidum (rapid plasma 
reagin test). 
Stool: C diff (Toxin A or B 
(cytotoxin) detection), enteric 
bacterial pathogens (selective 
stool culture), ova/parasites (light 
microscopy)
No antimicrobial therapy in 
previous 6 months
Fresh via NGT
time between stool collection and transplant not stated; 
30g of stool blended with 150mls saline and filtered; 
30mls infused via NGT
no bowel prep stated;30mls 
infused via NGT;omeprazole 
given prior to FMT; follow up 
methods not stated but 
retrospective analysis 
extracted from clinical record
No antibiotics for 6 months. Blood 
for FBC, CRP, protein,creatinine, 
LFTs, HBV, HCV, HIV 1 &2, 
treponema. Stools for Cdiff, 
pathogens, OCP, 
Fresh, within 6 hours 
colonoscopic
Stool obtained 6 or less hours prior to transplant. 
Homogenised in 100-200ml water.
Colonic lavage ith 4l PE 
solution.
No antibiotics for 3 months. 
Excluded chronic gastrointestinal 
condirions, active peptic ulcer 
disease, GERD, IBS,IBD,polyps, 
mlaignancy. Blood for HABCV, HIV, 
Treponema, stool for culture, OCP, 
cryptosporidium, microsporidia, 
Cdiff
Fresh, colonoscope
Donors given 30ml MgOh evening before donation. 
Stools within 6 hours of passage blended with 100ml 
Nsaline and sieved for delivery.
Bowel prep for colonoscopy 
(not stated which), 4mg 
operamide either before or 
after FMT
High risk behaviours, no antibiotics 
for 3 months, Blood for HIV, HABC, 
STDs, stooll for bacterial culture, 
OCP, Cdiff
Fresh, colonoscope 
(11); 1 nasoduodenal
Donor given mg citrate before. stool collected within 6 
hours of preocedure. 6-8 tablespoons to 1l tap water, 
shaken. 
PEG bowel prep, 400-500 ml 
to TI/Right colon. Patients 
given 2 tablets of 
diphenoxylate/atropine. A 
week later 2 month course of 
Saccharomyces boulardii
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3 unscreened. High risk 
behaviours, antibiotics in 3 
months, blood for HIV, HABC, 
terponema, stool for Cdiff, 
bacterial culture, OCP, Giardia, 
Cryptosporidium, 
Fresh, colonoscope Time between donation and colonoscopy not stated
On day of treatment patients 
given 2 imodium tablets 2 
hours prior and 1 after. Bowel 
prep not recorded.
Selective based on discretion. 
Blood from some for viruses 
(HABC, HIV), stool from some for 
Cdiff and enteric pathogens
Fresh colonoscope Time between donation and colonoscopy not stated
PEG bowel prep. Some (not 
clear how many) had 2 
immodium immediately after 
and then again6 hours after 
FMT
Screened for occult infectious 
conditions and no abx use in 
preceeding 3 months
Fresh, Upper GI (NG or 
PEG)
30 g of donor stool in mixed in saline. 25mls given in an 
infusion.
Pre-treated with 3 days of 
vancomycin and proton pump 
inhibitor prior to procedure
No significant medical history, no 
antibiotics for prior six months. 
Donor feces were screened for 
enteric pathogens and blood was 
screened for antibodies to 
hepatitis A, B, and C; HIV; and 
Treponema pallidum within 2 
weeks of donations
Fresh: 26 patients; 
Frozen: 23 patients. 
Administered by 
colonoscopy
30g of stool in 200mls of saline or glycerol. If frozen 
stored in -80C for up to 16 weeks.
Polyethylene glycol prior to 
procedure
Not reported Fresh, both routes Not reported Not reported
Donor feces were screened for 
enteric pathogens and blood was 
screened for antibodies to 
hepatitis A, B, and C; HIV
Fresh via colonoscopy
Stool collected morning of transplant, filtered and mixed 
with saline. 250 - 400mls infused into patient.
Abx stopped 3 days prior to 
FMT
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Age range 18-50 years, BMI 18.5 - 
25. No significant medical history, 
not pregnant, no antibiotics for 
prior six months. Donor feces were 
screened for enteric pathogens 
and blood was screened for 
antibodies to hepatitis A, B, and C; 
HIV; and Treponema pallidum 
within 2 weeks of donations. 
Donors refrain from common 
allergens for 5 days before 
donation. 
Capsule (oral) frozen 
for mean of 113 days 
(range 30-252 days).
Each inoculum was prepared from the feces of a single 
donor. The final slurry was concentrated by 
centrifugation and resuspended in saline at one-tenth 
the volume. Fecal matter solution was pipetted into size 
0 capsules (650 μL), which were closed and then 
secondarily sealed in size 00 capsules. Capsules were 
stored frozen at −80°C (−112°F) Wll use. A full treatment 
of 30 capsules contained sieved, concentrated material 
derived from a mean of 48 g of fecal matter (mean per 
capsule, 1.6 g; range, 1.0-2.05 g). Samples stored for 4 
weeks without use to allow for retesting for HIV, hep B 
and C. (full screening and exclusion details given in 
appendix)
Abx stopped 48 hrs prior to 
FMT
Donor feces were screened for 
enteric pathogens and blood was 
screened for antibodies to 
hepatitis A, B, and C; HIV
Fresh. Upper GI in 13 
patients, lower GI in 1 
patient
Fresh stool sample (30–50 g) homogenized and mixed 
with water. About 120–180 ml of the suspension was 
instilled through NGT; 300–500 ml was administered if 
IMT was done via colonoscopy.
Abx stopped 24 hrs prior to 
FMT and given proton pump 
inhibitor prior to procedure
Excluded if abx within preceding 3 
months. Exclusion criteria also 
included immunosuppressive 
agents, including 
chemotherapeutic agents; had 
known or recent exposure to 
HIV,hepatitis B or C;had a current 
communicable disease; 
participated in high-risk sexual 
behaviors; used illicit drugs; had a 
history of incarceration; traveled 
within 6 months to areas with 
endemic diarrheal illnesses; or had 
history of infl ammatory bowel 
disease, irritable bowel syndrome 
or chronic diarrhea, 
gastrointestinal malignancy or 
polyposis). Blood tested for HIV, 
Hep A/B/C and stool for OCP and 
giardia antigen and 
cryptosporidium
Fresh (within 8 hours), 
colonoscopy
Suspended in saline, mixed by hand or blender, filtered 
and infused as 300 to 700 mls 
Abx stopped 48 to 72 hrs prior 
to FMT. Bowel prep given 
before procedure
no abs for 3 months. No laxatives, 
hstory of constipation, no history 
of GI disease, travel in 3 months, 
not on immunosuppressives or 
chemo. No metabolic syndrome, 
autoimmune, atopic disease
Fresh (within 6 hours), 
colonoscopy
Fresh in blender 500ml Nsaline, strained. 60ml drawn up 
in 8-9 syringes per patient.
Abs stopped prior to 
procedure.
screening as per FDA guidelines 
2011
Frozen stool (> 2 
months in 16 patients 
and <2 months in 4 
patients), colonoscopy 
route in 19, jejunal 
30g in 120ml N.saline, divided into 50ml aliquots Not reported
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Excluded if "history of antibiotic 
use" (time not specified), high risk 
behaviour, prisoners, GI disease, 
Fresh. Initial FMT in 
118(81%) colonoscope, 
13(9%) OGD, 3(2%) 
Milk of magnesia to donors. 60-100g stool suspended in 
300-500ml nsaline, mixed, sieved. 75-200ml for upper 
route (OGD, enteroscopy), 250-400ml colnoscopically, 
Bowel prep given. Loperamide 
after FMT
Blood and stool screened for 
transmissible diseases
Fresh, given via a 
combination of jejunal 
and colonic route
25-30g of stool given as 180mls via enteroscopy and 
270mls via colonoscopy
Not mentioned
Potential donors were accepted 
only if serum antibodies against 
HIV 1 and 2, hepatitis C virus, and 
hepatitis B surface antigen were 
negative, as were stool cultures for 
Salmonella, Shigella, 
Campylobacter, enterohemolytic 
Escherichia coli, and Clostridium 
Fresh, given as enema 
(lower GI
50g of fresh faeces prepared in an anaerobic cabinet by 
adding and stirring small portions of pre-reduced and 
pre-warmed (37 °C) sterile isotonic saline, to a total of 
500 ml.
Not mentioned
Questionnaire adressing risk 
factors for potencially 
transmissible diseases. Donor 
feces were screened for parasites, 
including Blastocystis hominis and 
Dientamoeba fragilis; C.difficile, 
and enteropathogenic bacteria. 
Blood was screened for HIV; 
human T-cell lymphotropic virus 
types 1 and 2; hepatitis A,B, and C; 
cytomegalovirus; Epstein-Barr 
virus; Treponema pallidum; 
Strongyloides stercoralis; and 
Entamoeba histolytica. A dnor pool 
was created, and screening was 
repeated every 4 months. Before 
donation, another questionaire 
was used to screen for recent 
illnesses. 
Fresh via nasoduodenal 
tube
Feces were collected by the donor on the day of infusion 
and immediately transported to the hospital. Feces were 
diluted with 500mls of sterile saline 0.9%. This solution 
was stirred, and the supernatant strained and poured in 
a sterile bottle.  A mean (+-SD) of 141+-71g of feces was 
infused. The mean time from defecation to infusion was 
3.1+-1.9 hours
Bowel lavage with 4 liters of 
macrogol solution (Klean-Prep) 
on the last day of antibiotic 
treatment. Within 6 hours 
after collection of feces by the 
donor, the solution was 
infused through a 
nasoduodenal tube (2 to 3 
minutes per 50mls). The tube 
was removed 30 minutes after 
the infusion, and patients were 
monitored for 2 hours. 
Patients kept a stool diary and 
were questioned about stool 
frequency and consistency, 
medication use, and adverse 
effects. Stool tests for 
C.difficile toxin were 
performed on days 14,21,35, 
and 70 and whenever 
diarrhoea occured. 
Volunteers were excluded for any 
significant past medical history  or 
any use of antibiotics in the 
preceeding 6 months. Initial 
screening using the American 
Association of Blood Banks donor 
questionaire for exposure to 
infectious agents. Physical 
examination and general 
laboratory screening tests (within 
30 days of donations). All results 
had to be within normal range for 
age and sex. Donor feces were 
screened for enteric bacterial 
Frozen via colonoscopy 
or NGT
Donors were asked to take a dose of milk of magnesia 
the day before fecal collections to facilitate 
manipulation of the sample. A fecal suspension was 
generated in normal saline without preservatives, using 
commercial blender. Materials were passed through 4 
sieves to remove particulate material. The final slurry 
was concentrated 3-fold by centrifugation and then 
resuspended in sterile saline with 10% glycerol added as 
a bacterial cryoprotectant. Inocula were then frozen at -
80 C pending use. Each sieved inoculum was calculated 
to have been derived from approximately 41g of fecal 
material. Inocula were stored frozen for up to 156 days, 
range, 29-156 days; frozen material was thawed in a 37 
C water bath, and then kept on ice until delivery. 
Subjects assigned to 
colonoscopic administration 
underwent a standard bowel 
preparation with 4 liters of 
PEG solution, followed by 
endoscopic administration to 
the right colon of 90 cc thawed 
inoculum:further diluted to 
250cc for adults and 160 cc for 
paediatric patients. Patients 
were given a single oral dose 
of loperamide at the time of 
procedure. Subjects assigned 
to NGT delivery of FMT were 
Pre-medical examination was 
carried out with a questionnaire in 
order to rule out high-risk 
individuals (such as drug use, 
promiscuity, known illness, taking 
antibiotics or trips abroad in the 
past six months). Stool samples 
Fresh stool delivered 
via nasogastric route in 
15 patients and 
nasoduodenal route in 
15 patients
60 grams, it was placed in 200 mL of mortar 
physiological saline (0.9%) and harvested. then the 
homogenate of 4 × 4 cm was filtered sterile gauze pads 
transferred to another vessel and finally were taken 
from the filtrate up to 100 ml syringe and given to 
patient within 6 hours.
Antibiotics were stopped prior 
to transplant and patients 
were given laxatives. Patients 
received both metoclopramide 
and high dose proton pump 
inhibitor on the day of the 
transplant.
Page 116 of 156Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Total no of infusions Define primary outcome
not explicitly stated. Data 
implies a single infusion 
on a single occasion for 
each patient
Not explictly stated, but 
authors report outcome 
based on symptom 
resolution and / or CDI 
toxin negativity
NA
Clinical resolution of 
diarrhoea at 8 weeks
13/20 had 1 FMT; 6/20 
had co-existent PMC and 
received infusions every 3 
days until symptom 
resolution (4 had 2 
infusions, 1 had 3 
infusions and 1 had 4 
infusions
Resolution of diarrhoea 
10 weeks after the end of 
the treatments
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Not reported
Early Failure rate 
defined as non-
response or recurrence 
of diarrhoea with either 
toxin or PCR positive 
CDI within 1 month of 
FMT
1 infusion via 
enteroscopy
not defined in paper 
but implied symptom 
free to end of follow up
I infusion via gastroscopy 
or colonoscopy
successful treatment 
defined as no further 
contact with the clinic 
due to CDI symptoms 
within 80 days of FMT
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4 of 43 had repeat 
infusion
Not specified
1 infusion via 
colonoscopy or 1 course 
of capsules.
Defined as cure but no 
time period given
Five patients underwent 
a second FT because of 
ongoing diarrhea; 3 had 
symptom resolution and 
2 continued to 
experience diarrhea 
despite 2 FTs. 
resolution of symptoms-
no time period defined
not explicitly stated but 
imples single infusion for 
all patients
Prevention of further CDI 
relapse and/or significant 
diarrhoea requiring 
vancomycin; time frame 
for outcome not stated
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78 patients had single 
infusion; 12 patients had 
2 infusions
response defined as 
absence of diarrhoea or 
marked reduction in stool 
frequency and without 
need for further 
antibiotics within 12 
weeks after 1 or more 
FMTs
1 infusion via 
colonoscopy
Resolution of diarrhoea 
without need for anti 
CDI therapy during 8 
week follow up
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18 had single infusion; 2 
had 2 infusions
Resolution of diarrhoea 
without recurrence of 
symptoms within 3 
months of FMT
9 patients had single 
infusion, 1 patient had 2 
infusions
Not defined in paper but 
implied symptom free to 
end of follow up
if no resolution of 
diarrhoea after 7 days 
post FMT then further 
enema give. Range given 
1-10(46/94 had 1 FMT, 
20/94 had 2 FMT, 17/94 
had 3 FMT, 11/94 had 4 
or more)
Cured following FMT if no 
recurrence of diarrhoea 
at 6 months follow up
1, if no response at day 4, 
then further FMT and if 
no response then FMT or 
abx. Primary outcome 
based on up to 2 FMTs.
Clinical resolution of 
diarrhea without relapse 
at 13 weeks
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14/15 had 1 FMT;1/15 
had 2 FMT
Not explicitly stated but 
implied that "cure" was 
no symptoms at follow 
up after 1 FMT
67 had 1; 3 had 2
Resolution diarrhea 
without a positive C 
difficile toxin stool test at 
12 weeks
28 had 1; 3 had 2 Not defined.
1 infusion in all but 1 
patient who had repeat 
via ND route 
No strict definition. 
Authors state : 'A 
successful treatment was 
determined by the 
resolution of diarrhea, a 
fall in white cell count, or 
absence of fever and an 
improvement in vital 
signs'.
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1
Resolution defined as 
positive stools after FMT. 
1
not defined in paper but 
implied symptom free to 
end of follow up
1
Resolution of diarrhea 
without recurrence 
within 60 days of FMT
1
Resolution of diarrhoea 
with a negative C. difficile 
toxin stool test at 3 
months
1 infusion in 27 patients, 
multiple infusions in 4 
patients
Resolution was defined 
as the absence of 
significant diarrhea 
(diarrhea as defined by at 
least three episodes per 
day) or a marked 
reduction in diarrhea not 
requiring antibiotic 
therapy.
1
Clinical response was 
defined as absence of 
diarrhea, cramps, and 
fever within 3 to 5 days 
of transplant
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N/A
Response defined as less 
than 3 bowel movements 
in 24 hrs
 1 in 10 patients, 2 in 2 
patients, and 3 in 2 
patients received three 
FMTs 
 Defined as less than 3 
loose bowel movements 
a day for 2 consecutive 
days after FMT and no 
need for further CDI 
therapy on day 7. 
1 infusion in 75 patients, 
2 infusions in 2 patients
Resolution without 
recurrence within 90 days 
including those that 
needed a second infusion 
or antibiotics
1 infusion 
Primary outcome not 
defined
1 infusion in 17 patients, 
2 infusions in 3 patients
Resolution of diarrhoea 
and/or absence of CDI 
toxin in stool as 
measured by PCR after at 
least 3 months follow up 
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 146 had one infusion, 12 
out of 25 early 
recurrences had another 
Initial Resolution of CDI 
symptoms with no 
recurrence after 12 
1
Resolution of diarrhoea 
and disappearance of 
stool Cdiff toxin
1 in 22 patients and 2 in 1 
patient
Resolution of diarrhoea in 
3 days with no recurrence 
in 3 months
16 patients had 1 
infusion; 3 who did not 
respond in this group had 
2nd infusion.
Cure without relapse 
within 10 weeks after the 
initiation of therapy. For 
patients in the infusion 
group who required a 
second infusion of donor 
feces, follow up was 
extended to 10 weeks 
after the second infusion. 
Cure was defined as an 
absence of diarrhoea or 
persisent diarrhoea that 
could be explained by 
other causes with three 
consecutive negative 
stool tests for C.difficile 
toxin. Relapse was 
defined as diarrhoea with 
a positive stool test for 
C.difficile toxin. 
20 patients in both study 
arms had one infusion 
(14 was cured after the 
first infusion (70%)). One 
patient in the NGT arm 
refused subsequent 
retreatment. The 
ramaining 5 patients 
were given a second 
infusion (4 patients 
obtained cure after 
second infusion, resulting 
in an overall cure rate of 
90%). 
Clinical resolution of 
diarrhoea off antibiotics 
for C.difficile, without 
relapse within 8 weeks. 
For patients who 
required a second 
treatment dose, a follow-
up was calculated 
starting at the time of the 
second administration. 
1 infusion in 27 patients 
and 2 infusions in 3 
patients.
Primary cure rate was 
defined as resolution of 
symptoms without 
recurrence within 6 
weeks after a single FMT, 
while secondary cure rate 
was calculated 
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Flow/loss of patients
Response definition
Data on each response definition (and definition of demoninator) %
Notes
Outcome 1 infusion
Overall response rate: 15/16 (94%). Pretreatment vm eliminated or reduced diarrhoea in most patients.
1/19 patients had missing documentation
2/18 patients died
14/16 patients submitted post transplant stool samples (20 samples total). The two non-submitted 
appeared to be diarrhoea free (upto 90 days).
Response definition: c diff toxin negative.
13/14 had negative stool test for c.diff toxin
1/14 had relapse and positve c.diff toxin stoll test 17 days post transplant.
Therefore response rates are:
92.9% (13/14) for those submitting a stool sample
81.2% (13/16) for those followed up who were still alive; with those not submitting a stool sample assumed 
worse case (ie. c diff. toxin positive) 
81.2% (13/16) for those who provided a sample or died (assumed worse case- ie. c diff toxin positive)
72.2% (13/18) assuming those who died or did not submit a stool sample were worse case (ie. c diff. toxin 
positive).
68.4% (13/19)  assuming those who died or did not submit a stool sample or had missing documentation 
were worse case (ie. c diff. toxin positive)
As pateints were pre-treated with vm study authors state "It was not possible to differentiate between 
patients whose colitis resolved as a result of their pretransplantation course of vancomycin and those with 
colitis improved as a result of stool transplantation itself" although patients had previously had multiple ab 
treatments without overal success.
There were no episodes of post-transplantation diarrhoea among the the 15 patients (c diff negative or non 
samply supplying) who survived the 90 day follow-up period. (unclear statement: not sure what total follow 
up period was after 90 days or whether this means during the 90 days).
15/16 (94%)
7/9 (77%) high dose and 7/10 (70%) low dose diarrhoea free at 8 weeks. Of the 5 non-responders 4/5 (80%) 
cured with high dose re-challenge. -94% secondary cure rate
NA
Primary end point defined as resolution of diarrhoea associated with C. diff infection 10 weeks after the 
end of treatment; in FMT group 18/20 (90%) achieved primary end point; In vanc group 5/19 (26%)patients 
achieved primary end point
13/20(65%)
Results
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Breakdown cure rates from both derivation and validation cohorts: recurrent CDI - 357/403  (89%), severe 
CDI 10/40 (25%), severe-complicated CDI 8/19 (42%). Total cure rate 375/462 (81.2%)
not reported
12 patients treated but 6 month follow up only available for 11. Response rate 10/11 (91%) in 
patients with full follow up. Response rate 10/12 (83%) in all patients treated. In only one of 11 cases 
did the bacterial infection relapse, after a new cycle of antibiotic therapy to treat an urinary tract infection, 
without diarrhea. 
10/12 (83%)
A total of 33 of 40 treatment episodes (83%) were successfully treated with FMT. In 29 of 40 treatments 
(73%) the first treatment was successful, with no documented recurrence of diarrhoeal disease within 80 
days. Of the 11 patients failing to respond to the first instillation treatment, 6 patients received a second 
instillation, 4 of which were successful. Initially 38 patients given FMT via gastroscope (response to 
single infusion 28/38 (74%)) and 2 patients given FMT via colonoscopy (response 1/2 (50%)). 11 
non-responders 6 were given 2nd FMT responses 3/4 (75%) via gastroscope and 1/2 (50%) via 
colonoscope 
29/40 (73%)
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The overall rate of infection clearance was 41/43 (95%), as evidenced by symptom resolution and negative 
PCR testing for C. difficile toxin B after 2 months of follow-up. Response rate from fresh FMT was 11/12 vs 
19/21 from frozen FMT 
37/43 (86%)
Overall response rate: 41/43 (95%). Cure rate colonoscopy group 21/21 (100%) and 20/22 (91%) in 
capsule group.
41/43 (95%)
After FMT, 25 of 27 (93%) experienced clinical resolution. Of these, 22 resolved within 24 hours of 
transplant. Five patients underwent a second FMT because of ongoing diarrhea; 3 had symptom resolution 
and 2 continued to experience diarrhea despite 2 FMTs. 
22/27 (81%)
26 sequential patients follow up and analysis available for all. 24/26  (92.3%) achieved primary outcome; 24/26 (92.3%)
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82  patients met inclusion criteria but analysis based on results of 80 patients as 2 lost to follow up (2 
deaths so no 12 week follow up data fro these patients and excluded from final analysis); 80 patients in 16 
centres had FMT for CDI with co-existing immunocompromise (36 IBD and on immunosupression, 19 solid 
organ transplants, 3 HIV/AIDS, 7 cancer and treatment with chemo, 15 chronic illness); response defined as 
absence of diarrhoea or marked reduction in stool frequency and without need for further antibiotics 
within 12 weeks after 1 or more FMTs; cure after 1 infusion 62/80 (77.5%); cure after 2 infusions 70/80 
(87.5%); if 82 patients included in analysis cure after 1 infusion is 62/82 (75.6%) or 2 infusions is 70/82 
(85.3%)
62/80 (77.5%)
In the intention-to-treat analysis, 20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure 
com- pared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042). Resolution after autologous 
FMT differed by site (9 of 10 vs. 6 of 14 [P = 0.033]). All 9 patients who developed recurrent CDI after 
autologous FMT were free of further CDI after subse- quent donor FMT. Direct clinic follow up at 2 and 8 
weeks
20 / 22  (90.9%)
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20 patients analysed; Response defined as primary cure rate- no recurrence of symptoms of diarrhoea 
within 3 months of single FMT infusion; secondary cure rate was defined as no recurrence of symptoms 
within 3 months after2 infusions of FMT; 9/9 community aquired CDI had single infusion with cure rate of 
100%; 9/11 Hospital aquired CDI had single infusion with cure rate of 82%; 2 patents in the hospital aquired 
group had second infusion and cured so secondary rate in this group was 100%
18/20 (90%)
10 patients; response not explicity defined but appears to be resolution of infection (how this determined is 
not stated); 9/10 had resolution, 1/10 had further FMT after relapse at 2 months following course of 
antibiotics. 
9/10 (90%)
94 patients in total given FMT; response defined as no diarrhoea for 6 months post FMT; overall response 
to FMT alone was); 5/94 patients received responded to FMT and vancomycin combination giving a further 
increment in cure of 5.3%, giving an overall cure rate of 91.5%;8 patients did not respond to FMT of which 
6 died and included as FMT failures; 11 patients received 4 or more FMTs NB the authors state this 
cohort is an expansion of previously published series by Lee et al 2011 which included the same 
first 27 patients (are we double counting this?)
45/94 (47.9%) 
Overall response as per primary outcome - up to two infusions (ITT) -  159/219 (73%). 113/219 (52%)
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11/15 were diarrhoea free during follow up of median 16 weeks (range 4 to 24 weeks). Follow up period 
not used to define response; Response rate 73.3% calculated on being diarrhoea free at follow up after 
single infusion
11/15 (73%)
Resolution of symptms during 12 weeks follow up in 66/70 (94%). 34/34 (100%) in non-027 CDI; 32/36 
(89%) in 027-CDI. Of the 4 027-CDI all died 1.5-3 months after. One who refused colectomy, two of CDI, one 
with myelome reated uraemia. This patient was retreated with antbiotics for pneumococcal septicaemis 
and menignitis after 1st FMT
63/70 (90%)
Of the 30 patients who had diarrhoea 29/30 (97%) had improvement or resolution of diarrhoea. Median 
time to imrpovement 3 days. At 3 months 91% (21/23) had maintained improvement or resolution. Of 
those who had 2 2 had subtotal colectomies and second FMT via upper OGD. All three improved in 5 days; 
one had a recurrence.
26/30 (87%)
Overall cure rate: 12/12 (100%). 11/12 (92%)
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20/20 (100%) 20/20 (100%)
19/20 (95%) responded to first treatment remaining symptom free for follow up of 6 months to 5 years. 
The one patient who did not respond was retreated after 5 months with same donor-immediately 
successful -so secondary cure rate 100%. 3 patients represented at 4months-6 years after but these were re-
infections following repeat treatment with antibiotics 
19/20 (95%)
Overall response rate: 59/75 (79%). Response rate if patients only included if primary outcome and 
negative CDI toxin post FMT: 57/75 (76%). Secondary cure rate (patients failed FMT, but subsequently 
resolved diarrhea after a course of oral vancomycin): 68/75 (91%). 
59/75 (79%)
Overall response rate: 47/49 (96%). Other response rates: FMT with fresh faeces, individual donor: 14/15 
(93%). FMT with fresh faeces, universal donor: 11/11 (100%). FMT with frozen faeces, universal donor: 
22/23 (96%).
47/49 (96%)
Overall response rate 27/31 (87%). If given via upper GI route 3/9 (33%). If given via lower GI route 
(including those that didn't respond to upper GI route) 24/28 (85%). 
24/31 (77%) 
Overall response rate 12/12 (100%). If exclude pre-transplant CDI toxin negative patients: 9/9 (100%) 12/12 (100%)
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Overall response rate 18/20 (90% (95%CI 68-98%)) at 8 weeks. Initial response rate 14/20 (70%), those who 
failed retreated after average of 7 days.  NA
Overall response rate 11/14 (79%). 8 remained cured at 100 day follow up (3 deaths from underlying 
cancer).
8/14 (57%)
70/77 (91) met primary outcome at 90 days. 70/77 (91%)
20/22 (91%%) responded at 3 months. 2 that relapsed had a further infusion (one by upper GI route) with 
both responding
19/22 (86%)
20/20 (100%) overall response rate 17/20 (85%)
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Initial Resolution of CDI symptoms with no recurrence after 12 weeks-121/146. 25 developed recurence 
within 12 weeks. 12 had more than 1 FMT but with antibiotics therefore not included in the analysis 
121/146 (82.9%)
27/27 (100%) at 1-3 month after FMT. 27/27 (100%)
Overall response rate: 16/23 (70%) 15/23 (65%)
The primary end point was cure without relapse within 10 weeks after the initiation of therapy. For patients 
in the infusion group who required a second infusion of donor feces, follow up was extended to 10 weeks 
after the second infusion. The secondary end point was cure without relapse after 5 weeks. Cure was 
defined as an absence of diarrhoea or persistent diarrhoea that could be explained by other causes with 
three consecutive negative stool tests for C.difficile toxin. Relapse was defined as diarrhoea with a positive 
stool test for C.difficile toxin. An adjudication committee whose members were unaware of study-group 
assignments decided wchih patients were cured.
13/16 (81%)
The primary endpoint was clinical resolution of diarrhoea off antibiotics for C.difficile, without relapse 
within 8 weeks. For patients who required a second treatment dose, follow-up was calculated starting at 
the time of the second administration. Resolution of diarrhoea was defined as <3 bowel movements per 24 
hours. Secondary endpoints included improvement in subjective well-being per standardized questionaire 
and presence of adverse events. 
14/20 (70%)
With the use of the nasogastric tube, the primary and secondary cure rate was 80% and 93.3%, 
respectively. When given via nasoduodenal route, the primary cure rate was 100%. This results in an overall 
primary cure of 90.0% and a secondary cure rate of 96.7%.
27/30 (90%)
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1 or more infusions Total follow up period Adverse events - mild Adverse events - serious
1.Were 
selection/eligibility 
criteria adequately 
reported?
15/16(94%)
90 days post 
transplantion, assessed 
by examination of 
medical records. 
no mention
2 patients died between 
transplant and follow up 
stool testing for c.diff toxin. 
One had end stage renal 
disease and was receiving 
peritoneal dialysis. Developed 
peritonitis 3 days post 
transplant and died shortly 
after. The second patieint 
died 14 days post transplant 
of pneumonia complicating 
COPD and atherosclerosis 
(study authors state: "the 
possibility that the use of the 
nasogastric tube contributed 
to the peritonitis cannot be 
excluded" )
yes
19/20 (95%) Not reported None reported none reported yes
18/20(90%)
primary end point 10 
weeks after end of 
treatment 
none in vanc group; 
FMT group 19/20 had 
transient diarrhoea, 
12/20 had abdominal 
pain and bloating
2 deaths in FMT arm yes
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375/462 (81.2%) 3 months Not reported Not reported formally yes
10/12 (83%) 6 months Not reported None yes
33/40 (82.5%) 80 days Not reported
5 deaths; The remaining 5 
patients had serious co-
morbid conditions and died 3 
weeks–2 months after the 
FDIT procedure. Two of these 
5 patients were seriously 
weakened after long lasting 
diarrhoeal disease, 1 being 
the oldest patient in the 
series (94 y). Additionally, 1 
patient had advanced stage 
Wegener’s granulomatosis 
with complications, 1 patient 
had acute myelogenous 
leukaemia requiring repeated 
antibiotic treatment for other 
infections, and 1 patient with 
advanced cardiovascular 
disease developed fulminant 
colitis and underwent 
subtotal colectomy, and 
subsequently died of 
complications.
yes
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41/43 (95%) 12 months Not reported Not reported yes
41/43 (95%) Not specified
Transient nausea and 
vomiting
None yes
25/27 (93%)
mean follow-up at 
427.3 days after 
transplant. 
Not reported Not reported yes
24/26 (92.3%)
follow up  mean 10.7 
months ranged from 2-
30 months
mild diarrhoea post 
FMT in 3 patients
no serious adverse events yes
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70/80 (87.5%)
minimum of 12 weeks 
required; mean follow 
up 11m (range 3-46m)
self limited diarrhoea in 
3, fever in 1, bloating 
and abdo discomfort in 
3, hip pain in 1, Crohn's 
flare in 1, Pertussis in 1, 
nausea in 1, minor 
mucosal tear at 
colonoscopy in 1
deaths- 1 due to pneumonia, 
1 due to aspiration at time of 
colonoscopy; hospitilisations- 
1 due to fever and 
encephalopathy, 1 due to 
abdo pain after FMT, 3 due to 
IBD flare, 1 colectomy, 1 hip 
fracture, 1 influenza, catheter 
infection
yes
21 / 22  (90.9%)
8 weeks for efficacy, 6 
months for safety
Chills were reported 
more frequently after 
autologous than donor 
FMT (P = 0.053). Rates 
of other solicited AEs 
(fever, abdominal pain, 
bloating, nausea, 
vomiting, diarrhea, 
flatulence, anorexia, 
and constipation) did 
not differ significantly 
between groups. 
There were no SAEs related 
to FMT. 
yes
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20/20 (100%)
minimum of 6 months 
(range not stated) 
self limited diarrhoea in 
4; abdominal pain in 3; 
nausea in 2; fatigue 13
none stated yes
10/10 (100%)
median duration of 
follow up 44 days 
(range 13-700 days)
vomiting post FMT in 1; 
mucoid stools for 2 
days after FMT
none stated yes
 81/94 (86.2%) 6-24 months
10% had transient 
constipation and 
flatulence post FMT
6 deaths due to critical 
illness, not felt to be due to 
FMT or CDI directly but these 
6 are included in the 8 who 
failed to respond overall
Yes
 193/219 (88.1%) 13 weeks
Transient diarrhoea 
(70%), abdominal 
cramps (10%), nausea 
(5%) in 24 hours post 
FMT; constipation 
(20%) and flatulence 
(25%) in follow up 
period
19 deaths in total 13 week 
study period (unrelated). 12 
patients required 
hospitalization because of 
ilnesses unrelated to FMT
Yes
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12/15(80%)
median 16 weeks (4 
weeks to 24 weeks) not 
predefined
none none stated Yes
 66/70 (94%)
1 year. 4 with initial 
favourable response 
had replase after 
receiving antibiotics. 2 
of these were 
successfully treated 
with  FMT; 2 with 
recurrent antibitics for 
CDI
None reported None related to FMT Yes
29/30 (97%)
1 year 6 out of 6 
maintained 
imrpovemement
Not reported
Micro-perforation but not 
related to FMT. One death at 
3 months afer due to 
,metastatic pancreatic 
cancer.
Yes
12/12 (100%)
No recurrences within 
90 days of FMT. Total 
follow up from 2 to 29 
months
None reported None related to FMT Yes
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20/20 (100%)
Follow up mean 3 
months (range 0-10)
1 pain/nausea after 
colonoscopy, 1 
continued diarrhoea 
(CDIFF neg) ? Bile salt 
malabsorption after 
cholecystectom, 2 
transient bloat/ cramps
1 perforation related to 
colonoscopy sealed with clip
Yes
20/20 (100%) 6 months to 5 years None reported none reported Yes
59/75 (79%) 60 days None None Yes
47/49 (96%)
All followed up for 12 
weeks and 42 patients 
followed up for 1 year
Mild transient fever in 
2 (frozen FMT)
3 deaths (unrelated) Yes
27/31 (87%)
Mean 9 months (range 
2–24)
Worsening arthritis, 
constipation, 
diarrhoea, urinary tract 
infection.
5 deaths; not attributed to 
FMT. Stroke, myocardial 
infarction, aspiration 
pnuemonia, hospitalisation 
for CDI not as a consequnce 
of FMT.
Yes
12/12 (100%) 3 weeks to 8 years Not reported None Yes
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18/20 (90%)
Primary outcome based 
on 8 weeks however 
patients followed up 
for 6 months
Transient abdominal 
cramping and bloating 
in 6 patients (30%) that 
resolved in 72 hours
1 hospitalised with a 
documented relapse of 
severe CDI after taking 15 
capsules but had successful 
treatment after receiving the 
remaining 15 capsules after 
discharge. No other severe 
adverse events (grade 2 or 
above).
Yes
11/14 (79%) 100 days Not reported
4 deaths within 30 days of 
FMT unrelated to FMT.
Yes
70/77 (91%)
Minimum 90 days, but 
median 17 months
None reported
4 patients reported a new 
medical condition after FMT 
(peripheral neuropathy, 
Sjogrens, ITP and rheumatoid 
arthritis
No
21/22 (95%)
Range 2 weeks to 17 
months with ave length 
3 months
pain in one patient none No
20/20 (100%)
Minimum 3 months 
(but up to 14 months)
None None No
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121/146 (82.9%)
mean follow up 12.3 
(range 1-48) months
CDI-negative diarrhoea 
in 7(4.8%) and 
constipation in 4(2.7%)
within 12 weeks-6 
hospitalizations due to CDI 
and/or FMT. One debilitated 
No
27/27 (100%)
Ranged from 9.7 -34 
months (mean 20.6 
months)
Low grade fever 
(18.5%) and bloating 
(11.1%)
None Yes
16/23 (70%)
Median follow up of 18 
months (range 0-201 
months)
Nil Nil Yes
15/16(94%)
After first infusion at 10 
weeks; follow up was 
extended to 10 weeks 
after the second 
infusion
94% immediate 
diarrhoea, 31% 
abdominal pain with 
cramping, 19% 
belching - resolved 
within 3 hours. During 
follow up 3 patients 
had constipation (19%). 
2 patient had 
infections: one patient 
with recurrent UTI had 
UTI
1 hospitalisation for 
symptomatic 
choledocholithiasis 
(unrelated)
Yes
18/20 (90%)
8 weeks follow up for 
primary response
Mild abdominal 
discomfort and 
bloating in 4 patients 
(20%). One child 
treated 
colonoscopically had a 
transient fever of 38.8 
C on day 2 that 
resolved spontaneously
2 deaths (unrelated), 1 new 
diagnosis of malignancy 
(unrelated), 1 hospitalisation 
for Fournier gangrene 
(unrelated)
Yes
29/30 (97%) 6 weeks
Nausea in one patient. 
Nil else
Nil Yes
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2. Were patients 
recruited consecutively?
3. Were patients 
recruited 
prospectively?
4. Was loss to follow-
up reported or 
explained?
5. Were at least 90% 
of those included at 
baseline followed 
up?
Record all 
possibilities
yes Yes Yes
Y and N
18/19 (95%); one of 
19 receiving stool 
excluded due to 
missing 
documentation.
16/19  (84%); a  
further two did not 
submit stool sample 
for primary outcome 
of c diff toxin testing 
(determined to be 
diarrhoea free at 90 
days)
yes yes no-abtstract yes
yes yes yes yes
CRD criteria
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yes No No Not known
yes No No Yes
yes NO NO
No FU varied 
significantly
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yes No No Yes
yes yes no yes
yes No No Yes
yes yes no loss of follow up yes 100%
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yes no yes
yes. 2 patients 
excluded from final 
analysis as lost to 
follow up did not 
have 12 week follow 
up data. 
yes Yes Yes Yes
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yes no no loss of follow up yes
yes no no loss of follow up yes
yes yes no loss of follow up yes
Yes Yes no loss of follow up Yes
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yes no no loss of follow up yes
No;retrospective review No No loss to follow up Retrospective review
Yes no No loss to follow up
No. Although stated 
in results that none 
developed 
recurrence at 90 days 
from table patient 12 
only followed for 2 
months
yes no yes yes
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Yes no
No follow up very 
variable
yes
Yes No
No follow up very 
variable
yes
Yes No Yes Yes
Yes No Yes Yes for 12 weeks
Yes No No
No FU varied 
significantly
Yes No No
No FU varied 
significantly
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Yes Yes Yes Yes (100%)
Yes No No Yes
Yes No Yes
Retrospective data 
series based on 
quesitonares filled by 
patient or relative
yes No No Doesn’t state
Yes Yes No Yes
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yes No NO No
Yes Yes No Yes
No No No No
Yes Yes Yes, (reported) Yes
Yes Yes
None lost to follow up 
(reported)
Yes
Yes No
None lost to follow up 
(reported)
Yes
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Supplement 2.Funnel plot of the estimated proportion responding to treatment (ovals) in each 
included study (y-axis) versus it’s standard error (x-axis). Plot includes ‘studies’ added (crosses) by the 
Duval and Tweedie nonparametric "trim and fill" method of accounting for small study effects in a 
random effect meta-analysis model 
Case series – multiple infusions  
 
 
 
Filled funnel plot with pseudo 95% confidence limits
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EMBASE - Search strategy 
 
1. exp Clostridium difficile infection/ or exp Clostridium difficile toxin B/ or exp Clostridium difficile toxin 
A/  
2. clostridium difficile.ti,ab.  
3. c diff*.ti,ab.  
4. (CDAD or RCDI or CDI).ti,ab.  
5. pseudomembranous.ti,ab.  
6. exp pseudomembranous colitis/  
7. (antibiotic* adj2 (diarrhea or diarrhoea or colitis)).ti,ab.  
8. (FMT or HPI).ti,ab.  
9. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant* or infus* or transfus* or 
implant* or instil* or donat* or donor* or reconstitut* or therap* or bacteriotherapy)).ti,ab.  
10. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.  
11. transplant*.ti,ab.  
12. exp transplantation/  
13. 8 or 9  
14. 10 and (11 or 12)  
15. 13 or 14  
16. or/1-7  
17. 15 and 16 
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MEDLINE - Search strategy 
 
1. Clostridium difficile/  
2. clostridium difficile.ti,ab.  
3. c diff$.ti,ab.  
4. Enterocolitis, Pseudomembranous/  
5. (antibiotic$ adj2 (diarrhoea or colitis)).ti,ab.  
6. (antibiotic$ adj2 (diarrhea or colitis)).ti,ab.  
7. pseudomembranous.ti,ab.  
8. (CDAD or CDI).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms]  
9. RCDI.ti,ab.  
10. Clostridium Infections/  
11. FMT.mp. or HPI.ti,ab. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier, synonyms]  
12. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant$ or infus$ or transfus$ or 
implant$ or instil$ or donat$ or donor or reconstitut$ or therap$ or bacteriotherapy)).ti,ab.  
13. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.  
14. (transplant$ or infus$ or transfus$ or implant$ or instil$ or donat$ or donor or reconstitut$ or 
therap$ or bacteriotherapy).ti,ab.  
15. Transplantation/  
16. Transplants/  
17. 11 or 12  
18. 14 or 15 or 16  
19. 13 and 18  
20. 17 or 19  
21. or/1-10  
22. 20 and 21 
Page 156 of 156Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
